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Summary 
Bacillus amyloliquefaciens is a Gram-positive bacterium that is widely distributed in the soil. 
It colonizes the plant roots and several of its natural isolates, such as the FZB42 strain, are 
used as bio-fertilizers, since they can promote plant growth and suppress plant pathogenic 
organisms. The features and mechanisms governing the biocontrol-related function of the 
strain have not yet been fully characterized. The domesticated strain of B. subtilis 168, a 
model organism for studies on Gram-positive bacteria, is closely related to B. 
amyloliquefaciens FZB42, but does not promote plant growth. 
As a first approach to detect gene differentiation between B. amyloliquefaciens FZB42 
and B. subtilis 168, and since only the genome sequence of the latter was known at that point, 
Suppression Subtractive Hybridization (SSH) was employed. Thereby, several unique genes 
of B. amyloliquefaciens FZB42 could be identified. Among others, it was established that the 
genome of B. amyloliquefaciens FZB42 harbours genes with high similarity to nonribosomal 
peptide synthetases and polyketide synthases of various Bacillus species, yet different from 
the ones present in the genome of B. subtilis 168. 
Meanwhile, our laboratory became engaged in a project aiming to define the complete 
genome sequence of B. amyloliquefaciens FZB42, in collaboration with the GenoMik 
Network in Göttingen. The major part of the work and the co-ordination of the whole process 
were performed by Xiao-Hua Chen and myself. Shotgun and fosmid library approaches, 
primer walking and multiplex PCR were used in order to decipher the complete sequence of 
B. amyloliquefaciens FZB42. Sequencing of the whole genome has since been completed and 
the second round of annotation is currently in process (performed by Xiao-Hua Chen). 
Strain FZB42 is the first member of the B. amyloliquefaciens species to have its genome 
sequenced. The genome of strain FZB42 consists of a single circular chromosome of 3916 kb, 
and thus is smaller than that of B. subtilis 168 (4214 kb). It contains 3931 genes, 80% of 
which show more than 50% amino acid similarity to genes of B. subtilis 168. Comparative 
genome analysis revealed several characteristics of the bacterium that might be associated 
with its biocontrol activity. Striking is the presence of eight gene clusters that control the non-
conventional synthesis of secondary metabolites, some of which with reported antifungal and 
antibacterial activities. 
B. amyloliquefaciens FZB42 possesses the srf, fen, pks1 (bae), bac and dhb operons, 
which are responsible for the synthesis of surfactin, fengycin, bacillaene, bacilysin and 
bacillibactin, respectively, and are also shared by B. subtilis 168. In addition, and as initially 
detected by the SSH experiments, the genome of B. amyloliquefaciens FZB42 contains the 
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bmy, dif, pks2 gene clusters, which control the synthesis of bacillomycin D, 
difficidin/oxydifficidin and macrolactin respectively. The functionality of all eight gene-
clusters was verified by a series of mass spectrometry analysis (MALDI-TOF MS and HPLC-
ESI MS), in collaboration with Xiao-Hua Chen and Dr J. Vater. It is conceivable that the 
profound genetic capacity of B. amyloliquefaciens FZB42 to produce antagonistically acting 
secondary metabolites enables the strain to cope successfully with competitors within its 
natural environment and to promote plant growth. Therefore, the biological activity of those 
compounds was further examined. Bacillomycin D and fengycin were the only antibiotics 
produced by the strain, which could exhibit a general inhibitory effect on fungal growth, 
acting in a synergistic manner. 
A further issue pursued in this work was to identify the regulatory pathways that govern 
the expression of bacillomycin D. Global regulators, such as DegU, DegQ and ComA, the 
alternative sigma factors, σB and σH, and a novel Rap protein were found to affect the 
transcriptional activation of the main promoter of the bmy operon identified in this work. In 
particular, DegU was shown to mediate its effects, after binding directly to two distinct A/T-
rich sites at the bmy promoter region. The other regulatory players were associated with more 
indirect effects, which were mostly exerted via DegQ, a protein that seems to optimise the 
activity of DegU, or via DegU itself. 
DegU was shown to play an additional role on bacillomycin D production, presumably a 
post-transcriptional one, apart from activating the main promoter of the bmy operon. 
Therefore, its presence was critical for the production of bacillomycin D. Similarly, YczE, a 
membrane protein of unknown function, encoded adjacently to sfp (a 4'-phosphopantetheinyl 
transferase that post-translationally modifies nonribosomal peptide synthetases and makes 
them functionally active), proved to be essential for bacillomycin D production, but 
dispensable for the production of the rest peptide antibiotics produced by B. 
amyloliquefaciens FZB42. The effect was mediated at a post-transcriptional level (prior to the 
peptide’s export) and was independent of DegU. 
To conclude, this work provides information concerning the genetic identity of B. 
amyloliquefaciens FZB42, its lifestyle and its production of secondary metabolites by it. In 
addition, it defines the complex regulatory network that controls the expression of the most 
abundant lipopeptide of the organism, bacillomycin D. It is the first time that the gene 





Bacillus amyloliquefaciens ist ein im Boden weit verbreitetes Gram-positives Bakterium. Es 
kolonisiert Pflanzenwurzeln und mehrere natürliche Isolate, wie zum Beispiel der Stamm 
FZB42 werden als Biodünger verwendet, da sie in der Lage sind, Pflanzenwachstum zu 
fördern und Pflanzenpathogene zu unterdrücken. Die Eigenschaften und Mechanismen, 
welche diese Biokontrollfunktionen steuern wurden bislang noch nicht vollständig 
charakterisiert. Der domestizierte Stamm B. subtilis 168, ein Modellorganismus für Studien 
an Gram-positiven Bakterien, ist eng verwand mit B. amyloliquefaciens FZB42, fördert 
jedoch kein Pflanzenwachstum. 
Als ein erster Ansatz zur Ermittlung von Gendifferenzen zwischen B. amyloliquefaciens 
FZB42 und B. subtilis 168 - wobei zum damaligen Zeitpunkt nur die Genomsequenz letzteren 
Organismus bekannt war - wurde die “Supression Subtractive Hybridisation” (SSH) 
angewandt. Hierdurch wurden mehrere einzigartige Gene in B. amyloliquefaziens identifiziert. 
Unter anderem wurde gezeigt, dass das Genom von B. amyloliquefaziens FZB42 Gene mit 
starker Ähnlichkeit zu nichtribosomalen Peptid-Synthetasen und Polyketid-Synthasen 
verschiedener Bacillus-Arten beinhaltet, die sich jedoch von den im B. subtilis 168-Genom 
enthaltenen Genen unterscheiden. 
Unterdessen beteiligte sich unser Labor in Kollaboration mit dem GenoMik Network in 
Göttingen an einem Projekt, dessen Ziel die komplette Sequenzierung des Genoms von B. 
amyloliquefaciens war. Der Hauptanteil der Arbeit, sowie die Koordination des gesamten 
Projekts wurden von Xiao-Hua Chen und mir selbst durchgeführt. Zur Entschlüsslung der 
vollständigen Genomsequenz von B. amyloliquefaciens wurden Shotgun und Fosmid-Library 
Ansätze, Primer walking und Multiplex-PCR angewandt. Die Sequenzierung des gesamten 
Genoms wurde mittlerweile abgeschlossen und derzeitige Arbeiten sind bis zur zweiten 
Annotationsrunde vorangeschritten (durchgeführt von Xiao-Hua Chen). 
Der Stamm FZB42 ist das erste Mitglied der B. amyloliquefaziens-Art, dessen Genom 
sequenziert wurde. Das Genome von Stamm FZB42 besitzt ein einziges kreisförmiges und 
3916 kb großes Chromosom, das damit kleiner ist als das Chromosom von B. subtilis 168 
(4214 kb). Es enthält 3931 Gene, von denen 80% mehr als 50%ige Aminosäuren-Ähnlichkeit 
mit Genen von B. subtilis zeigen. Vergleichende Genomanalysen offenbarten mehrere 
Charakteristika des Bakteriums, welche mit seiner Biokontrollaktivität assoziiert sein 
könnten. Auffällig ist die Präsenz von acht Genclustern, die die unkonventionelle Synthese 
von sekundären Metaboliten kontrollieren, von denen einige bereits beschriebene antifungale 
und antibakterielle Aktivitäten besitzen. 
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B. amyloliquefaciens FZB42 besitzt die srf, fen, pks1 (bae), bac und dhb Operons, welche für 
die Synthese von Surfactin, Fengycin, Bacillaene, Bacilysin und Bacillibactin verantwortlich 
sind und die ebenfalls im Genom von B. subtilis 168 enthalten sind. Wie bereits durch die 
anfänglichen SSH-Experimente gezeigt worden war, beinhaltet das Genom von B. 
amyloliquefaciens FZB42 die bmy-, dif-, pks2-Gencluster, die die Synthese von Bacillomycin 
D, Difficidin/Oxydifficidin und Macrolactin kontrollieren. Die Funktionalität dieser acht 
Gencluster wurde in Zusammenarbeit mit Xiao-Hua Chen und Dr. J. Vater durch eine Serie 
von Massenspektrometrie-Analysen (MALDI-TOF MS and HPLC-ESI MS) nachgewiesen. 
Es ist vorstellbar, dass die umfangreiche genetische Kapazität, antagonistisch wirkende 
sekundäre Metabolite zu produzieren, es B. amyloliquefaciens FZB42 ermöglicht, erfolgreich 
gegen Konkurrenten in seiner natürlichen Umgebung vorzugehen und das Pflanzenwachstum 
zu fördern. Daher wurde die biologische Aktivität dieser Komponenten weiter untersucht. 
Bacillomycin D und Fengycin waren die einzigen von diesem Stamm produzierten 
Antibiotika, welche einen generellen inhibitorischen Effekt auf das Wachstum von Pilzen 
zeigten, wobei sie in synergistischer Weise wirkten. 
Ein weiteres in dieser Arbeit verfolgtes Ziel war die Identifizierung der regulatorischen Wege, 
die die Expression von Bacillomycin D steuern. Es wurde gezeigt, dass globale Regulatoren, 
wie beispielsweise DegU, DegQ und ComA, die alternativen Sigmafaktoren σB und σH und 
ein neuartiges Rap-Protein die transkriptionale Aktivität des in dieser Arbeit identifizierten 
Hauptpromotors des bmy-Operons beeinflussen. Insbesondere wurde gezeigt, dass DegU 
seine Effekte nach direkter Bindung an zwei unterschiedliche A/T-reiche Regionen im bmy-
Promotor ausübt. Die anderen Regulatoren wurden mit eher indirekten Effekten assoziiert, 
welche meist über DegU oder DegQ ausgeübt wurden. Letzteres Protein scheint die Aktivität 
von DegU auf unbekannte Weise zu optimieren. 
Es wurde außerdem gezeigt, dass DegU abgesehen von der Aktivierung des Hauptpromoters 
des bmy-Operons eine zusätzliche, vermutlich post-transkriptionale Rolle bei der 
Bacillomycin D-Produktion spielt. Daher war die Präsenz von DegH essentiell für die 
Produktion von Bacillomycin D. Auf ähnliche Weise erwies sich YczE, ein Membranprotein 
unbekannter Funktion, das neben sfp (eine 4´-Phosphopantetheinyl-Transferase, die 
nichtribosomale Peptide post-translational modifiziert und sie aktiviert) kodiert liegt, als 
essentiell für die Bacillomycin D-Produktion, jedoch als entbehrlich für die Produktion der 
restlichen von B. amyloliquefaciens FZB42 produzierten Peptid-Antibiotika. Der Effekt 
wurde auf einem post-transkriptionalen Level ausgeübt (vor dem Peptid-Export) und war 
unabhängig von DegU. 
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Abschließend kann gesagt werden, dass diese Arbeit Informationen über die genetische 
Identität von B. amyloliquefaciens FZB42, seine Lebensweise und die Produktion sekundärer 
Metabolite durch das Bakterium liefert. Außerdem definiert sie das komplexe regulatorische 
Netzwerk, das die Expression des meistvorhandenen Lipopeptides des Organismus, 
Bacillomycin D, kontrolliert. Es ist die erste Untersuchung der Genexpression eines Mitglieds 



































































Bacillus amyloliquefaciens strain FZB42 
Bacilli are aerobic, rod-shaped, Gram-positive bacteria, with low G/C content. They are 
widely distributed in soil, air and water, and form oval endospores, as a consequence to 
deprived environmental conditions. Representatives of this genus, comprising some 51 validly 
described species, are being used in a wide range of industrial processes, mainly due to their 
ability to produce extracellular enzymes, antibiotics and insecticides, and secrete them in high 
concentrations [1]. 
In particular, Bacillus amyloliquefaciens and its numerous natural isolated strains serve 
for the production of a-amylase, an enzyme necessary for liquefaction of starch prior to 
saccharification for the production of sugar syrups in food industry [2, 3]. The habitat of this 
species is the soil, especially the rhizosphere where it colonizes plant roots [4, 5]. The 
commercially available strain of B. amyloliquefaciens FZB24 is applied as bio-fertilizer, as it 
stimulates plant growth and suppresses plant pathogenic organisms. These abilities are also 
shared by strain FZB42 [6]. 
The soil is also the natural environment of Bacillus subtilis, the best characterized 
member of the genus. Strain 168 was the first Gram-positive bacterium to be sequenced and 
has been used as a model organism to study the behavior of microorganisms for more than a 
century [7]. It is closely related to Bacillus amyloliquefaciens strain FZB42, but does not 
promote plant growth. The features and mechanisms governing the biocontrol-related 
function of B. amyloliquefaciens FZB42, which are obviously not active in the domesticated 




The genome contains the complete set of genetic information that organisms require to live 
and thrive. Therefore, the complete sequencing of the genomic DNA of an organism offers 
better understanding in respect with the mechanisms the organism adopts to withstand its 
environment. The function of several sequenced genes can be predicted as a basis of the 
genetic organisation of the gene’s surrounding region, the conserved regions within the gene 
and the degree of its alignment with other genes of established function. The existence of 
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databases that compile information about sequenced organisms/genes in combination with 
powerful bioinformatics tools that perform multi-level gene comparisons / annotations in a 
very short time (seconds), makes the task of assigning a gene’s putative function easier, faster 
and more successful. The information obtained by comparisons with such databases can serve 
as a basis for further molecular and biochemical work. Finally comparisons of complete 
genome sequences are very informative from an evolutionary aspect, as they allow better 
phylogenetic taxonomy of sequenced organisms and highlight the genetic reorganisation that 
evolution has imposed within closely related organisms.  
The first complete genome sequence of a microbial organism was that of Haemophilus 
influenzae Rd KW20, published in 1995 [8]. Bacillus subtilis was the first Gram-positive 
bacterium to be sequenced as its biochemistry, physiology and genetics had been already 
thoroughly studied for many years [7]. In the following years, various other Bacilli were 
sequenced [9, 10, 11]. It is interesting to mention that the fully sequenced microbial genomes 
has rapidly risen from only 30 in year 2000 to more than 300 today. Shortly after the 
completion of sequencing of the first prokaryotic organism, the complete sequence of major 
eukaryotic organisms (such as drosophila, mouse and human) was accomplished and this 
marked a major breakthrough in science of the last century [12, 13, 14]. It is therefore 
apparent that information concerning complete sequenced genomes accumulates 
exponentially and combined with the development of more powerful databases (that reflect 
the advances in bioinformatics) provides better understanding / prediction of the abilities and 
functions of newly sequenced organisms. 
 
 
Antibiotic production from Bacilli 
Antibiotics are a diverse group of chemical substances produced by both prokaryotes and 
eukaryotes and are of great importance in medicine due to their ability to disrupt pathogenic 
microbial metabolism, by various mechanisms. They can be classified according to their 
structure or their action (Fig. 1). In the medical field, the two most important groups of 
antibiotics are the β-lactam and tetracyclines. Members of the first group, such as penicillins 
and cephalosporins, are produced by fungi and are potent inhibitors of cell wall synthesis of 
bacteria. The tetracyclines consist of a naphthacene ring system that can be substituted at 
several positions to form new analogs. They are produced by prokaryotes and inhibit almost 
all Gram-positive and negative bacteria, by interfering with 30S ribosomal subunit function. 
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In addition, aminoglycoside antibiotics, a separate group of antibiotics, exhibit the same way 
of function. They contain amino sugars bound to each other by glycosidic linkage, as in the 
case of streptomycin and kanamycin. Furthermore, macrolide antibiotics are widespread 
antibiotics in medicine that contain large lactone rings connected to sugar moieties. 
Erythromycin belongs to this group and inhibits protein synthesis at the 50S subunit of the 
ribosome (Fig. 1) [15].  
 
Figure 1: Chemical structural representation of different classes of antibiotics with 
major importance. 
A. Penicillin core, B. Tetracycline core, C. Neomycin; aminoglycoside antibiotic and D. 
Erythromycin; a macrolide antibiotic 
 
 
Bacilli are widely known and used microorganisms for production of a wide range of 
antibiotics, such as polymyxins (B. polymyxa) which destroy membrane integrity as well as 
edeines (B. brevis) which inhibit the formation of the initiation complex on the 30S ribosomal 
subunit [16]. The predominant class though of antibiotics produced by Bacilli are peptide 
antibiotics. These exhibit highly rigid hydrophobic and/or cyclic structures with unusual 
constituents like D-amino acids, and are generally resistant to hydrolysis by peptidases and 
proteases [17]. Furthermore, they are insensitive to oxidation, because cysteine residues are 
either oxidized to disulphides and/or modified to characteristic C-S (thioether) linkages. The 
peptide synthesis is achieved ribosomally, followed by post-translational modifications, or 
nonribosomally by multienzyme complexes [18]. 
 20
Ribosomally synthesized peptide antibiotics 
Synthesis 
For the production of proteins and peptides three basic enzymes are required: tRNA 
synthetases, tRNAs and the ribosome [19]. First the aa-tRNA synthetase selects the cognate 
amino acid and loads it onto the 2’- or 3’- hydroxyl group of the corresponding t-RNA [20, 
21]. Subsequently, with help of the elongation factor (EF-Tu), the ribosome selects the correct 
aa-tRNA during each cycle of polypeptide elongation, according to the mRNA sequence [22]. 
Therefore a complex comprising aa-tRNA, EF-Tu and GTP enters the acceptor site of the 
ribosome. The large ribosomal subunit stimulates GTP hydrolysis when there is 
complementary base-pairing between the mRNA and the cognate aa-tRNA. Peptide bond is 
formed when the aa-tRNA has been accommodated to the acceptor site, whereupon 
translocation can occur regenerating the ribosome. Eventually, post-translational modification 
events lead to the completion of synthesis of these peptide antibiotics [23]. 
 
Ribosomally synthesized peptide antibiotics in Bacilli; classification and control of gene 
regulation 
Lantibiotics are the major group of ribosomally synthesized antibiotics in Bacilli. They 
contain lanthionine, which is formed post-translationally through dehydration of serine or 
threonine residues followed by addition of neighbouring cysteine thiol groups, leading to 
inter-residual thioether bonds [24, 25]. Based on structural properties, two types of 
lantibiotics are distinguished: type A, with a more linear secondary structure, and type B, with 
a more globular one [26]. 
Subtilin and ericin are members of the type A group and are lethal against Gram-
positive bacteria by forming voltage-dependent pores into the cytoplasmic membrane [27]. 
Mersacidin belongs to the type B group and inhibits cell wall biosynthesis by complexing 
lipid II [28]. Other unusual lantibiotics produced by Bacilli are sublacin and subtilosin, which 
also act against Gram-positive bacteria through yet unknown mechanisms. The organization 
of these gene clusters is shown in figure 2. 
Subtilin biosynthesis is mediated by the prepeptide SpaS [29], which is post-
translationally modified by SpaBC [30]. Furthermore, the translocator SpaT exports the 
lantibiotic. Immunity to the producer strain is conferred by the lipoprotein SpaI and the ABC 
transporter SpaFEG [31]. In a positive feedback loop, subtilin activates the two component 
regulatory system SpaRK (response regulator and sensor histidine kinase) and directly 
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stimulates expression of genes involved in biosynthesis and immunity [32, , 33]. SpaRK 
expression is also controlled by the sporulation transcription factor SigH [33]. 
Ericin has the same gene cluster organization as subtilin, but surprisingly two structural 
genes, eriA and eriS. However, the production of ericin A and ericin S, that differ in amino 
acid composition and ring structure, is under the control of the same synthetase (EriBC) [34]. 
 
 
Figure 2: Bacillus subtilis lantibiotics, lantibiotic-like peptides and specifying gene 
clusters. 
The organisation of gene clusters (boxed) specifying lantibiotic and lantibiotic-like peptides are 
presented along with schematic structure representations of the mature peptides. The size of gene 
clusters is given in kilobases (kb). Black boxes indicate structural genes and genes involved in post-
translational modification and transport; grey boxes indicate regulatory genes; filled boxes stand for 
immunity genes. The figure is reproduced from [35]. 
 
mrsA is the structural gene in the mersacidin gene cluster, whereas the genes mrsM 
and mrsD are involved in its post-translational modification [36]. Furthermore, mrsT, coding 
for a transporter with an associated protease domain, mediates the transport while the operon 
mrsFGE, an ABC transporter, confers self-protection against the lantibiotic. mrsR1 is a 
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response regulator that controls biosynthesis of mersacidin whereas the putative two 
component regulatory system mrsR2K2 controls immunity [36, 37]. 
The structural gene for sublancin biosynthesis is sunA and it belongs to the B. subtilis 
temperate bacteriophage SPβ. An ABC transporter (SunT) and two thiol-disulphide 
oxidoreductases (BdbAB) belong to the same locus [38]. Until now, only BdbB is proven to 
be involved in the sublancin production, most probably for the formation of the disulphide 
bonds [39]. The genes conferring immunity are unidentified. 
Finally, the gene cluster of subtilosin (sbo-alb) encodes AlbA protein, probably 
involved in post-translational modification of presubtilosin, and AlbBCD proteins, a putative 
ATP-binding transporter, involved in immunity [40]. The expression of alb genes is under the 
negative control of AbrB [41]. 
 
Nonribosomally synthesized peptide antibiotics 
Structural diversity is a predominant feature of nonribosomally synthesized peptides, as they 
are assembled from an exceedingly heterogeneous group of precursors. There are more than 
300 members in this group including pseudo, nonproteinogenic, hydroxy, N-methylated and 




In spite of their structural heterogeneity, the peptide antibiotics of this group share a common 
mode of synthesis, the multicarrier thiotemplate mechanism [43]. According to this model, 
peptide bond formation takes place on multienzymes designated nonribosomal peptide 
synthetases (NRPS), which are arranged in modules. Modules are the units responsible for 
the incorporation and/or modification of a specific amino acid into the peptide product, and 
their arrangement and number are usually colinear to the amino acid sequence and the length 
of the peptide respectively (colinearity rule) [44, 45, 46]. Modules are further divided into 
domains; the enzymatic units involved in a specific step of synthesis, such as substrate 
activation, covalent binding, elongation etc [47]. 
According to the multicarrier thiotemplate mechanism, the carboxy group of amino acid 
is activated to the corresponding adenylate by ATP hydrolysis and then it is transferred onto 
the free thiol-group of an enzyme bound 4'-phosphopantetheinyl cofactor (4'-PP), forming a 
thioester. At this stage, the substrates can undergo modifications such as epimerization or N- 
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methylation. Peptide assembly is achieved via peptide bond formation steps, by binding of the 
thioester-activated carboxyl group of the upstream module to the free amino group of the 
adjacent downstream module. During this N to C stepwise elongation, the intermediates are 
covalently attached to the multienzyme complex. The termination of the synthesis is induced 
by the release of the thioester-bound peptide product by hydrolysis, cyclization or transfer to a 
functional group [19, 44, 48]. As an example figure 3 shows a prototype NRPS assembly line 
for the cyclic lipoheptapeptide surfactin [49]. 
 
Figure 3: Surfactin assembly line. 
The multienzyme complex consists of seven modules which are responsible for the incorporation of 
seven amino acids. 24 domains catalyse the same number of chemical reactions. The peptide chain is 
elongated stepwise from N to C end. The last domain is responsible for release and cyclization 




Domains of nonribosomal peptide synthetases 
Domains are not just imaginary sections in the module. They are enzymatically active, as well 
as structurally and catalytically independent. They can be excised from the peptide chain and 
still retain their activity [45]. 
 
Adenylation domain 
Nonribosomal peptide synthesis is initiated by the recognition and activation of the designated 
substrate. This is the role of the adenylation domain (A), which recognizes and incorporates 
the suitable amino acid substrate into the peptide. At the expense of Mg+2-ATP and release of 
PPi, the amino acid is activated as aminoacyl adenylate (Fig. 4A) [50, 51, 52]. There is a 
specific adenylation domain for each amino acid included in the peptide antibiotic and its 
location indicates the primary structure of the product [45]. Sequence comparison of the A-
domains (ca 550aa) deriving from various genes that code for peptide synthetases revealed 10 
residues as the major determinants of substrate specifity; this result was also confirmed by 
introducing specific point mutations at these sites [45, 53, 54]. 
 
Thiolation domain (peptidyl carrier protein domain) 
The thiolation domain (T), also known as peptidyl carrier domain (PCP), accepts the activated 
amino acid. The prerequisite for the functionality of the T-domain is its post-translational 
modification with the 4'-phosphopantetheine cofactor (4'-PP). Associated 4'-
phosphopantetheinyl transferases catalyze the transfer of the 4'-PP moiety from the coenzyme 
A to a conserved serine residue of the T-domain, converting thus the inactive apo-T to its 
active holo-T (see also Fig. 6) [43, 55, 56]. Furthermore, the aminoacyl adenylate from the A-
domain forms a thioester with the cysteamine thiol group of 4'-PP cofactor and therefore can 
be transported to the next module (Fig. 4B) [43, 47, 55, 57, 58]. The thiolation domain has 
around 100 amino acid residues and is located downstream of the adenylation domain [45]. It 
represents the transport unit that enables the elongation intermediates to move between the 
catalytic centers. The combination of adenylation and thiolation domains is referred to as 
initiation module, since both domains are required to activate and covalently tether the first 




Figure 4: Domain catalyzed reactions. 
A) The adenylation domain recognizes and activates the suitable amino acid as aminoacyl adenylate at 
the expense of ATP. B) Covalent attachment of the activated aminoacyl adenylate onto the free thiol 
group of the 4'-phosphopantetheine cofactor bound to the peptidyl carrier domain. C) Peptide 
elongation by the condensation domain, which catalyses the attack of the nucleophilic amine of the 
acceptor substrate onto the electrophilic thioester of the donor substrate. A1- A2, adenylation domains; 
PCP, thiolation / peptidyl carrier domain; C, condensation domain; d and a, donor and acceptor sites 
on condensation domain; ppan, 4'-phosphopantetheine cofactor. Domains in action are indicated in 





Condensation domain  
The condensation domain (C), ca. 450 amino acid length, is responsible for the formation of 
the peptide bond between two activated amino acids on adjacent modules and therefore 
controls the elongation of the growing peptide chain [19]. It catalyses the attack of the 
nucleophile aminoacyl-S-4'-PP-T to the electrophile aminoacyl/peptidyl-S-4'-PP-Ts, that lye 
downstream and upstream of the C-domain respectively (Fig. 4C) [59]. For this scope the C-
domain harbors two selective substrate-binding sites: an enantioselective electrophilic donor 
site and an amino acid selective nucleophilic acceptor site [60]. The amino acid acceptor site 
is responsible for preventing internal mis-initiation as well as for controlling the timing of 
substrate epimerization [61], whereas the donor site for incorporating the correct isomer [60, 
62]. 
The C-domain is found between two consecutive initiation modules located on the same 
synthetase (intramolecular amino acid transfer). In case the initiation modules belong to 
different synthetases, the C-domain is located at the N-terminus of the one accepting the 
substrates (intermolecular amino acid transfer). Peptide synthetases involved in lipopeptide 
biosynthesis contain an additional C-domain preceding the first initiation module, probably 
involved in the coupling of the fatty acid moiety to the first amino acid of the peptide moiety 
[63]. 
Variations on the peptide backbone can be obtained by the replacement of C-domains 
with the structurally and mechanically related heterocyclization (Cy) domains. Five-
membered heterocyclic rings such as oxazoline in vibriobactin or thiazoline in bacitracin are 
common features of nonribosomal peptides and significant for chelating metals and 
interaction with proteins, RNA, DNA [48, 64]. The formation of such heterocyclic rings and 
the subsequent peptide elongation is catalyzed by Cy-domains with the nucleophilic attack of 
a T-bound cysteine, threonine or serine acceptor substrate onto the thioester of the donor 
substrate. As observed for C-domains, the free α-amino group of the cysteine, threonine or 
serine is the nucleophile. Subsequently, the side chain hydroxyl or thiol group carries out a 
nucleophilic attack onto the α-carbonyl C atom of the donor amino acid, producing a 




Figure 5: Schematic representation of the catalytic functions of Cy-, TE-, E- and N-MT-
domains. 
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A) Formation of thiazoline heterocyclic rings from cysteine precursors catalyzed by Cy-domain. Three 
reactions are catalyzed by the Cy-domains: amide bond formation, cyclization and dehydration. Cy, 
heterocylization domain. Example from yersiniabactin nonribosomal synthetase present in Yersinia 
pestis. ArCP, aryl carrier protein; Sal-S-ArCP, activated salicyl group onto the N-terminal ArCP. The 
figure is reproduced from [65]. 
B) Peptide release by the TE-domain. Peptide release is achieved either by external nucleophile water 
resulting in a linear product (A) or by an internal nucleophile resulting in a cyclic product (B), 
depending on the NRPS template. The figure is reproduced from [48]. 
C) Peptide synthesis order in the presence of an E-domain within the elongation modules. 1. Substrate 
adenylation by A-domain. 2. Transfer of the activated amino acid to the PCP domain. 3. Binding on 
the upstream C-domain acceptor site and formation of peptide bond. 4. The resulting peptidyl-PCP has 
lower affinity for the acceptor site and is transferred to the subsequent E-domain. Equilibrium of D/L 
isomers is produced. 5. Binding of the D-isomer on the donor site of the downstream C-domain. AA, 
amino acid; AAx,, upstream peptidyl chain; E-epimerization domain. The figure is reproduced from 
[48] 
D) Cyclization strategies. The majority of cyclization reactions within NRPS are catalyzed by TE-
domains. A putative C-domain accounts for cyclization of cyclosporine A while a T-C domain 
controls oligomerization of the trilactone enniatin. A reductase domain (R) is responsible for 
cyclization of the imine nostocyclopeptide. The figure is reproduced from [48] 
E) N-Methylation of nonribosomal peptides by embedded N-MT domains. N-methylation occurs on 
the aminoacyl thioester monomer prior to amide bond formation with the upstream peptidyl chain. 





The thioesterase domain (TE), ca 250 amino acid length, is responsible for the release of the 
peptide from the multienzyme complex. During synthesis, the growing peptide chain is 
transported between the T-domains of the subsequent modules from the N to the C-terminus 
of the synthetase until it reaches the final module. This module usually contains the TE-
domain, causing product liberation by a two-step process. This involves an acyl-O-TE- 
enzyme intermediate that is attacked by either a peptide-internal nucleophile [67, 68] or water 
[69], and results in a macrocyclic [70] or a linear product [71] (Fig. 5B). 
TE-domains are very diverse since they catalyze various reactions (Fig. 5D) [72]. In the 
case of tyrocidine (B. brevis), head to tail cyclization is achieved by amide bond formation 
between the N-terminal amine and the C terminus of the peptide, yielding a lactam product 
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[52], whereas for surfactin and mycosubtilin (B. subtilis et al.) lipo branched chain cyclization 
is accomplished by connection of a β-hydroxy and a β-amino fatty acid to the C-terminus, 
yielding a lactone and a lactam respectively [63, 70]. The same situation is observed for the 
calcium dependent antibiotic (CDA) produced by Streptomyces coelicolor A3(2) [73]. For 
fengycin (B. subtilis et al.) and syringomycin (P. syringae), amino acid branched chain 
cyclization occurs by using a tyrosine and a serine from the peptide chain as nucleophiles, 
discriminating them from other peptide antibiotics that use the β-hydroxyl group of the 
attached fatty acid moiety [74, 75, 76]. Some TE-domains do not permit cyclization of one 
peptide chain, but force the multienzyme to repeat the synthesis once or twice more. 
Subsequently, they have the ability to count the assembled synthetase monomers at the end 
and initiate release by cyclic dimer or trimer formation, when the desired length is achieved 
[48]. This mechanism, though not yet fully characterized, applies for the synthesis of 
gramicidin S (B. brevis) [67], enterobactin (E. coli) [77] and bacillibactin (B. subtilis) [78]. As 
they control such different mechanisms of cyclization, TE-domains show high degree of 
specialization and therefore share low sequence homology (10%-15%) [72]. 
Nevertheless, cyclization is not accomplished exclusively by TE-domains. For 
cyclosporin A (Tolypocladium niveum), a putative C-domain is responsible for the final 
peptide bond [79], whereas for enniatin (Fusarium script), a T-C didomain accounts for the 
oligomerization [80]. In the case of nostocyclopeptide (Nostoc sp.), the C-terminal residue of 
the linear peptide is reduced by a reductase domain (R-domain) to give an aldehyde, that is 
intramolecularly captured by the α-amino group of the N-terminal amino acid residue to 
produce a cyclic imine [81]. 
Epimerization domain 
The epimerization domain (E) controls the conversion of amino acids, that belong to the 
attached growing peptide chain, from L to D-configuration. Usually these domains (ca 450 
amino acid length) are located internally in the synthetases upstream of the condensation 
domain [82]. They represent a class of cofactor independent amino acid epimerases that 
catalyze the de- and reprotonation of the α-carbon atom of an enzyme bound aminoacyl or 
peptidyl-S-4'-PP thioester in both directions (L-to-D, D-to-L), resulting in a mixture of both 
isomers. However, the L-isomer is rejected by the enantioselective donor site of the following 
C-domain, whereas the D-isomer is used from the same domain for the elongation of the 
peptide chain [83, 84]. 
If the E-domain is part of the initiation module, an equilibration between the two 
isomers takes place as the amino acid is bound as thioester at the thiolation domain, prior to 
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peptide bond formation [83, 85, 86]. The downstream C-domain is selective for the D-isomer, 
which is eventually incorporated [60, 62]. However, if an E-domain is embedded in the 
elongation modules, epimerization occurs at the peptidyl-4'-PP-T stage. The corresponding A-
domain recognizes and activates the L-isomer, which is then transferred onto the following T-
domain and then onto the upstream C-domain for peptide bond formation. Then, E-domain 
acts to produce a D/L equilibrium of peptidyl-S-4'-PP thioesters. Furthermore, downstream C-
domain catalyses only the transfer of the D-isomer to the next elongation module (Fig. 5C) 
[61, 84, 87]. 
Quite rarely, D-amino amino acids are present in the peptides independently from the 
catalytic function of E-domains. These substrates are first epimerized by racemases, which are 
not intergrated in the peptide synthetase, and then recognized and incorporated by the 
corresponding A-domain. This is the case for D-Ala1 in the cyclosporine synthetase [88]. 
 
N- and C-Methyltransferase domains 
The N-Methyltransferase (N-MT) and C-Methyltransferase (C-MT) domains are responsible 
for the N-or C-methylation of amino acid residues, thus making the peptide less susceptible to 
proteolytic breakdown. N-MT, which is usually located between the corresponding A- and T-
domains, catalyzes the transfer of S-methyl group from S-adenosyl methionine (SAM) to the 
α-amino group of the thiosterified amino acid (Fig. 5E) [89]. This reaction is accomplished 
prior to peptide bond formation, as determined for the enniatin synthetase [90]. C-MT 




Nonribosomal peptide synthetases require posttranslational modification to be functionally 
active. As it has been already mentioned, thiolation domains are unable to serve as transport 
proteins immediately after translation, resulting in blocking of peptide synthesis. A 
modification by transfer of the 4'-PP moiety of coenzyme A onto a conserved serine residue 
of each T-domain, converts the latter from apo- to holo-form and unblocks the synthesis. The 
mobile 4'-PP prosthetic group is about 20Å in length and since it is covalently bound as a 
phosphothioester to the multienzyme [91], it serves as a “flexible arm”, which initially 
accepts the activated substrates and later on delivers them to the next building-block [43, 55, 
57]. The conversion of T-domain is catalyzed by a dedicated 4'-phosphopantetheinyl 
 31
transferase (4'-PPTase) in a Mg+2-dependent way, thereby releasing 3', 5'-ADP (Fig. 6) [92, 
93]. Sfp and Gsp proteins control this reaction in B. subtilis and B. brevis, respectively [56, 
92, 93]. 
Recent studies have shown that Sfp accepts as substrates CoA derivatives, such as 
acetyl-CoA and aminoacyl-CoA [60, 94]. It is therefore likely that PPTases also modify the 
T-domains of NRPSs with acyl-4'-PP, rendering the enzyme inactive, as misprimed transport 
units are unable to accept activated amino acids. The activity can be restored by thioesterases 
II (TE-II) which hydrolyze the acyl-4'-PP, leaving only the 4'-PP bound, and are found in 
association with the peptide synthetases [95]. TE-IIs contribute as proofreading enzymes, 
since they preferentially hydrolyze acetyl-Ts versus aminoacyl or peptidyl-Ts [96]. 
Consequently, the capable of nonribosomal peptide synthesis holo-Ts are made either by 
direct priming of the apo-derivatives, catalyzed by PPTases ,or by deblocking misprimed 
derivatives, catalyzed by TE-IIs. 
 
 
Figure 6: Conversion of thiolation domain from apo- to holo-form. 
The 4'-phosphopantetheine moiety of coenzyme A is covalently attached onto an invariant serine 
residue of the thiolation domain (PCP) by dedicated phosphopantetheinyl transferases; thus PCP-
domains are activated. The figure is reproduced from [48]. 
 
Hybrid synthetases 
In recent years increasingly more peptide synthetases have been identified that contain 
domains normally present in fatty acid (FASs) or polyketide (PKSs) synthases. The first 
determined mixed NRPS-PKS biosynthetic gene cluster was that of rapamycin in 
Streptomyces hydroscopius, that contains a NRPS module for the incorporation of pipecolic 
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acid into the polyketide [97, 98]. In addition, synthesis of melithiazole and myxothiazole 
requires six multifunctional enzymes that switch back and forth between NRPS and PKS [99, 
100]. Furthermore, hybrid systems of peptide synthetase and fatty acid synthase, such as 
mycosubtilin and iturin were characterized in various Bacillus strains [63, 101]. Most 
recently, a genomic island (54kb) that consists of three nonribosomal peptide synthetases, 
three polyketide synthases and two hybrid NRPS/PKS synthases was identified among 
pathogenic E. coli strains of the B2 group. Interestingly, it was shown that E. coli strains 
expressing this gene cluster induce double-strand breaks in eukaryotic cells leading to cell 
death [102]. 
 
Fatty acid synthases (FASs) 
Fatty acids are essential for primary and secondary metabolism, because they are used as a 
form of energy storage, but also as building blocks for cell membranes or for nonribosomally 
synthesized peptides. The fatty acid synthase (FAS) of bacteria is a multienzyme complex that 
consists of individual, highly conserved enzymes [103, 104]. 
The first step in fatty acid production is the synthesis of malonyl-CoA from acetyl-CoA 
and CO2, which involves the biotin carboxyl carrier protein and is catalyzed by biotin 
carboxylase [105, 106]. The manolyl units are subsequently transferred to the 4'-PP of the 
holo-acyl carrier protein (ACP) by action of malonyl-CoA:ACP transacylase [107]. The 
acylated β-ketoacyl-ACP synthase III is then in the position to initiate chain elongation via 
condensation with malonyl-ACP and release of CO2, resulting in an ACP-bound acyl chain 
that is extended by C2 [108]. The β-carbon of the intermediate tethered to the ACP is reduced 
by a ketoacyl-ACP reductase (KR) and then dehydrated by a β-hydroxyacyl-ACP dehydratase 
(DH) (Fig. 7A). Finally, the enoyl-ACP reductase (ER) catalyzes reduction of the β-carbon to 
CH2. This elongated acyl-ACP can participate in subsequent rounds of synthesis that involve 
additional keto synthases (KSs) with different substrate selectivities [19, 100]. 
 
 
Polyketide synthases (PKSs) 
Polyketides are secondary metabolites which are synthesized on modularly organized giant 
multienzymes (polyketide synthases, PKSs) by decarboxylative Claisen condensations. In 
general, their biosynthetic pathway shares similarities to nonribosomally synthesized peptides 
and requires at least three domains [19]. 
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The acyltransferase (AT) domain is responsible for the selection of substrate, which can 
be malonyl-, methyl-, ethyl- or propylmalonyl-CoA [109]. This appears to be a significant 
difference to FASs whose substrate selectivity is limited only to malonyl-CoA. Further on, the 
AT-domain transfers the chosen substrate to the 4'-PP of the corresponding holo-ACP, which 
is analogous to the transport protein of FASs. Like in NRPSs, ACPs are posttranslationally 
modified by 4'-phosphopantetheinyl transferases [110]. Relocation of the malonyl-derivative 
occurs to an active cysteine residue of the KS-domain. The substrate of the next module binds 
to the ACP-domain and is decarboxylated, resulting in the free nucleophile necessary for the 
subsequent Claisen-condensation with the KS-bound ketide. Therefore, an enzyme-bound β-
ketoacyl intermediate is generated. Moreover, the produced intermediates are always 
transferred on the synthase according to the indicated elongation steps and finally a TE-
domain catalyzes the cleavage of the product by macrocyclization. Like in the case of NRPSs, 
the order of modules determines the sequence of polyketide synthesis (Fig. 7B) [19]. 
“Optional” domains, such as KR-, DH-, ER- domains, are also observed in PKSs, such 
as and they operate in a similar manner to those used by FASs [110, 111]. In general, even 
though fatty acid and polyketide synthases share striking architectural and organizational 
similarities with the peptide synthetases, they are more closely related to each other. 
 
Figure 7: FASs and PKSs; multienzyme complexes with distinct domains. 
A. Fatty acid synthases (FASs). A malonyl residue loaded onto the central ACP is condensed with an 
acyl chain bound to the KS. After condensation with release of CO2, the β-keto group is first reduced 
by a KR, dehydrated by a DH and finally reduced to the methyl group by an ER. ACP, acyl carrier 
protein; KS, keto synthase; KR, ketoacyl-ACP reductase; DH, β-hydroxyacyl-ACP dehydratase; ER, 
enoyl-ACP reductase.B. A fictitious dimodular polyketide synthase (PKS). The ACP of the first 
module is loaded with propionyl by the AT domain of the first module, while the second AT domain 
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loads its ACP with methylmalonyl. The propionyl residue is translocated to an active-site cysteine of 
the KS-domain, whereas the methylmalonyl is decarboxylated resulting in the nucleophile for the 
condensation with the KS-bound propionyl. The product of condensation is covalently tethered to the 
4'-PP present at the ACP of the second module. KR domain causes reduction of the β-carbonyl group 
to a hydroxyl one. ACP, acyl carrier protein; AT, acyl transferase; KS, keto synthase; KR, ketoacyl-
ACP reductase. The figure is reproduced from [19]. 
 
 
Distribution-organization-function of peptide synthetase operons in Bacilli 
Nonribosomally synthesized peptide antibiotics are widespread among Bacilli. Some of them 
are characteristically produced by only one member of the genus whereas others are more 
conserved. Nowadays more information concerning their diversity and distribution has 
accumulated, partly as a result of the increased number of sequenced genomes. Due to their 
conserved genetic structure and huge size, these synthetases can be easily recognized. 
Together with the polyketide synthases, they are the largest operons in the genome. In this 
section, an attempt will be made to summarize the current knowledge in respect with how the 
most well studied antibiotics of this group are organized and operate. 
Different Bacillus strains produce small cyclic peptides with long fatty moiety, the so-
called lipopeptides. Based on their structure, they can be generally classified into three 
different groups: i) the surfactin [112], ii) the fengycin [76, 113, 114] and iii) the iturin group 
[115]. 
Surfactin is a heptapetide linked via lactone bond to a β-hydroxy fatty acid composed 
of 13 to 15 carbon atoms (Fig. 8A) [116, 117]. Its operon comprises four open reading frames 
(ORFs) codifying the proteins SrfAA, SrfAB, SrfAC, SrfAD (Fig. 9A) [49, 118, 119, 120, 
121]. SrfAC protein ends with a TE-domain, responsible for peptide release and cyclization, 
whereas the following protein SrfAD shows high homology to TE-IIs. Remarkably, 
disruption of this gene leads to severe reduction but not abolishment of the antibiotic’s 
production [95, 96]. Furthermore, SrfAD acts in a double manner by hydrolyzing 4'-PP bound 
acetyl groups of misprimed NRPSs, according to the TEII ability [95] as well as by mediating 
the transfer of the fatty acid substrate to the Glu-module and stimulating β-hydroxyacyl-
glutamate formation [122]. In general, the number of amino acids and their configuration 
agrees totally with the organization of modules and domains on the surfactin synthetase, 
confirming the colinearity rule mentioned earlier. An example is the presence of two D-
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configurated amino acids that correspond exactly to the position of two epimerization 
domains. 
Surfactin is one of the best characterized lipopeptides, since it possesses various 
beneficial abilities. Firstly, surfactin is able to lower surface and interfacial tension, thanks to 
its amphiphilic structure. In particular, surfactin produced by B. subtilis ATCC 21332 is 
considered one of the most powerful biosurfactans, since it can lower the surface tension of 
water from 72 to 28 mN/m at concentrations as low as 24µM [123, 124]. Furthermore, 
surfactin is responsible for inhibition of fibrin clot formation [124] and for erythrocytes lysis 
[125]. Other beneficial properties, with potential biotechnological and pharmaceutical 
applications are. i) antitumor activity [126], ii) activity against enveloped viruses [127], iii) 
antibiotic function against the protoplast of B. megaterium [128] and Mycoplasma [129, 130]. 
Furthermore, the srf operon encodes the regulatory gene, comS [131], which is involved in the 
development of genetic competence, an active process aimed at acquiring new genetic 
material that enables the cell to survive under changing environmental conditions [1]. 
Surfactin is also essential for swarming motility [132, 133, 134, 135], a flagellum-driven 
social form of surface locomotion, as well as for formation of biofilms, i.e. surface-associated 
multicellular communities [136, 137]. 
Fengycin, synonymous to plipastatin, is a cyclic decapeptide linked to a β-hydroxy fatty 
acid moiety, with lengths that vary from 14 to 18 carbon atoms (Fig. 8E, 9B) [138, 139, 140]. 
Fengycin demonstrates strong surface activity, although lower compared to surfactin [141]. 
Fengycin is active against filamentous fungi [76, 139, 140], and inhibits the enzymes 
phospholipase A2 [142] and aromatase [143]. 
Iturin, mycosubtilin and bacillomycin belong to the same group of lipopeptides. These 
compounds consist of seven α-amino acids and one β-amino fatty acid, that distinguishes 
them from the already mentioned groups. The peptide moiety contains a tyrosine in the D-
configuration at the second amino acid position as well as two additional D-amino acids at 
positions three and six (Fig. 8B, 8C, 8D). Gene sequences encoding enzymes for biosynthesis 
of iturin A and mycosubtilin, but not bacillomycin D, have been reported (Fig. 9C) [63, 101]. 
Thereby it has been revealed that these lipopeptides are synthesized on hybrid synthases, 
since domains homologous to fatty acid and polyketide synthases are situated at their N- 
terminus [63]. These domains are absent from the peptide synthetases of surfactin and 
fengycin groups, so it appears very likely that these domains are involved in the incorporation 
of the β-amino fatty acid moiety into the peptides of the iturin group lipopeptides [63]. 
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Moreover, these antibiotics exhibit strong antifungal and hemolytic activities, whereas their 
antibacterial function is more limited [76, 115]. 
 
Figure 8: Schematic structure of various lipopeptides produced by Bacilli. 
A Surfactin, n = 10-12, B Iturin A, n = 10-13, C Mycosubtilin, n = 10-13, D Bacillomycin D, n = 10-
13, E Fengycin, n = 13-17, F Lichenysin, n = 9 -14 
 
 
The above mentioned lipopeptides are produced by different Bacilli, such as B. subtilis 
and B. cereus. However, one lipopeptide with similar structure to surfactin is exclusively 
composed by B. licheniformis [144, 145, 146]. It is designated as lichenysin and is a cyclic 
heptapeptide with a β-hydroxy fatty acid moiety, composed of 12-17 carbon atoms (Fig. 8F, 
9D) [146]. It demonstrates antimicrobial properties and reduces the surface tension of water 
[144, 146]. In particular, lichenysin A can cause a similar reduction in water surface tension 
as surfactin from B. subtilis ATCC 21332, albeit in lower concentration (12µM versus 24µM) 
[145]. 
Another nonribosomally synthesized antibiotic compound is bacitracin found in B. 
licheniformis [147, 148]. This thiazoline ring-containing dodecapeptide is synthesized by the 
large multienzyme complex BacABC (Fig. 9E) [149]. Bacitracin is a prominent inhibitor of 
cell wall biosynthesis and most active against Gram-positive bacteria [147]. However, B. 
licheniformis and several other Gram-positive bacteria are not susceptible to this antibiotic 
suggesting the existence of specific resistance mechanisms [150]. Its primary mode of action 
is the formation of a tight ternary complex with the peptidoglycan carrier C55-isoprenyl 
pyrophosphate (IPP) and a divalent metal cation. This carrier is responsible for the 
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translocation of cell envelope building blocks from the cytosol to the external side of the 
cytoplasmic membrane, where they are incorporated to the macromolecular network of the 
cell envelope (i.e. peptidoglycan, teichoic acids and polysaccharide capsule). Binding of 
bacitracin to IPP prevents its recycling by dephosphorylation to the monophosphate form that 
is normally reloaded on the inner face of the membrane [150, 151]. 
Another member of the Bacillus genus, B. brevis, produces two cyclic decapeptides, 
tyrocidine and gramicidin S (Fig. 5D, 9F) [52, 84, 152]. The first one characteristically 
contains a nonproteinogenetic residue, the L-ornithine and acts as antibiotic by membrane 
perturbation [17, 52]. Gramicidin S is synthesized on the enzymes GrsTAB, where only five 
amino acids are activated and incorporated. However, the peptide is dimerized to the 
decapeptide prior to its release. Furthermore, gramicidin S exhibits strong antibacterial 
activities against Gram positive and negative bacteria [153, 154], probably due to an 
interaction with membrane phospholipids. Thereby, gramicidin S causes a phase separation of 
negatively charged phospholipids from other lipids leading to a disturbance of the 




Figure 9: Schematic representation of peptide synthetase operons in Bacilli. 
The genes comprising each peptide synthetase operon and their sizes are indicated. Organisation 
within the modules is presented, while the respective activated amino acid are depicted within the 
adenylation domains. A. Surfactin operon in B. subtilis [49]. B. Fengycin operon in B. subtilis [140]. 
C. Iturin A and mycosubtilin operons in B. subtilis [63, 101]. D. Lichenysin A operon in B. 
licheniformis [146]. E. bacitracin operon in B. licheniformis [149]. F. Tyrocidine and gramicidin S 
operons in B. brevis [52, 152]. The figure is adapted from [157]. 
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Multiple control of expression of peptide synthetase operons in Bacilli. Export and 
immunity mechanisms. 
In the last few decades, the pathways that govern the synthesis of antibiotics on large 
multienzymes have been thoroughly studied. Significant progress has been made on the 
functional analysis of various domains as well as on the role of their assembly in the peptide 
synthetases. Moreover, high resolution structures obtained for several enzymatic subunits 
from different antibiotics led to a better understanding of their architectural organization, 
substrate specificity and catalytic action [70, 158, 159, 160]. In contrast, our knowledge 
concerning how the organism regulates expression of these systems or the mechanisms which 
govern export of the peptides and/or resistance to them is rather limited. An exception is the 
case of surfactin, for which studying the regulation of gene expression received increased 
attention due its connection with the development of genetic competence. 
The expression of surfactin is growth-phase dependent and is induced during transition 
to stationary phase [161]. Its transcription is driven by a σA-dependent promoter [161] and its 
expression is regulated via a complex network, including the two component regulatory 
system, ComAP [161, 162]. ComP is the sensor histidine kinase that is autophosphorylated 
after sensing increase in the concentration of the pheromone ComX [163]. The phosphoryl 
group is then transferred to the response regulator, ComA and activates it. Phosphorylated 
ComA can bind upstream of the srf operon and induce its expression. Therefore, systems 
involved in the phosphorylation / DNA-binding ability of ComA (ComXQ, RapC-CSF, RapF) 
modify indirectly the antibiotic’s expression [163, 164, 165, 166, 167]. PerR, a general 
repressor of the peroxide stress regulon, is shown to positively regulate surfactin in a direct 
manner, independently of ComA [168]. In contrast CodY, a GTP-activated global regulator, 
acts as a direct repressor under casamino acids rich conditions [169]. Furthermore, YerP, a 
protein homologous to the RND (resistance, nodulation and cell division) family of efflux 
pumps in Gram-negative bacteria, seems to contribute in secretion of surfactin and self-
resistance of the producer strain against it [170]. 
Knowledge on transcriptional regulation of the remaining lipopeptides is rather limited. 
The promoters of fengycin and iturin operons have been successfully identified and show 
similarity to a housekeeping σA promoter [101, 113]. Furthermore, deletion of degQ, a 
pleiotropic regulator gene that controls the production of several secreted and degradative 
enzymes [171], reduces severely the production of these antibiotics, via an unidentified 
mechanism [172, 173]. 
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All these lipopeptides are post-translationally regulated by sfp, a 4'-phosphopantetheinyl 
transferase which converts T-domains to their active form (see corresponding chapter; [92, 
137]. The importance of this gene is demonstrated in strains that contain intact synthetases but 
dysfunctional sfp. B. subtilis strain 168 contains intact srf and fen operons but is unable to 
produce the antibiotics, due to a frameshift mutation on the sfp gene [174]. However, when 
complemented with a functional 4'-PPTase, the antibiotic production of the strain is restored 
[172, 175]. 
Mechanisms that govern regulation of lichenysin and bacitracin are studied only in a 
preliminary basis. Lichenysin expression is dependent on the two component regulatory 
system ComAP [176]. In the case of bacitracin, an ABC transporter (BcrABC) conferring 
resistance to the producer strain against the antibiotic was determined [177, 178]. It is located 
about 3 kb downstream of the bacitracin biosynthetic operon bacABC and its expression is 
induced by the dodecylpeptide [150, 179]. Moreover, a two component regulatory system 
BacRS, situated between the bac operon and the bcrABC genes, negatively regulates 
expression of the transporter genes [150]. 
Transcription of the tyrocidine operon is driven by a typical σA promoter and its 
expression is induced at the end of exponential phase of growth. Spo0A, Spo0B and Spo0E, 
involved in the sporulation process, are required for full activation of the operon, whereas 
AbrB, a transition-phase regulator, acts as its repressor [180]. Further studies revealed that 
AbrB inhibits tyrocidine expression directly by binding to the upstream region of tycA [181]. 
Moreover, tycD and tycE, which are located downstream of the operon, show high similarity 
to members of the ABC transporter family and thus may confer immunity to the producer 
strain [52]. However, their role remains to be verified. 
 
Approaches to new antibiotics 
Years of research revealed that NRPS and NRPS-PKS hybrids can produce biologically active 
compounds exhibiting high antimicrobial activity. Their modular architecture allows the 
possibility to manipulate the enzymatic machinery in order to increase or alter their biological 
action. In the last decade, successful steps have been made in creating novel improved 
antibiotics by genetically redesigning natural synthesized compounds. 
Genetic engineering has been achieved using different approaches. The first approach 
was based on exchanging the A-T units of the terminal module of surfactin synthetase that is 
originally responsible for the incorporation of leucine. Different A-T units have replaced the 
already existing one and novel surfactins with aliphatic (Val), charged (Orn) and aromatic 
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(Phe) residues at position 7 were created. However, their hemolytic activity did not differ 
significantly from that of the wild type product [182]. Nevertheless, swapping of numerous 
domains indicated for the first time that a rational design of antibiotics is accomplishable 
[183]. 
A further strategy for constructing synthetic antibiotics involves entire module swapping 
as well as insertions or deletions of modules. Conistent to this concept, deletion of the second 
module of the srf operon produced a new hexapeptide surfactin [184]. Alternatively, the 
manipulation of the A-domain’s specificity via point mutagenesis can also result in novel 
antibiotics. The altered A-domain recognizes and activates a different amino acid, which is 
then incorporated in the polypeptide chain to yield a new product [185]. Another pathway to 
novel antibiotic production involves the replacement of TE-domains on the synthetase to 
force earlier release and cyclization [186]. It has been already shown that the bioactivity of 
many peptide antibiotics is attributed to small heterocyclic compounds, such as thiazoline and 
oxazoline, which are composed by heterocyclization domains present on the synthetases. 
Therefore incorporation of such domains on peptide synthetases could lead to new 
pharmaceutical substances [187]. 
Nowadays, there are an increasing number of examples for functional engineered 
peptide synthetases. Genetic redesign requires well-defined sequence information about the 
biosynthetic system that will be altered. Although this is often provided, manipulation has 
been unsuccessful in some cases, due to possible disruptions on some catalytic site(s) [182]. 
Therefore, information on domain structures as well as on possible protein-protein interaction 
sites between domains would improve manufacturing of novel antibiotic compounds. 
 
Miscellaneous antibiotics produced by Bacilli 
Bacilli do not produce only peptide antibiotics, but also several other secondary metabolites 
such as polyketides. Their biosynthesis occurs on PKSs by step-wise decarboxylative 
condensations (see chapter 1.3.2.4.2). Difficidin, oxydifficin as well as bacillaene are 
polyketides produced by various Bacilli strains and exhibit antibacterial activity. 
Posttranslational modification occurs by the 4'-PPTase Sfp [137]. Therefore, strains 
containing intact PKSs but defective sfp gene are deprived of polyketide production. 
Furthermore, some new antibiotics have been recently isolated from various Bacilli. One 
of them is bacilysocin, a phospholipid that accumulates within the cells. It possibly derives 
from phosphatidylglycerol via acyl ester hydrolysis, a reaction controlled by YtpA. 
Bacilysocin inhibits the growth of various organisms such as Staphylococcus aureus, 
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Saccharomyces cerevisiae and the fungi Candida pseudotropicalis, Cryptococcus neoformans 
[188]. Furthermore, Bacilli produce low weight phenylpropanol derivative substances named 
isocoumarins with antibacterial and anti-inflammatory activity. Among them, amicoumacins 
could be used for treatment of chronic gastritis and peptic ulcer in humans, as they act against 
Heliobacter pylori [189]. Moreover, 3, 3'-neotrehalosadiamine (NTD), an aminosugar 
antibiotic produced by B. pumilus and B. circulans, inhibits the growth of Staphylococcus 
aureus and Klebsiella pneumoniae. In B. subtilis production is achieved only in RNA 
polymerase mutated strains that show resistance to rifampicin and is driven by the operon 




Bacillus amyloliquefaciens and its numerous natural isolates are closely related to the already 
sequenced “Methuselah of the labs” Bacillus subtilis 168, but in parallel show broad 
biotechnological interest and often unique and remarkable characteristics. Since no 
representative of the B. amyloliquefaciens species had been yet sequenced, the molecular and 
biochemical work on these strains was hindered and the elucidation of the pathways that 
contribute to the organism’s characteristics remained incomplete. Therefore, our laboratory, in 
collaboration with the GenoMik Network in Göttingen, set out to map the sequence of the 
plant growth promoting strain of B. amyloliquefaciens FZB42. This strenuous work that 
started in 2001 comprised a big part of my research the past years. 
Nevertheless the primary focus of my work has been the elucidation and 
characterisation of pathways involved in the beneficial features of Bacillus amyloliquefaciens 
FZB42. For this scope and since the genome sequencing project did not immediately deliver 
results, alternative methods had to be employed in order to compare the FZB42 strain with its 
sequenced relative B. subtilis 168 and find the unique genomic regions that might be 
associated with the plant growth promoting abilities of Bacillus amyloliquefaciens FZB42. 
The finding of such gene candidates (by both genomic and non-genomic approaches) 
generated new questions that I explored to answer. What are their products and what is the 
mechanism of action? When and how are they produced? How is their expression regulated? 
What is the effect of global regulators in their expression? But before all these questions 
could be answered, a protocol had to be established for the genetic manipulation of the natural 
isolate strain of Bacillus amyloliquefaciens FZB42. 
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To conclude, my thesis aimed to provide a first insight view of the unique features that 
enable Bacillus amyloliquefaciens FZB42 to promote plant growth. In order to accomplish 
such a task, a dual genomics and functional genomics approach was adopted. In parallel to 
this, the elucidation of the organism’s genome sequence sets the ground for future work with 
other isolated strains of the same species and adds important information to the function and 





























Materials and Methods 
 
Chemicals and materials 
All chemicals and materials used in the present study are listed in table 1. 
 




[γ- 32P]ATP, Plus One Tris-Base, Plus One EDTA, Plus One boric acid, 
Ready to Go DNA labelled Beads 
BD Difco medium 3 
Biorad Blotting grade blotter non-fat dry milk 
Bioron Taq polymerase 
Fermentas DNA markers, dNTPs, prestained protein ladder, RevertAid M-MuLV 
reverse transcriptase (200U/µl), restriction endonucleases, RiboLock 
ribonuclease inhibitor (40U/ µl), T4 DNA ligase, T4 kinase, T4 
Polynucleotide kinase 
Fluka CaCl2, EDTA 
Macherey-Nagel Nitrocellulose membrane porablot NCL, Nucleo Spin ® Extract II, Nucleo 
Spin RNA L, Porablot NY plus, Protino® Ni-1000 kit 
Merck Meat extract 
MP Biomedicals Urea pure 
New England 
Biolabs 
MidRange II PFG marker, Vent Polymerase 
Promega BCIP (50 mg/ml), NBT (50 mg/ml), pGEM-T® Vector systems 
Qiagen QIAEX II gel extraction kit, QIAprep Spin mini prep kit, Qiaquick PCR 
purification kit 
Roche Anti-DIG AP, Ampicillin, blocking reagent, DIG-dUTP, kanamycin 
Roth Agarose, chloramphenicol, citric acid, CuSO4, DEPC, FeCl2, FeCl3, 
Fe2(SO4)3, formaldehyde, L-glutamic acid, glycerol, HEPES, IPTG, KCl, 
K2HPO4, H2KPO4, maleic acid, MgSO4, MnCl2, MnSO4, Na-acetate, Na-
citrate, Na2CO3, NaCl, NaOH, (NH4)2SO4, peptone, SDS, Proteinase K, 
Rotiphorese Gel 40 (19:1), Rotiphorese Gel 40 (29:1), TEMED, Tris, 
Triton-X 100, Tween 20, XGal, yeast extract, ZnCl2 
Santa Cruz Biot. His-probe H15 sc-803 rabbit polyclonal IgG (200 mg/ml) 
Serva Agar, APS, boric acid, casamino acids, DTT, EGTA, erythromycin, 
glucose, N-Lauroylsarcosine-sodium, lincomycin/HCl, MgCl2, MOPS, 
NaN3, Na2SO4, ONPG, L-tryptophan 
Sigma Oligonucleotides, Anti-rabbit IgG AP 
USB Low-melting point agarose, Thermo Sequenase cycle Sequencing kit 
 
Plasmids, bacterial strains and primers 




Table 2: Plasmids used in the present study 
Plasmid/reference Description 
pDG148/[191] E. coli and B. subtilis shuttle vector, IPTG-inducible Pspac promoter, 
Apr Kmr Phleor 
pDG268/[192] pBR322 derivarive with promoterless lacZ, integrative vector for 
recombination into B. subtilis amyE, Apr Cmr 
pGEM-T/Promega Cloning vector, Apr 
pECE73/[193] Cmr→Kmr exchange vector, Apr 
pMX39/[194] E. coli and B. subtilis shuttle vector based on pBR322 and PDB101, 
Apr Emr 
pQE60/Qiagen Expression vector, IPTG-inducible promoter, His6-Taq, Apr 
pREP4/Qiagen Repressor plasmid encoding lacI, Kmr 
pAK1a pGEM-T carrying 1,2 kb fragment of bmyA 
pAK2 pGEM-T carrying bmyA::Emr 
pAK3 pGEM-T carrying 1,3 kb fragment of fenA 
pAK4 pGEM-T carrying fenA::Cmr 
pAK5 pDG268 carrying a fragment of bmyD from -400 to +126 bp (relative 
to the start codon) 
pAK6 pDG268 carrying a fragment of bmyD from -183 to +126 bp (relative 
to the start codon) 
pAK7 pDG268 carrying a fragment of bmyD from -120 to +126 bp (relative 
to the start codon) 
pAK8 pDG268 carrying a fragment of bmyD from -30 to +126 bp (relative to 
the start codon) 
pAK9 B. amyloliquefaciens FZB42 integrative vector amy::lacZ, Apr Cmr, 
pDG268 derivative 
pAK10 pGEM-T carrying a kanamycin cassette, Kmr 
pAK12 pAK10 derivative carrying flanking regions of yvrGyvrH 
pAK15 pAK12 derivative;Kmr is replaced by Cmr 
pAK16 pAK9 carrying a fragment of bmyD from -400 to +126 bp (relative to 
the start codon) 
pAK17 pAK9 carrying a fragment of bmyD from -183 to +126 bp (relative to 
the start codon) 
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Plasmid/reference Description 
pAK18 pAK9 carrying a fragment of bmyD from -120 to +126 bp (relative to 
the start codon) 
pAK19 pAK9 carrying a fragment of bmyD from -30 to +126 bp (relative to 
the start codon) 
pAK25 Integrative vector carrying Cmr cassette flanked by bmyA-His6- Taq 
and BmyB sequences; pAK15 derivative 
pAK27 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of yerPyerO; pAK15 derivative; used for ∆yerPyerO::Cmr 
pAK29 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of sig01; pAK15 derivative; used for ∆sig01::Cmr 
pAK33 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of spaR; pAK15 derivative; used for ∆spaR::Cmr 
pAK35 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of sigW; pAK15 derivative; used for ∆sigW::Cmr 
pAK39 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of aat; pAK15 derivative; used for ∆aat::Cmr 
pAK41 Integrative vector carrying Cmr cassette flanked by sequences of 
bmyB-moduleB1 and moduleB2 ; pAK15 derivative 
pAK43 Integrative vector carrying Cmr cassette flanked by sequences of 
bmyB-moduleB2 and moduleB3 ; pAK15 derivative 
pAK45 Integrative vector carrying Cmr cassette flanked by sequences of 
bmyB-moduleB3 and moduleB4 ; pAK15 derivative 
pAK47 Integrative vector carrying Cmr cassette flanked by sequences of 
bmyB-moduleB4 and bmyC- moduleC1 ; pAK15 derivative 
pAK49 Integrative vector carrying Cmr cassette flanked by sequences of 
bmyC-moduleC1 and moduleC2 ; pAK15 derivative 
pAK51 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of codY; pAK15 derivative; used for ∆codY::Cmr 
pAK54 pQE60 derivative carrying degU 
pAK58 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of sigD; pAK15 derivative; used for ∆sigD::Cmr 
pAK60 Integrative vector carrying Cmr cassette flanked by neighbouring 
sequences of sigH; pAK15 derivative; used for ∆sigH::Cmr 
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Plasmid/reference Description 
pAK61 pGEM-T carrying 1,2 kb fragment of rapX 
pAK63 pGEM-T carrying rapX::Cmr 
pAK64 pDG148 carrying a bp fragment of degQ 
 




Table 3: Bacterial strains used in the present study 
Strain Genotype Reference 
B. amyloliquefaciens FZB42 Wild type FZB Berlin 
B. amyloliquefaciens FZB45 Wild type FZB Berlin 
B. amyloliquefaciens FZB24 Wild type FZB Berlin 
B. subtilis 168 trpC2 Laboratory stock 
B. subtilis MO1099 JH642; MLSr; amyE::erm trpC2 pheA1 [195] 
B. subtilis FZB37 Wild type FZB Berlin 
AK1 FZB42 bmyA::Emr This study 
AK2 FZB42 fenA::Cmr This study 
AK3 FZB42 bmyA::Emr fenA::Cmr This study 
AK4 MO1099 amyE::PbmyD400bp-lacZ (Cmr) This study 
AK5 MO1099 amyE::PbmyD183bp-lacZ (Cmr) This study 
AK6 MO1099 amyE::PbmyD120bp-lacZ (Cmr) This study 
AK7 MO1099 amyE::PbmyD30bp-lacZ (Cmr) This study 
AK8 FZB42 ∆RBAM01839/RBAM01840::Cmr This study 
AK9 FZB42 amyE::PbmyD400bp-lacZ (Cmr) This study 
AK10 FZB42 amyE::PbmyD183bp-lacZ (Cmr) This study 
AK11 FZB42 amyE::PbmyD120bp-lacZ (Cmr) This study 
AK12 FZB42 amyE::PbmyD30bp-lacZ (Cmr) This study 
AK13 FZB42 amyE::P0-lacZ (Cmr) This study 
AK14 AK9 yczE::Emr  This study 
AK15 FZB42 bmyA-His6-Taq::Cmr This study 
AK16 FZB42 amyE::PbmyD400bp-lacZ (Kmr) This study 
AK17 FZB42 amyE::PbmyD183bp-lacZ (Kmr) This study 
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Strain Genotype Reference 
AK18 AK16 ∆RBAM01839/RBAM01840::Cmr This study 
AK19 AK17 ∆RBAM01839/RBAM01840::Cmr This study 
AK20 AK16 ∆yerPyerO::Cmr This study 
AK21 AK17 ∆yerPyerO::Cmr This study 
AK22 AK16 comA::Emr This study 
AK23 AK17 comA::Emr This study 
AK24 FZB42 ∆yerPyerO::Cmr This study 
AK25 FZB42 ∆sig01::Cmr This study 
AK26 AK16 yczE::Emr This study 
AK27 AK17 yczE::Emr This study 
AK28 AK16 ∆sig01::Cmr This study 
AK30 AK16 ∆spaR::Cmr This study 
AK31 FZB42 ∆spaR::Cmr This study 
AK32 AK16 degU::Emr This study 
AK33 AK17 degU::Emr This study 
AK34 AK16 ∆sigW::Cmr This study 
AK35 AK17 ∆sigW::Cmr This study 
AK36 FZB42 ∆sigW::Cmr This study 
AK37 AK17 ∆spaR::Cmr This study 
AK39 FZB42 bmyB-moduleB2::Cmr This study 
AK40 FZB42 bmyB-moduleB3::Cmr This study 
AK41 FZB42 bmyB-moduleB4::Cmr This study 
AK42 FZB42 bmyC-moduleC1::Cmr This study 
AK43 FZB42 bmyC-moduleC2::Cmr This study 
AK44 FZB42 ∆aat::Cmr This study 
AK45 FZB42 ∆codY::Cmr This study 
AK46 AK16 ∆aat::Cmr This study 
AK47 AK17 ∆aat::Cmr This study 
AK48 FZB42 sigX::Kmr  This study (pECE73→UL1) 
AK49 FZB42 sigX::Kmr ∆sigW::Cmr This study 
AK50 FZB42 ∆sigH::Cmr This study 
AK51 FZB42 ∆sigD::Cmr This study 
AK52 AK16 ∆sigH::Cmr This study 
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Strain Genotype Reference 
AK53 AK17 ∆sigH::Cmr This study 
AK56 AK16 ∆sig01::Cmr This study 
AK57 FZB42 sigB::Emr rapX::Cmr This study 
AK58 FZB42 degU::Emr with pAK64 (Kmr, 
Phleor) 
This study 
AK59 FZB42 rapX::Cmr This study 
AK60 AK4 with pAK64 (Kmr, Phleor) This study 
AK61 AK5 with pAK64 (Kmr, Phleor) This study 
CH1 FZB42 srfAA::Emr [196] 
CH3 FZB42 sfp::Emr [197] 
CH4 FZB42 yczE::Emr X.-H.Chen, unpublished 
CH23 FZB42 comA::Emr X.-H.Chen, unpublished 
CH30 FZB42 sigV::Emr X.-H.Chen, unpublished 
CH33 FZB42 sigB::Emr X.-H.Chen, unpublished 
TF1 FZB42 degU::Emr T.-F. Huang, unpublished 
UL1 FZB42 sigX::Emr U. Leppert, diploma work 
E. coli DH5α supE44 ∆lacU169 (Φ80 lacZ∆M15) 
hsdR17 recA1 gyrA96 thi-1 relA1 
Laboratory stock 
E. coli JM101 supE thiA (lac-proAB) tra D36, pro AB , 
lac 9,Z A M15 
Laboratory stock 





Table 4: Primers used in this study 
Primer name 
(restriction site) 
Sequence (5' to 3' end) Use 
pRB1601 [6] TAATACATGCAAGTCGAGCGG Riboprint analysis 
pRB1602 [6] ACGTATTACCGCGGCTGCTGGC Riboprint analysis 
ssh1 TCGAGCGGCCGCCCGGGCAGGT SSH 
ssh2 AGCGTGGTCGCGGCCGAGGT SSH 





Sequence (5' to 3' end) Use 
bmyAb CGATTCAGCTCATCGACCAGGTAGGC pAK2 
fenAa AAGAGATTCAGTAAGTGGCCCATCCAG pAK3 
fenAb CGCCCTTTGGGAAGAGGTGC pAK3 
cm1KpnI  TGAGGTACCATGTTTGACAGCTTATCATCGGC pAK4 
cm2HindIII TATGCCAAGCTTTTCTTCAACTAACGGGGCAGG pAK4, pAK63 






bmyB1(SpeI) TCATACTAGTGATGAAGAAGACGGCCTAAGCG pAK25 
bmyB2(PstI) TCATCTGCAGATTCGCCTTCTCATTCAGTTCCC pAK25 
bmyB12b1(SphI) TCATGCATGCAACAGCTTTTGGAGCAGACGCG pAK41 




bmyB12f2(SalI) GCAAGTCGACGATTAGTACGCCTTTTGGCC pAK41 
bmyB23b1(SphI) TCATGCATGCTATCCATTGACGAATTGGATCAGC pAK43 
bmyB23b2(AgeI) AACTACCGGTGAAGACAACGTCTGCGGACCC pAK43 
bmyB23f1(SpeI) GAGGACAGCACTAGTGCTGATACG pAK43 
bmyB23f2(SalI) GCAAGTCGACGTCACAACATGAGTGCAGCTGC pAK43 
bmyB34b1(SphI) ATTCGCATGCTCAAGCGAAAGAAGAACAGGCGG pAK45 
bmyB34b2(AgeI) TTACACCGGTCGTTCGTATCGCCAGTGTGCC pAK45 
bmyB34f1(SpeI) TCTTACTAGTTTCCGGGAGTACGTGCAGG pAK45 
bmyB34f2(SalI) GCTTTTCTCGTCGACTGCGGC pAK45 
bmyB4C1b1(SphI) ATTCGCATGCCAGGAGTTGTTCTGGAGCAGC pAK47 
bmyB4C1b2(AgeI) CGTTTGATCACCGGTACGTTCCG pAK47 
bmyB4C1f1(SpeI) AAAGGGCGAATCAACTAGTTCG pAK47 
bmyB4C1f2(SalI) CAAACTTCTCGGCCGTCGACTCGGG pAK47 
bmyC12b1(SphI) ATCAACAAGATCACAAGCATGCGTCAG pAK49 
bmyC12b2(AgeI) AATGCGTCTGCAACCGGTCGACACTTGC pAK49 
bmyC12f1(SpeI) TCTTACTAGTAAATTATGAAGCAAATGGCGGACG pAK49 
bmyC12f2(SalI) GCAAGTCGACTTCGGAATAATCACTAATTTGCCC pAK49 
bmyD1(EcoRI) CCGGAATTCCAGATCCATCTCTTGCGCC pAK5, pAK16, 
EMSA, FT 





Sequence (5' to 3' end) Use 
bmyD3(EcoRI) CCGGAATTCCGAACAATAACTCCTCCG pAK7, pAK18 
bmyD4(EcoRI) CCGGAATTCTCCCCTGTTCAATATGATCGGAGG pAK8, pAK19 
bmyD5(BamHI) TCGGGATCCCAAGGAGATCGCATCGCTCG pAK5 to pAK8, 
pAK16 to pAK19 
FM2 TATCGGCCTCAGGAAGATCGCACTC Fusions control 
amyEf1(XbaI) TCGATTCTAGACGTCATCGGTCAAAAACGGG pAK9 
amyEf2(XhoI) TGACTCTCGAGCGGGAACCAATCACTGCCC pAK9 
degQ1(HindIII) ACTCAAGCTTAAAAAAAGGAGTGTGGAAACGG pAK64 
degQ2(SphI) ACTCGCATGCTGCACAAAAAAAAGACTTGTTTCC pAK64 
spac GACTATTCGGCACTGAAATTATGGG pAK64 control 
rev1 CCTACAAATTGAGACCCTTGTCCAGG PE (Pbmy), EMSA, 
FT 
rev2 TAAAACATGGGGGTTTCACCG PE (Pbmy) 
sigHb1(ApaI) ATTCGGGCCCACATGATTGGAGCTTGGCCG pAK60 
sigHb2(AgeI) TTACACCGGTAATGACCTGCTCGTCCTCC pAK60 
sigHf1(SpeI) ATTCACTAGTGATAATGCCCTGCAGCGCG pAK60 
sigHf2(SalI) TTACGTCGACGGCTCAGGGCCTATGAATCC pAK60 
yvrGb1(SpeI) TTTCACTAGTATCACCATTCACAGCACCGC pAK15 
yvrGb2(PstI) TCTTCTGCAGCTCCTTCGCATCATTTTGGC pAK15 
yvrHf1(SphI) TTCTGCATGCTTTGAACGATCCGCAGGC pAK15 
yvrHf2(NcoI) TATCTCCATGGCTTATTGCGATGCTGATGCC pAK15 
gatB1(ApaI) TACTGGGCCCTTTGAACTGCGAAATCGCAACGG pAK27 
gatB2(SphI) TACTGCATGCATCTTGTTGACCATCGGCGGG pAK27 
yerQ1(SpeI) TACTACTAGTAATCCGACTTCAGGACGGGAGC pAK27 
yerQ2(PstI) TTACTCTGCAGTTCGCCGTCCAGGTTCAGCTGC pAK27 
spaG1(AgeI) GTTTGCCACCGGTCGAATCGCTCC pAK33 
spaG2(SphI) CCGTGCTTTTACGATAGCATGCGGGCCG pAK33 
spaK1(PstI) GTAAGCCCCCTGCAGTGATGCCCC pAK33 
spaK2(SpeI) GGGGTGTCGGATACTAGTGGGAATAGC pAK33 
sigWb1(SphI) CGTAACGTCTTCGCCGCATGC pAK35 
sigWb2(AgeI) CCTCTGCCCTTCACCGGTCTG pAK35 
sigWf1(SpeI) GGCTCTTAGAAAACTAGTGAGGG pAK35 
sigWf2(PstI) GTTATCGCTTGGTCCTGCAGCC pAK35 
srfDDb1(SphI) ATTCGCATGCTATTCCGCATCATTCCGCC pAK39 




Sequence (5' to 3' end) Use 
aatf1(SpeI) ACTTACTAGTGTTGAAGAAGAACACATCGC pAK39 
aatf2(SalI) TCTTGTCGACTTTCCTGATCCTGTTGTCCG pAK39 
asig01a(EcoRI) TTCGGAATTCGAAGCAGGAGCTGGAAAAGGAGG pAK29 
Asigo1b(PstI) TTCGCTGCAGGCTTTCGGGTCTATCGGTTTGC pAK29 
guaA1(SphI) CAAGGCATGCATGAAGCGGACAAGCTGAAAGG pAK29 
guaA2(AgeI) CAAGACCGGTCTTCCTTCACCTTATCCACCTCC pAK29 
sigDb1(ApaI) GATTCGGGCCCGCTTTATGAGCCGTGCGG pAK58 
sigDb1(AgeI) TTACACCGGTCCGGCTTTAGGATCTTTCC pAK58 
sigDf1(SpeI) ATTCACTAGTACAGATTCATTCAAAGGCGC pAK58 
sigDf2(SalI) TTACGTCGACCGTTTGCAGCACCCTCTGC pAK58 
codYb1(SphI) ATTCGCATGCCAGGCAAATTAATCGATATGG pAK51 
codYb2(AgeI) TTACACCGGTATAAATAATCCTCCTAGAATTCC pAK51 
codYf1(SpeI) TTCTGAACAACTAGTTCCGTATCG pAK51 
codYf2(SalI) GCAAGTCGACATTTTCCTCCTGTCAAGACGG pAK51 
degU60a(NcoI) AATCCATGGCTAAAGTAAATATTGTTATTATCG pAK54 
degU60b(BglII) AATAGATCTACGCATCTCTACCCAGCCG pAK54 
bmyD6 AGTCTTAAAGAGAGATGATGAAAGCC n.r.EMSA 
rapX1 GATTTGTTCGGCTTGTGCCGTTGAAC pAK63 
rapX2 TACTTGTCAGACTGTGACGGCG pAK63 
cm1(HindIII) TTCTAAGCTTCATGTTTGACAGCTTATCATCG pAK63 
yczeu CGGCAAAATAAAACGTCCAGCG PE(PyczE) 
 
FT, DNAse I footprinting; PE, primer extension; Pbmy, promoter of the bmy operon; PyczE, promoter of 





2.3 Media and supplements 
All media used in this work were prepared and sterilized according to [198, 199]. 
Supplements with different antibiotics and compounds are listed in table 5. For antibiotic 
production and mass spectrometry measurements, bacteria were grown either in Landy 




●LB (Luria-Broth) medium ●Landy medium 
1 % w/v peptone  2% w/v  glucose 
0,5 % w/v yeast extract  0,5 % w/v  Na-glutamate 
0,5 % w/v NaCl   2 mM   MgSO4 
6,7 mM  KCl 
0,007 mM  KH2PO4 
0,015x10-3 % w/v  Fe2(SO4)3 
5x10-4 % w/v  MnSO4 
0,016x10-3 w/v CuSO4 
 
●Naehr agar      ●ACS medium 
0,5 % w/v peptone    10% w/v sucrose 
0,3 % w/v meat extract    0,06 M citric acid 
1,5 % w/v agar     0,028 M Na2SO4 
0,5 % w/v yeast extract 
0,032 M (NH4)2HPO4 
0,01 M KCl 
2 mM  MgCl2 x6H2O 
0,001% w/v ZnCl2 
0,0024% w/v FeCl2 x 6H2O 
0,018 % w/v MnCl2 x 4H2O 
 
Fungi were grown on “potato agar” at room temperature. When fungi and bacteria had to be 
simultaneously grown on plates, then Waksman agar was used and the microorganisms were 
let to grow at 27°C. 
 
●Potato agar      ●Waksman agar 
4% w/v Potato puree (without milk)  0,5% w/v peptone 
2% w/v glucose    1% w/v glucose 
2% w/v agar     0,085 M NaCl 
0,3% w/v yeast extract 
2% w/v agar 
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Table 5: Supplements 
Supplement Final concentration 
Agar 1,5 % w/v, 0,75 % w/v (soft agar plates) 
Amplicillin 100 µg/ml 
Chloramphenicol 20 µg/ml (for E. coli), 5 µg/ml (for Bacilli) 
Erythromycin 1 µg/ml (for Bacilli) 
IPTG 1 mM 
Kanamycin 20 µg/ml (for E. coli), 5 µg/ml (for Bacilli) 
Lincomycin 25 µg/ml (for Bacilli) 
XGal 40 µg/ml 
 
 
Molecular Biology techniques 
Standard molecular biology methods 
DNA manipulation, such as digestion with restriction endonucleases and ligation, was 
performed according to the instructions supplied by the manufacturer. Agarose-gel-
electrophoresis, fluorescent visualization of DNA with ethidium bromide, spectrophotometric 
quantitation of DNA as well as preparation of CaCl2-competent E. coli cells followed by 
transformation of plasmid DNA were carried out with standard procedures described by 
[198]. Bacterial chromosomal DNA from Bacilli was prepared as described by [202]. 
Polymerase chain reaction (PCR) was done using the GeneAmp PCR system 2700 (Applied 
Biosciences) according to [203], under the appropriate conditions in each case. Ligation of 
PCR products to pGEM-T vector was carried out following the instructions of the 
manufacturer (Promega). Plasmid DNA isolation and recovery of DNA from agarose gels 
were performed with QIAprep Spin mini prep kit and QIAEX II gel extraction kit, 
respectively. 
 
Transformation in Bacillus subtilis 
Competent cells of Bacillus subtilis were prepared according to the protocol published by 
[204]. Cells were grown overnight in 10 ml KM1 buffer at 32°C on a rotary shaker (150 rpm) 
and the next morning were 1:10 diluted in 50 ml KM1 buffer. Cells were further grown at 
37°C under vigorous shaking (175 rpm). Every 30 minutes, samples were collected and the 
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optical density at 600 nm was determined. At the beginning of stationary phase the culture 
was diluted 1:10 in 100 ml KM2 buffer and was further incubated at 37°C for 75 minutes (75 
rpm). Subsequently the cells were harvested by a 10 minute centrifugation at 5000 rpm (room 
temperature) and the pellet was resuspended in 2 ml of the supernatant. Aliquots of 0,5 ml 
competent cells with 10% glycerol were stored at -80°C. 
For the transformation, one aliquot was unfrozen by short incubation at 37°C. 1 µg of 
the desired DNA (chromosomal or linearized/circular plasmid DNA) was added and cells 
were incubated at 37°C for 30 minutes (50 rpm). Subsequently, 0,5 ml of LB medium, 
containing inducing concentration (0,1 µg/ml) of the appropriate antibiotic was added to the 
cells and they were further grown at 37°C for 75 minutes (200 rpm). Aliquots of the culture 
were plated on selective agar plates. 
 
Buffers 
●KM1 buffer   ●KM2 buffer    ●10 x SMM buffer 
1 x SMM buffer  1 x SMM buffer   0,15 M (NH4)2SO4 
1mM  MgSO4  1 mM MgSO4   0,8 M  K2HPO4 
0,025 M glucose 0,015M glucose  0,45 M H2KPO4 
0,04% w/v casamino acids 5x10-4 % w/v casamino acids 0,034 M Na-citrate 
0,005% w/v tryptophan 0,005% w/v tryptophan 
1 mM  CaCl2 
 
 
Transformation in Bacillus amyloliquefaciens 
Competent cells of Bacillus amyloliquefaciens were obtained by modifying the two-step 
protocol published by [205]. Cells were grown overnight in LB medium at 28°C (170 rpm). 
The next day, they were diluted in glucose-casein hydrolysate-potassium phosphate (GCHE) 
buffer to an OD600 of 0,3. The cell culture was then incubated at 37°C under vigorous shaking 
(200 rpm) until the middle of exponential growth (OD600 ~1,4). Dilution with an equal volume 
of GC medium followed and the cells were further incubated under the same conditions for 1 
hour. Further on, the culture was divided in 2 ml Eppendorf tubes and cells were harvested by 
centrifugation at 6000 rpm for 5 minutes (room temperature). The pellets were resuspended in 
200 µl of the supernatant and the desired DNA (1 µg) with 2 ml transformation buffer was 
added to them. After incubation at 37°C under shaking at 75 rpm for 20 minutes, 1 ml LB 
medium containing sublethal concentration (0,1 µg/ml) of the appropriate antibiotic was 
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●GCHE buffer     ●GC buffer 
1 x   PC buffer    1 x  PC buffer 
0,1 M  glucose    0,1 M  glucose  
0,005% w/v tryptophan    0,005% w/v tryptophan 
0,04 M FeCl3 / Na-citrate   0,04 M FeCl3 / Na-citrate 
0,25% w/v potassium glutamate   3 mM  MgSO4 
3 mM  MgSO4 
0,1% w/v casein hydrolysate 
 
●10 x PC buffer     ●Transformation buffer 
0,8 M  K2HPO4    1 x  SMM buffer  
0,45 M H2KPO4    1 mM  EGTA 
0,028 M Na-citrate    0,025 M glucose 
       0,02 M MgCl2 
 
Suppression Subtractive Hybridization (SSH) 
Suppression Subtractive Hybridization (SSH) is applied to two strains of the same species or 
genus and aims to find major sequence differences between them. SSH identifies unique DNA 
sequences of target strain (tester) that are absent from the reference strain (driver). The 
method was performed according to the protocol published by [206] and [207]. 
In principal, genomic DNA from two strains was digested separately with RsaI, yielding 
fragments of 100 to 1000 bp. The tester DNA was subdivided into two portions, each of 
which was ligated with a different adaptor (1 and 2R, see their sequence at the end of this 
section). The ends of the adaptors are unphosphorylated and thus only one strand of each 
adaptor attaches to the 5' end of the DNAs. At first ligation of the adaptor to the fragments of 
the tester strain was performed for 16 hours at room temperature. The mixture was then 
heated at 72°C for 5 min in order to inactivate the ligase. 
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Subsequently two hybridizations were performed. In the first one, excess of driver DNA 
was added to each adaptor-ligated lot separately. After denaturation of the two mixtures at 
98°C for 2 minutes, the samples were allowed to anneal at 63°C for 90 minutes thus 
generating type a, b, c, d molecules (Fig. 10). During the second hybridization, the two 
primary hybridization samples are mixed together without denaturation in order to assure that 
the remaining single-stranded tester-specific DNAs can form the new type e molecules. The e 
molecules are double-stranded tester-specific DNAs with different ends that have resulted 
from ligation with different adaptors. Fresh denaturated driver is added to the mix to further 
enrich fraction e for tester-specific sequences. The samples were allowed to anneal at 63°C 
for 16 hours. 
The entire population of molecules was then subjected to PCR. First the reaction mix 
was incubated in the thermal cycler at 72°C for 2 min in order for the adaptors to be extended 
(their recessed 3' ends were filled in during this step). PCR was performed using primers 
ssh1/ssh2 (Table 4), that annealed on the adaptors 1 and 2R respectively [Tden=94°C (30 sec), 
Tanneal=66°C (30 sec), Text=72°C (30 sec) for 35 cycles]. During the PCR, molecules a and d 
were missing the primer-annealing sites while type b molecules formed a panhandle-like 
structure. As a result, these three types of molecules could not be amplified. Type c molecules 
had only one primer annealing site and were thus amplified linearly. Due to the suppression 
PCR effect only type e molecules that had two different adaptors and contained tester-specific 
sequences could be exponentially amplified. The substracted DNAs were cloned into pGEM-
T vector and sequenced. 
 









50 mM HEPES-HCl PH=8.0 
0,5 mM MgCl2 
0,2 mM EDTA PH=8.0 
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Figure 10: Schematic diagram of Suppression Subtractive Hybridization. 
Tester DNA fragments that are ligated with adaptors 1 and 2R separately are further hybridized 
separately with excess of driver DNA. The samples are mixed together without denaturation and are 
hybridized in the presence of fresh denaturated driver. After the second hybridization, the PCR 
mixture is incubated at 72°C for 2 minutes in order for the recessed 3' ends of the adaptors to be filled 
in. Type a, b and d molecules cannot be amplified, due to lack of primer annealing site (a and d) and 
to formation of a panhandle-like structure (b).Type c molecules have only one primer annealing site 
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and thus are amplified linearly. Type e molecules are amplified exponential only if the sequence is 
present in the tester strain but absent from the driver strain. Solid lines stand for RsaI digested DNAs. 
Filled boxes represent the outer identical parts of adaptors 1 and 2R. Clear and shaded boxes indicate 
the inner parts of adaptors 1 and 2R, respectively and correspond to the sequence of primers ssh1, 
ssh2. The figure is reproduced from [207]. 
 
Pulsed Field Gel Electrophoresis (PFGE) 
Pulsed Field Gel Electrophoresis allows size separation of DNA fragments ranging from a 
few kilobase pairs to 10 megabase pairs. It operates by applying electric fields from different 
angles, thus making even very large DNA fragments to move through the gel and be 
efficiently separated. DNA is embedded in agarose in order to prevent shearing during 
purification. 
Mid-exponential-phase Bacillus cells were used to prepare DNA for the PFGE [208]. 
After centrifugation for 10 minutes at 4°C and 4000 rpm, the pellet was resuspended in wash 
buffer. Plugs of cell suspensions prepared by mixing with 1% low-melting point agarose were 
first incubated overnight with lysis buffer at 56°C and were subsequently incubated overnight 
with digestion buffer at 50°C. After incubation with 1 x TE buffer containing 100 µM PMSF 
for 1 hour at 37°C, the plugs were stored at 4°C in 1 x TE buffer. Digestion was performed 
overnight using SfiI according to the instructions of the manufacturer and was stopped by 
addition of stop buffer. The plugs were loaded on a 1,2 % agarose gel in TBE buffer and 
PFGE was performed at 10°C using the Gene navigator electrophoresis unit of Pharmacia 
Biotech. Direction of the applied electric fields (160V) changed every 2 seconds for the first 2 
hours of the run, every 10 seconds for the next 8 hours, every 25 seconds for the next 8,5 
hours and every 40 seconds for the last 6 hours of the run. Visualization of the DNA was 




●Wash buffer     ●Lysis buffer 
10 mM Tris-HCl PH=7.2   10 mM Tris-HCl PH=7.5 
200 mM NaCl     50 mM NaCl 
100 mM EDTA PH=8.0   100 mM EDTA PH=8.0 
0,1 % w/v lysozyme 
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●Digestion buffer      ●Stop buffer 
0,5 M   EDTA PH=8.0   10 mM Tris-HCl PH=8.0 
1 % v/v  N-Lauroylsarcosine-sodium  50 mM EDTA PH=8.0 
0,05 % w/v  Proteinase K 
Hybridization analysis of Southern blots 
Southern blot is a way of permanently immobilizing DNA (that has been separated by agarose 
gel electrophoresis) to a solid support. It is designed to locate a particular sequence of DNA 
within a complex mixture, such as an entire genome. Hybridization and detection occurs by 
“anealling” with a complementary labelled DNA probe. 
 
Synthesis of DIG-labelled probe 
For each southern hybridization, an appropriate probe was labelled with Digoxigenin-11-
dUTP (DIG-dUTP), according to the Ready-to-Go kit from Roche. The desired DNA region 
was amplified by PCR and purified, prior to labelling. 100 ng of the PCR fragment were 
denaturated by heating at 100°C for 10 minutes and then mixed with 5 µl dCTP (10 mM), 2,5 
µl DIG-dUTP (1mM) to a final volume of 50 µl. The mixture was incubated at 37°C for 1,5 
hours and was stored at -20°C until use. 
 
Preparation of samples; transfer and fixation on a membrane 
1-2 µg of the chromosomal DNA in question were digested overnight with a suitable 
restriction endonuclease. Samples were initially separated on a 0,8 % agarose gel in 1 x TAE 
buffer at 70 Volt. The gel was washed twice for 20 minutes, initially with denaturation buffer 
and subsequently with neutralization buffer. Transfer on a nylon membrane was performed 
using the Biorad vacuum blotter (model 785). The DNA was fixed permanently on the 




●Denaturation buffer    ●Neutralization buffer 
1,5 M  NaCl     1,5 M   NaCl 
0,5 M  NaOH     1 M   Tris-HCl PH=8.0 
 
 61
Hybridization and detection 
The membrane was initially incubated for 1 hour at 65°C with 40 ml hybridization buffer and 
was hybridized overnight at 55°C with 5-10 ml hybridization buffer containing 5-25 ng/ml of 
denaturated DIG-labelled probe. The membrane was washed twice for 15 minutes, first with 2 
x SSC/0,1 % SDS at room temperature and then with 0,5 x SSC/0,1 % SDS at 55°C. 
Detection was achieved by a colorimetric approach. The membrane was first 
equilibrated with P1-DIG buffer and was then incubated for 30 minutes with P1-DIG buffer 
containing 3,75 units of the antibody Anti-Digoxigenin-Alkaline-Phosphatase. Unbound 
antibody was removed after a fifteen minute washing step. Addition of 10 ml Ap buffer 
containing 2,25 mg nitroblue tetrazolium salt (NBT) and 1,75 mg 5-bromo-4-chloro-3 –
indolyl phosphate (BCIP) to the membrane and incubation in the dark allowed visualization 
of the hybridized DNA with our labelled probe. 
 
Buffers 
●Hybridization buffer     ●20 x SSC 
5 x  SSC      3 M  NaCl 
1 % w/v blocking reagent    0,3 M  Na-citrate 
0,1 % v/ N-Lauroylsarcosine-sodium 
0,02 % w/v SDS 
 
●P1-DIG buffer  ●Wash buffer  ●Ap buffer 
0,1 M  Maleic acid 0,1 M Maleic acid  0,1 M Tris-HCl PH=9.5 
0,15 M NaCl  0,15 M NaCl  0,1 M  NaCl 
1 % w/v blocking reagent/0,3 % v/v Tween-20 0,05 M MgCl2 
 
Denaturating Gel Electrophoresis for Sequencing 
Samples from primer extension, DNAse I footprinting and sequencing reactions were 
analysed on denaturating sequencing gels. High concentrations of urea in the gel secured that 
the DNA was completely denaturated and thus could be better separated. 
The gel was let to prerun before loading the samples for 1 hour at 60 Watt in 1x TBE 
buffer, using the SequinGen Sequencing Cell of Biorad. After loading the samples, DNA 
separation was allowed for approximately 2 hours more using the same running conditions. 
The gel was dried at 80°C for 1 hour using the vacuum SlaB Gel Dryer Model SE1160. An IP 
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screen was put on the top of the dried gel and visualization was achieved using the Molecular 
Imager FX scanner (Biorad) or the phosphoimager 445SI (Molecular Dynamics). 
 
●7 %  Denaturating gel 
8 M  Urea 
1 x  TBE 
7%  Rotiphorese Gel 40 (29:1) 
0,08% w/v APS 
0,06 % v/v TEMED 
Radioactive labelling of oligonucleotides 
Oligonucleotides can be radio-labelled at their 5'-OH end by the T4 Polynucleotide kinase (T4 
PNK) that catalyses the transfer of the γ-phosphate from 32P- ATP. 
Therefore, 40 pmol of primer were mixed with 4 µl [γ-32P]ATP (10µCi/ml) and 
phosphorylation took place by incubation of the mixture with T4-Kinase at 37°C for 30 
minutes. The reaction was stopped by heat inactivation at 70°C for 10 minutes. 
 
Radioactive sequencing DNA 
Sequencing reactions were carried out using the Thermo Sequenase cycle Sequencing kit 
(USB) according to the manufacturer’s instructions. 300 ng of plasmid DNA containing the 
desired fragment and 1 pmol of the radioactive primer were included in the reaction. 
Amplification was performed using a 23 cycle PCR program [Tden=94°C (30 sec), 
Tanneal=58°C (sec), Text=72°C (30 sec)] 
 
RNA preparation 
Stationary-phase cells of Bacillus amyloliquefaciens were harvested for preparation of total 
RNA. 20 ml of the culture was mixed with 10 ml “killing” buffer (stops mRNA production) 
and centrifuged for 10 minutes at 4°C and 12000 rpm. The pellet was washed once more with 
1 ml “killing” buffer and was then stored at -80°C. 
Isolation of RNA was performed using the Nucleo Spin RNA L (Macherey Nagel). In 
order to remove possible DNA contaminations, the isolated RNA was additionally extracted 
with an acidic Phenol:Chloform:Isoamylalcohol (25:24:1) mixture and then chloroform. 
Ethanol precipitation followed and the pellet was resuspended in 20 µl DEPC-H2O. The 
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concentration of total RNA was spectrophotometrically determined, according to [198] 
whereas its quality was checked on a 1,5% RNA agarose gel under denaturating conditions 
(1xMEN, 16% formaldehyde). The samples were mixed with 1,6 volume loading buffer and 
were incubated at 65°C for 5 minutes prior to loading on the gel. The gel was run in 1 x MEN 




●“Killing buffer"    ●10 x  MEN 
20 mM Tris-HCl PH=7.5  200 mM MOPS 
5 mM  MgCl2    50 mM Na-acetate 
20 mM NaN3    10 mM EDTA PH=7.0 
 
Primer extension 
Primer extension was used to map the 5' termini of mRNAs. 40 µg of total RNA was mixed 
with 0,15 µM radioactively (32P) labelled primer at 70°C for 5 minutes. Then 4 µl 5 x reverse 
transcriptase buffer, 2 µl dNTPS (10 mM each) and 1 µl Ribonuclease inhibitor (40 units) 
were added to a final volume of 19 µl. After incubation at 37°C for 5 minutes, 1 µl reverse 
transcriptase (200 units) was added to the mixture and further incubation was allowed for 1 
hour at 42°C. The primers used for identifying the transcriptional start(s) of bmy operon and 
yczE can be seen in table 4. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
Electrophoretic Mobility Shift Assay (EMSA) is a technique used for determining protein-
DNA interactions. It is based on the observation that DNA-protein complexes migrate slower 
through a non-denaturating polyacrylamide gel than free DNA fragments. Therefore, EMSA 
is a useful tool to determine if a protein binds directly to a DNA fragment or not. 
In our case, the desired DNA fragment of the bmyD promoter region was amplified by 
PCR using primers bmyD1 and rev1 (Table 4), one of which was previously labelled at its 5'-
end with [γ-32P]ATP. The radio-labelled product (450bp) was purified with the Qiagen PCR 
purification kit. After dilution of the labelled DNA fragment to attain final activity of 10.000 
cpm, the DNA was incubated at 37°C for 20 minutes with increasing concentrations of DegU 
protein in the 1xbinding buffer. The reaction mixtures were separated on 8% polyacrylamide 
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gels, under non-denaturating conditions, in 1 x TBE buffer at 60 V. The gels were visualized 
using the Biorad Molecular Imager FX scanner. 
Non radioactive EMSA experiments were performed in a similar manner, but 
visualization was done fluorescently using ethidium bromide. In particular, two smaller DNA 
fragments were amplified using primers bmyD1 / bmyD6 and bmyD2 / rev1. The obtained 
fragments, D1 (217 bp) and D2 (233 bp) respectively, result together in the whole 450 bp 
fragment used in the radioactive EMSA. 
 
●5 x Binding buffer    ●8% polyacrylamide gel ( non-denaturating) 
100 mM Tris-HCl PH=8.0  2 ml Rotiphorese Gel 40 (29:1) 
500 mM KCl    1 ml 10 x TBE 
25 mM MgCl2    0,285 µl glycerol 
2,5 mM DTT    0,075 µl 10% APS 
50%  glycerol   7,5 µl TEMED 
0,25 %  Nonidet P40   6,63 ml H2O 
0,025 % w/v poly(dI-dC) 
0,025 % w/v BSA 
 
DNase I footprinting 
DNase I footprinting is a method of studying protein-DNA interactions and identifying the 
DNA region to which a protein binds. These experiments were done as described by [209]. A 
DNA fragment (450 bp) obtained by PCR, using primers bmyD1 and rev1, or plasmid DNA 
carrying the same fragment (pAK16), were incubated in binding buffer with 0, 0,8 and 1,6 
µM DegU protein for 20 min at 37°C. Complexes were then treated with DNase I (0,6 µg/ml) 
for 20 seconds and the reaction was stopped by addition of 10 µl stop buffer containing 1,75 
ng/µl non-specific DNA (salmon sperm) and rapid chilling on ice. Primer extension followed 
with 32P-labelled primers bmyD1 and rev1, for the template strand and for the non template 
strand, respectively [Tden=94°C (30 sec), Tanneal=58°C (30 sec), Text=72°C (30 sec) for 23 
cycles]. 
 
●Stop buffer (10 µl) 
2 µl  10xTaq buffer 
1 pmol  32P-labelled primer 
0,2 µl  dNTPS (100mM) 
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0,5 µl  non-specific DNA (salmon sperm, 35 ng/ µl) 
0,2 µl  Taq polymerase 
6,6 µl  H2O 
 
Biological tests 
For the antifungal tests, B. amyloliquefaciens FZB42 and its derivatives were grown in Landy 
medium at 37°C for 24 hours. The cultures were centrifuged and 2 µl of the supernant were 
spotted on Waksman agar together with regularly arranged growing fungi. The plates were 
incubated at 27°C. 
For the antibacterial tests, B. amyloliquefaciens FZB42 and its derivatives were grown 
treated in the same manner. The indicator strain was grown overnight at 37°C under vigorous 
shaking. 300 µl of the culture was mixed with 3 ml soft agar and poured on LB dishes. 
Supernatants obtained from the B. amyloliquefaciens FZB42 strains, grown in Landy medium 




B. amyloliquefaciens FZB42 was grown overnight on agar plates of Landy medium at 37°C. 
To record mass spectra, cell material was picked from the plate, spotted onto the target and 
covered with matrix medium, i.e. a saturated solution of α-cyanocinnamic acid in 40% 
acetonitrile-0,1% trifluoroacetic acid. It was air dried and then analyzed by matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS), as 
described in [210]. 
Alternatively, culture filtrate extracts were prepared by lyophilisation of the 
supernatants that resulted from cultures grown for 12, 24 or 48 hours at 37°C in Landy or 
ACS medium. A small sample of the culture filtrate was extracted with 70% acetonitrile-0,1% 
trifluoroacetic acid and then mixed with an equal volume of matrix medium. 1 µl aliquots 
were spotted on the target and were air dried prior to MS measurement [211]. Postsource 




Quantification of specific β-galactosidase enzymatic activity 
Specific β-galactosidase activity was determined from growing liquid cultures in Difco 
medium, according to [199]. At different times of the growth curve the optical density of the 
culture at 600nm was determined and cells were harvested. Their pellets were frozen in order 
to be further used in the β-galactosidase assay. Pellets were resuspended in 640 µl Z-buffer 
and mixed with 160 µl lysozyme-buffer. After short vortexing, they were incubated at 37°C 
for 10 min. Further on, 8 µl of a 10% Triton-X solution was added to the samples, followed 
by ten-minute incubation on ice. The reaction began by addition of 200 µl ortho-nitrophenyl-
β-D-galactopyranoside (ONPG) 4 mg/ml at 30°C and was stopped by addition of 400 µl 1M 
Na2CO3 when their colour changed to yellow. The samples were then centrifuged for 5 min 
and the supernatant’s absorbance was measured at 420 and 550 nm. Specific β-galactosidase 
activity was calculated in Miller units (MU) [212], according to the formula. 
 
Miller units (MU) = 1000 x (OD420 – 1,75 x OD550) / (t x V x OD600) 
 
OD420, OD550, OD600  = optical density at 420, 550, 600 nm 
T = reaction time (min) 
V = volume of the sample of bacterial cells used for the reaction (ml) 
 
Buffers 
●Z-buffer  ●Lysozyme-buffer    ●ONPG-buffer  
60 mM Na2HPO4 PH=7.0  2,5 mg/ml Lysozyme   4 mg/ml ONPG 
40 mM NaH2PO4  50 U/L Benzonase   in Z-buffer 
10 mM KCl   in Z-buffer 
1 mM  MgSO4 x H2O 
 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was performed according 
to [198]. The proteins were separated by 4% upper and 10% lower gels, using the “Mini-
Protean II” apparatus of Biorad. Gels were run at 200 Volt in 1 x running buffer and were 




●4% upper gel     ●10% lower gel 
0,5 ml Rotiphorese Gel 40 (19:1)   3 ml  Rotiphorese Gel 40 (19:1) 
1,25 ml 0,5 M Tris-HCl PH=6.83,28ml  1,5 M  Tris-HCl PH=8.8 
0,05 ml 10% SDS  0,13 ml 10% SDS 
0,025 ml 10% APS  0,066 ml 10% APS 
0,006 ml TEMED  0,005 ml TEMED 
5,52 ml H2O  3,2 ml  H2O 
 
●1 x running buffer 
25 mM Tris-HCl PH=8.3 




The gels were electroblotted onto nitrocellulose membranes (0,45 µm pore size) using the 
“Trans-Blot SD Semi-Dry transfer cell” (Biorad). After incubation for 15 min with TBST 
buffer containing 10% powdered milk, the membranes were incubated overnight at 4°C with 
TBST buffer containing 1% powdered milk and 20 µl antibody “His-probe H15 sc-803 rabbit 
polyclonal IgG” (200 mg/ml; Santa Cruz). The membranes were washed 3 times with TBST 
buffer for 10 minutes and were then incubated with TBST buffer containing 2% powdered 
milk and 6 µl of the “Anti-rabbit IgG alkaline phoshatase conjugate” antibody (dilution 
1:10.000) for 1 hour. Detection was achieved colorimetricly by addition of 10 ml Ap buffer 
containing 2,25 mg nitroblue tetrazolium salt (NBT) and 1,75 mg 5-bromo-4-chloro-3 –




25 mm Tris-HCl PH=8,7 
150 mM Glycin 
  
Overexpression and purification of 6xHis-tagged DegU 
A DNA fragment containing the whole degU gene of B. amyloliquefaciens FZB42 was 
amplified using primers degU60a / degU60b (table 4), that contain restriction sites for the 
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endonucleases NcoI and BglII respectively. DegU was cloned in the expression plasmid 
pQE60 (Qiagen) as a C-terminal His6-tag fusion under regulation of an isopropyl β-D-
thiogalactoside (IPTG) –inducible promoter. The resulting plasmid, pAK54, was used to 
overexpress DegU-His6 fusion protein in E. coli. For this scope, DH5α strain was 
simultaneously transformed with pREP4 (a repressor plasmid carrying the lacI repressor) and 
pAK54 resulting in strain AK38. 
Strain AK38 was grown overnight at 37°C in LB medium containing 100 µg/ml 
ampicillin and 20 µg/ml kanamycin. The culture was diluted in 500 ml LB-Ap/Km to an 
OD600 of 0,03 and was further grown at 30°C under vigorous shaking. When the cells grew to 
an OD600 of 1, ethanol was added to a final concentration of 3% to induce chaperone synthesis 
and minimize formation of inclusion bodies. After 15 minutes, IPTG was added to the 
cultures at 1 mM final concentration. The cultures were grown for 2,5 hours and were then 
centrifuged at 6000 rpm for 20 minutes. The pellets were stored at -80°C. The protein was 
then purified with the Protino® Ni-1000 kit according to the manufacture’s instructions 
(Macherey Nagel) and was subsequently dialysed overnight against storage buffer at 4°C. 
 
●Storage buffer 
50 mM  Tris-HCl PH=8.0 
0,5 mM  EDTA 
100 mM  NaCl 
0,5 mM  DTT 
50% v/v  glycerol 
 
Complete genome sequencing and annotation strategies 
The genome of B. amyloliquefaciens FZB42 was sequenced in collaboration with the 
GenoMik Network in Göttingen using the random shotgun approach. Total genomic DNA 
was shared randomly or partially digested with Sau3AI, and DNA fragments 1 to 3 kb in size 
were cloned into pTZ19R or pCR2.2 TOPO (Invitrogen) to establish a shotgun library. The 
inserts of the recombinant plasmids were sequenced from both ends using the MegaBACE 
DNA Sequencing Systems 1000 and 4000 (Amersham-Biosciences) and ABI Prism 377 
sequencers (Applied Biosystems) with dye terminator chemistry. Fosmid library and 
combinatorial multiplex PCR were performed in order to determine the RNA sequences 
present in the genome and their location within it. 
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Approximately 44068 sequences were processed with PHRED, assembled into contigs 
by using the PHRAP assembling tool [213] and edited with GAP4, which is a part of the 
STADEN package software [214]. The resulting contigs of B. amyloliquefaciens FZB42 were 
sorted using the genome of B. subtilis 168 as scaffold [7]. PCR-based techniques and primer 
walking on recombinant plasmids were applied in order to close remaining sequence gaps. 
Identification of ORFs in all six different frames was performed using the Glimmer2 
program. Annotation of the genome was done using the GeneSOAP program provided by 
Rainer Cramm. The full length of each ORF was determined according to the presence of 
putative ribosome-binding sites and putative start codons as well as by comparison to the 
ortholog ORFs in B. subtilis 168 [7] and in B. licheniformis DSM13 [11]. In addition, using 
GeneSOAP it was possible to look for conserved protein domains within the ORFs of B. 

























Identifying unique DNA regions in the genome of B. 
amyloliquefaciens strain FZB42 
Taxonomic classification of Bacillus strains FZB24, FZB37, FZB42, 
FZB45 and 168 
Bacillus strains FZB24, FZB37, FZB42 and FZB45 have been isolated from plant-pathogen-
infested soil and their contribution in plant growth promotion as well as in suppression of 
plant pathogenic organisms has been documented [5]. Initial studies on growth characteristics 
and carbon source utilization of those strains showed that they are closely related to the 
Bacillus subtilis and Bacillus amyloliquefaciens groups [6]. The main criterion for 
distinguishing between the two Bacillus subspecies was the ability shared within the B. 
amyloliquefaciens strains to produce lipase and acid from lactose [216]. Thereby it was 
concluded that FZB24, FZB42 and FZB45 belong to the B. amyloliquefaciens group whereas 
FZB37 is more related to B. subtilis [5]. However, another study classified strain FZB24 as a 
member of the Bacillus subtilis group. In order to further verify these results, ribotyping 
analysis and macrorestriction profiling by PFGE were performed. 
The same amount (2 µg) of genomic DNA from FZB24, FZB37, FZB42, FZB45 and B. 
subtilis 168 was digested overnight at 37°C using the restriction endonuclease EcoRI. After 
transfer and fixation of the samples on a nylon membrane, overnight hybridization at 55°C 
was performed (see materials and methods). A DNA fragment, part of the 16S rrnE gene of 
B. subtilis, was amplified by PCR using primers pRB1601 and pRB1602 [6] and after 
labelling with DIG-dUTP, it was used as the probe for Southern hybridization. The ribotyping 
analysis revealed that the patterns obtained for FZB24 and FZB42 were almost identical (Fig. 
11). FZB45 displayed a unique riboprint with high similarity to those belonging to FZB24 and 
FZB42. In contrast, FZB37 and B. subtilis 168 provide profiles that are identical to each other 
but quite distinct from the ones observed for the rest FZB strains. Comparison of these 
patterns with a database of known riboprints was performed in DSMZ (Deutsche Sammlung 
von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany). Thereby it was 
confirmed that FZB24, FZB42 and FZB45 belong to the B. amyloliquefaciens group, whereas 
FZB37 belongs to the B. subtilis group. 
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Figure 11: Riboprints of various B. subtilis / B. amyloliquefaciens strains. 
Ribotype patterns obtained after digestion of genomic DNA of B. amyloliquefaciens FZB24 (1), 
FZB37 (2), FZB42 (3), FZB45 (4) and B. subtilis 168 (5) with EcoRI and hybridization with a DIG-




Moreover, B. subtilis 168 and B. amyloliquefaciens FZB42 were further investigated by 
macrorestriction profiling. PFGE is a more analytical approach than riboprinting since it 
allows better separation of larger DNA fragments. The profiles of B. subtilis 168 and B. 
amyloliquefaciens FZB42 obtained by PFGE after digestion with the restriction endonuclease 
SfiI are very distinct from each other, as seen in (Fig. 12). Furthermore, the patterns obtained 
with the commercially available B. amyloliquefaciens strain FZB24, after digestion with the 
same restriction endonuclease, were identical to the ones resulting from FZB42 as reported by 
[6]. Similarly, FZB37 has the same macrorestriction pattern as B. subtilis 168 [6]. 
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Figure 12: Genomic DNA macrorestriction profiles of B. subtilis 168 and B. 
amyloliquefaciens FZB42. 
Genomic DNA of B. subtilis 168 and B. amyloliquefaciens FZB42 was digested with the rare-cutter 
restriction endonuclease SfiI and then separated by pulsed field gel electrophoresis (PFGE). The 
obtained macrorestriction profiles of B. subtilis 168 and B. amyloliquefaciens FZB42 can be seen in 
panels A and B respectively. M, molecular mass marker (MidRange II PFG marker); bands from 
bottom to top 24,5/48,5/73/97/121,5/145,5/170/194/218,5/242,5/267 kb. 
 
 
Suppression Subtractive Hybridization (SSH) 
Suppression Subtractive Hybridization (SSH) was used as means of identifying extensive 
gene differentiation between B. amyloliquefaciens FZB42 and B. subtilis 168. At the time 
point that these experiments were performed, only preliminary data existed for the genome 
sequence of B. amyloliquefaciens FZB42 (see chapter 3.2 for the updated data), whereas the 
complete genome of B. subtilis 168 had already been published [7]. Therefore SSH provided 
us with a rapid but thorough first view of genetic variation between the strains, long before 
that was possible by direct comparison of both strains’ complete sequences. For these 
experiments, B. amyloliquefaciens FZB42 was used as tester strain in order to rapidly detect 
its unique DNA sequences that are absent from B. subtilis 168 (driver strain). 
Sixty-six clones were obtained by this approach. After sequencing analysis, the clones 
were aligned at nucleotide level to the known genome of B. subtilis 168. Three of these clones 
appeared twice in the screen and ten displayed more than 60% nucleotide homology to the 
driver strain. The SSH application can be thus considered as very successful, since 84% of the 
gained clones contained sequences with low (less than 60%) nucleotide homology to the 
driver strain. Thereby for the first time fifty-three DNA segments of various lengths present in 
B. amyloliquefaciens FZB42 but not in B. subtilis 168 were identified. Furthermore, their 
putative function was deduced by basic alignment search tool analysis (BLAST). The results 
are presented in table 6. 
Most interestingly, eight clones showed high similarity to genes of nonribosomal 
peptide synthetases and polyketide synthases. In particular, clone cAK6 displayed 81% amino 
acid homology to MycC, involved in mycosubtilin biosynthesis, whereas clone cAK49 was 
98% similar to ItuB, involved in iturin A biosynthesis. These findings suggest that the 
genome of B. amyloliquefaciens FZB42 may contain an operon for the nonribosomal 
biosynthesis of an iturin-like antibiotic. In contrast, such operon is not part of B. subtilis 168 
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genome. In this strain only the peptide sythetase operons encoding for surfactin and fengycin 
are present. Furthermore, six clones displayed similarity to polyketide synthases. For 
example, clones cAK24 and cAK48 were respectively 58% and 31% homologous, at amino 
acid level, to PksR and PksM, proteins that are encoded within the single polyketide synthase 
operon (pksX) in B. subtilis 168 (Table 6). Low similarities between the pks operon present in 
the driver strain and the six sequences from the tester strain indicated that B. 
amyloliquefaciens FZB42 might contain operon(s) responsible for polyketide biosynthesis 
that differ from the one present in B. subtilis 168. 
Clone cAK30 displayed 99% similarity to MrsG, a protein probably involved in the 
immunity against the lantibiotic mersacidin [36] (see also 1.3.1.2). mrsG is transcribed from 
the same operon as mrsF and mrsE, in the mersacidin-producer Bacillus sp. strain HIL Y-
85,54728. These genes encode an ABC transporter that could be involved in protection 
against the antibiotic [36]. The question that arose was whether B. amyloliquefaciens FZB42 
possessed the whole mrsFGE operon or even the entire biosynthetic gene cluster of 
mersacidin; none of these genes are encoded in B. subtilis 168. For this purpose, primer 
walking was performed on the region neighbouring clone cAK30. Thereby the presence of the 
mrsFGE operon and of mrsR2K2, the two-component regulatory system that controls the 
operon’s transcription, was demonstrated; the biosynthetic genes of mersacidin were not 
found in this genomic region. 
A putative IS3-like transposase was identified in clone cAK2, indicating that horizontal 
gene transfer in B. amyloliquefaciens FZB42 might be achieved by transposases. 
Interestingly, such phenomena are not observed in B. subtilis 168 which does not contain any 
transposase in its genome. Moreover, two clones (cAK9 and cAK38) are similar to phage-
related proteins. In addition to the phage-related protein, cAK38 harbours a hypothetical 
protein, conserved in B. licheniformis DSM13 and absent from the driver strain. The 
remaining clones exhibit similarity to proteins with various functions, such as transcriptional 
regulators (cAK10), thymidylate synthases (cAK11), membrane or cation efflux proteins 
(cAK17/cAK20) etc. Moreover, several obtained sequences, parts of ORFs or putative 
proteins, score the best homology to unknown proteins of B. subtilis 168. Considering that the 
nucleotide and amino acid homology is very low, it seems plausible that these proteins are 
new and non-existing in the already sequenced strains of the Bacilli family. 
Since SSH is based exclusively on DNA similarity, it was only expected that some of 
the clones would contain non-coding regions. These regions are of high interest and can have 
regulatory function since RNA polymerase and various transcriptional regulators might bind 
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to them. Moreover, these can be regions where non-coding RNAs are located. Even though 
such clones are considered as positive attempts towards identifying sequence variations 
between B. amyloliquefaciens FZB42 and the driver strain, since they exhibit low nucleotide 
similarity to B. subtilis 168, they are not included in the table 6; 39,6% of the positive clones 
mostly contained non-coding region. 
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Clones obtained by SSH containing sequences of B. amyloliquefaciens FZB42 that exhibit less than 
60% nucleotide similarity to B. subtilis 168. The sequence’s size and its exact overall nucleotide 
similarity to the driver strain are indicated; less than 20% similarity is considered non significant 
(n.s.). The putative functions of the DNA segments are presented, as derived by BLASTX alignment. 
Similarities on amino acid level are indicated for the aligned part of the sequences. Clones that mostly 
comprise of non-coding regions are not included in the table. 
 
 
When later the sequencing task of B. amyloliquefaciens FZB42 advanced, the 
identification of the regions flanking the sequences obtained by SSH was possible. Moreover, 
in many cases sequencing of the strain was directed by the clones obtained by SSH. Our focus 
was particularly drawn on those regions that contained genes coding for nonribosomal peptide 
synthetases and polyketide synthases and further attempts to obtain detailed sequence 
information of these regions were conducted (mainly by primer walking). 
Sequence analysis of these regions revealed the presence of three distinct pks gene 
clusters (pks1-72442 bp, pks2-54350 bp, pks3-69548 bp) (Fig. 13). Clone cAK24 belongs to 
pks1 gene cluster whereas clones cAK27, cAK53, cAK54 belong to pks2 gene cluster. pks3 
polyketide synthase includes sequences obtained by clones cAK48 and cAK59. From these 
three gene clusters only the pks1 system from B. amyloliquefaciens FZB42 is similar to the 
pksX operon present in B. subtilis 168; a strain unable to synthesize polyketides due to a 
mutation in the sfp gene [174]. The polyketide synthases pks2 and pks3 are novel gene 
clusters. Various types of mass spectrometry, mutant construction and biological tests were 
used for verifying the functionality of these gene clusters. These experiments were in majority 
performed by Xiao-Hua Chen and can been seen in detail in [197]. 
Finally, clones cAK6 and cAK49 were found to be part of a ~37 kb operon that showed 
homology to the iturin A operon of B. subtilis RB14. Further experiments were performed for 
the characterization of this gene cluster (see 3.3 and 3.4). 
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Figure 13: Organization of the gene clusters involved in polyketide biosynthesis in B. 
amyloliquefaciens FZB42 (pks1, pks2, pks3) and B. subtilis 168 (pksX). 
The size and location of the three polyketide gene clusters in the genome of B.amyloliquefaciens 
FZB42 are shown. Filled and bold arrows indicate discrete AT domains and modular PKS 
respectively. NRPS portions occurring in hybrid NRPS-PKS enzymes are shaded. Gene clusters pks1, 
pks2 and pks3 are responsible for the biosynthesis of bacillaene, macrolactin and 




Sequence analysis of B. amyloliquefaciens FZB42 genome 
Sequencing of the B. amyloliquefaciens FZB42 genome was performed as a joint 
collaboration between our laboratory and the GenoMik Network in Göttingen. The major part 
of the work and the co-ordination of the whole process were done by Xiao-Hua Chen and 
myself. Shotgun and fosmid library approaches, primer walking and multiplex PCR were used 
in order to obtain the complete genetic information encoded in the chromosome of B. 
amyloliquefaciens FZB42 (for more details see Materials and Methods, chapter 2.6). 
Sequencing of the whole genome of the strain has been completed whereas the second round 
of annotation using the GeneSOAP program is currently in process (performed by Xiao-Hua 
Chen). 
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The genome of B. amyloliquefaciens FZB42 is a single chromosome consisting of 3916 
kb. The G+C content is about 46% and it contains 11 rRNA clusters. Even though the genome 
annotation is not yet completed, preliminary data revealed the presence of 3931 genes. 
BLAST comparison with SUBTILIST (a database containing all annotated genes of B. 
subtilis 168) showed that around 80% of the genes (3125) encoded by B. amyloliquefaciens 
FZB42 are more than 50% homologous at amino acid level to genes of B. subtilis 168. 
However, more than 200 of them are located in regions different than in the B. subtilis 168 
genome, possibly due to rearrangement events that occurred during evolution of the two 
genomes. Moreover, co-linear regions exhibiting high similarity to the B. subtilis genome, 
which are then interrupted by regions of variable length containing genes unique for FZB42 
were also detected. The unique genes of B. amyloliquefaciens FZB42 were found distributed 
in at least 14 DNA islands and islets around the whole genome. In contrast to B. subtilis 168, 
horizontal gene transfer is achieved not only by phages but also by different types of IS 
elements which are present in different copy numbers within the FZB42 genome (Table 7). 
The circular map of the chromosome of B. amyloliquefaciens FZB42 demonstrating some of 
its basic characteristics as well as an illustrated comparison to the B. subtilis 168 genome are 
presented in figure 14. 
 
Table 7: Transposases present in B.amyloliquefaciens FZB42 genome 
Transposase 
type 










IS3Bli1 2452 405 208/405 (51%) B. licheniformis 
ATCC 
14580/AF459921 
transposase 3456 199 87/147 (59%) Staphylococcus 
epidermidis ATCC 
12228/AAO03698 








The positions of the transposases on the genome of B. amyloliquefaciens FZB42 are indicated in kb. 




Striking is the presence of eight gene clusters encoding for secondary metabolites. In 
addition to srf, fen and pks1 (bae) operons that are responsible for the synthesis of surfactin, 
fengycin and bacillaene and are also present in the B. subtilis genome [7, 197], B. 
amyloliquefaciens FZB42 contains several additional gene clusters coding for 
peptide/polyketide antibiotics. bmy, pks2 and pks3 operons are involved in bacillomycin D, 
macrolactin, difficidin / oxydifficidin polyketide synthesis and further information about them 
can be found in other sections (see 3.3 and 3.1) [196, 197]; K.Schneider and Xiao-Hua Chen, 
unpublished results). Moreover, B. amyloliquefaciens FZB42 genome contains the bac operon 
responsible for the biosynthesis of the dipeptide bacilysin [217]. This antibiotic consists of an 
L-alanine at the N-terminus and a unusual amino acid, L-anticapsin, at the C-terminus and 
displays antibacterial activity [218]. The unusual epoxy-modified amino acid anticapsin is 
probably generated through the action of a prephenate dehydratase and an aminotransferase 
encoded by bacA and ywfG respectively, as a branching off from the prephenate of the 
aromatic amino acid pathway [219]. Additionally, the dhb operon is present in the genome of 
B. amyloliquefaciens FZB42 (see also section 3.5). The dhbACEBF operon is involved in the 
synthesis of 2,3-dihydroxybenzoate (DHB) as well as its modification and esterification to the 
iron siderophore bacillibactin [78] that enables microorganisms to efficiently scavenge iron 
[220, 221]. DhbE is a stand-alone adenylation domain that activates DHB in an ATP-
dependent reaction. The activated DHB is subsequently transferred to the free thiol group of 
the co-factor phosphopantetheine of the bifunctional isochorismate lyase/aryl carrier protein 
DhbB. The third synthetase, DhbF, is a dimodular nonribosomal peptide synthetase that 
specifically adenylates threonine (and to a lesser extent glycine) as well as covalently loads 
both amino acids onto the corresponding peptidyl carrier domains [78]. 
The eight gene clusters encoding peptide/polyketide antibiotics and a siderophore 
represent about 8% of the total genome and control synthesis of bioactive compounds by 
processes based on nonconventional translation. Interestingly, three of these gene clusters 
 80
(bmy, fen, pks1) are localized at the replication terminus, indicating that this region is 
probably more susceptible to horizontal gene transfer. 
bacillibactin B. amyloliquefaciens FZB42
3916 kb
 
Figure 14: Whole genome map of B. amyloliquefaciens FZB42 (kindly provided by Xiao-
Hua Chen). 
The scale on the inner circle shows coordinates, in bp. The blue circle is the GC-skew, which is 
correlated with the replication start point. Total 11 sets of rRNA are shown by the pink arrows. The 
grey circle represents all 3931 genes detected in FZB42. The colored circle displays the distribution of 
the homologous genes with B. subtilis 168, detected by BLASTX and BLASTP comparison. Around 
80% of the total genes bear similarity of more than 50%. The color code indicates identities greater 
than 90%, 80%, 70%, 60%, 50%. The green arrows within the outer circle indicate genes which are 
unique in the FZB42 and might contribute to the plant growth promotion or involved in horizontal 
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gene transfer. The orange GC-content circle shows consistency between horizontal gene transfer and 
low GC-content. 
 
Lipopeptides produced by B. amyloliquefaciens strain FZB42 
Organization of nonribosomal peptide synthetases on the FZB42 
chromosome 
The SSH experiments revealed the presence of nonribosomal peptide synthetases and 
polyketide synthases in the genome of B. amyloliquefaciens FZB42. With the later 
acquirement of the first assembly of the organism’s genome sequence, it became clear that B. 
amyloliquefaciens FZB42 encodes operons srf, fen and bmy which are responsible for the 
synthesis of three lipopeptides: surfactin, fengycin and bacillomycin D. This was the first 
report revealing the coding sequence of bacillomycin D and evidence for its functionality was 
provided by MALDI-TOF MS analysis (see 3.3.2). B. amyloliquefaciens FZB42 also encodes 
three polyketide synthases [197]. 
The cluster of bmy is a FZB42-specific DNA island comprising of 4 genes (bmyD, 
bmyA, bmyB and bmyC) and is close to the fen operon on the chromosome. Regions flanking 
the large gene cluster are characterized by DNA rearrangements joining the antibiotic DNA 
islands with sequences originally present in different regions of the B. subtilis 168 
chromosome (Fig. 15A). In particular, right from the 37.2 kb bmy gene cluster two rearranged 
clusters are situated: yxjCDEF and bioIBDFAW, that are present in B. subtilis 168 at positions 
3999 to 4002 kb and 3088 to 3094 kb, respectively. On the left site, regions located in B. 
subtilis 168 at positions 1910 to 1943 kb (yndG, bglC, ynfJ and xynD) were detected. 
Interestingly, the bmy operon is inserted at the same position as the iturin A gene cluster in B. 
subtilis RB14. This “coincidence” and the high homology between bacillomycin D and iturin 
A made us initially assume (before the MS results; see 3.3.2) that FZB42 could encode the itu 
operon. 
The fen five-gene cluster (fenA-E) present in B. amyloliquefaciens FZB42 is related to 
the pps operon in B. subtilis 168 and is situated at the same locus as this, about 25 kb distant 
from the bmy operon (Fig. 15A). Amino acid similarity between the operons of the two strains 
is between 60% (fenB) and 65% (fenC). The nonribosomal peptide synthetase directing 
biosynthesis of fengycin is also present in B. subtilis strains F29-3 [222] and A1/3 [140]. 
However, in B. subtilis ATCC 6633, mycosubtilin, another iturin-like lipopeptide, is found at 
the same genetic locus as fengycin [63]. There seems to be an exchange of these two operons 
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between different strains, implying high degree of genetic flexibility in this region. Moreover, 
this suggests that additional NRPS operons might be integrated in this area either as insertions 
or as substitutions of already existing NRPS operons. 
 
Figure 15: Organisation of the bacillomycin D, fengycin and surfactin operons in B. 
amyloliquefaciens FZB42. 
In panel A is presented the chromosomal organization of bacillomycin D and fengycin operons in B. 
amyloliquefaciens FZB42 as well as of operons producing highly homologous antibiotics in other 
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Bacilli strains. In panel B is compared the organisation of the surfactin operon in B. amyloliquefaciens 
FZB42 with that of B. subtilis 168. The intersecting dotted lines indicate events of insertion or 
rearrangement in FZB42 compared to the respective B. subtilis 168 genome region, whereas full lines 
demonstrate conservation of gene order between the two strains. Black-filled boxes indicate genes 
present in B. subtilis 168 but absent from the respective genome region of B. amyloliquefaciens 
FZB42. The organisation of the homologous gene clusters in B. subtilis 168 (fengycin operon-pps, 
surfactin-srf), B. subtilis RB14 (iturin A operon-itu) and B. subtilis ATCC6633 (mycosubtilin operon-
myc) are presented according to [7, 49, 63, 101]. 
 
 
The 26.5 kb srf operon present in B. amyloliquefaciens FZB42 genome is organized in a 
similar manner as in B. subtilis 168 (see introduction). The corresponding genes of these two 
strains exhibited similarity between 72% (srfAA) and 83% (srfAC) on amino acid level. The 
genes present at the left flanking region of the operon are hxlBAR, like in the case of B. 
subtilis 168. However, on the right flank of srfAD, the B. subtilis 168 ycxAB are substituted by 
two ORFs with unknown function (Fig. 15B). Moreover, the comS gene, encoding a 
competence signal molecule, is embedded in the srfAB sequence, as already detected for 
various Bacillus strains and displays 63% homology to its orthologue in B. subtilis 168. The 
4'-phosphopantetheinyl transferase Sfp is located 4kb downstream and exhibits 70% amino 
acid homology to the one encoded by strain 168. 
 
Functional analysis of lipopeptide production in B. amyloliquefaciens 
FZB42 
MS identification of the lipopeptide products of B. amyloliquefaciens FZB42 
In order to check the functionality of the lipopeptide-encoding gene clusters, culture filtrate 
extracts and whole cells were investigated by matrix-assisted laser desorption/ionization-time 
of flight (MALDI-TOF) mass spectrometry (MS). The spectra obtained by both methods were 
found identical and revealed the presence of three different lipopeptides, as three groups of 
mass peaks were detected (Fig. 16). A summary of their mass numbers is presented in table 8. 
Surfactins and fengycins have been identified by comparing their mass data with those 
previously obtained by MS analysis of numerous B. subtilis strains [211]. Moreover, B. 
amyloliquefaciens FZB42 produces surfactins and fengycins with fatty acid side chains of 13 




Figure 16: MALDI-TOF MS analysis of lipopeptides produced by B. amyloliquefaciens 
FZB42 (performed in collaboration with Dr. J. Vater). 
Detection of surfactin (A), bacillomycin D (A) and fengycin (B) mass peaks in culture filtrate extracts 
prepared from B. amyloliquefaciens FZB42 grown for 24 hours in Landy medium. Spectra of intact 
whole cells grown on Landy medium agar plates; detection of surfactin (C), bacillomycin D (C) and 
fengycin (D) mass peaks. See table 8 for peak identification. 
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Table 8: Lipopeptide products of B. amyloliquefaciens FZB42 detected by MALDI-TOF 
mass spectrometry 
Observed peaks m/z Assignment 
Surfactin  
1030.8*/1046.8 C13-surfactin [M + Na, K]+ 
1044.8*/1060.8 C14-surfactin [M + Na, K]+ 
1058.8*/1074.8* C15-surfactin [M + Na, K]+ 
Bacillomycin D  
1031.7/1053.7*/1069.7 C14-bacillomycin D [M + H, Na, K]+ 
1045.7*/1067.7*/1083.7* C15-bacillomycin D [M + H, Na, K]+ 
1059.7/1081.7/1097.7* C16-bacillomycin D [M + H, Na, K]+ 
1095.7/1111.7* C17-bacillomycin D [M + Na, K]+ 
Fengycin  
1449.9*/1471.9*/1487.9 Ala-6-C15-fengycin [M + H, Na, K]+ 
1463.9*/1485.9*/1501.9* Ala-6-C16-fengycin [M + H, Na, K]+ 
1477.9*/1499.9/1515.9* Ala-6-C17-fengycin [M + H, Na, K]+ 
1491.8/1513.9/1529.9* Val-6-C16-fengycin [M + H, Na, K]+ 
1505.8/1527.8/1543.8* Val-6-C17-fengycin [M + H, Na, K]+ 
 
Peaks indicated in figure 16 are marked by an asterisk. 
 
 
Furthermore, postsource decay (PSD) MALDI-TOF MS revealed that the third produced 
lipopeptide is bacillomycin D. In the mass spectra obtained for whole cells and surface 
extracts the mass peaks of sodium and potassium adducts dominate, whereas the protonated 
species appear with minor intensities. However, the protonated species are preferred for PSD 
MALDI-TOF MS mediated sequence analysis because they decompose into fragments more 
readily than the alkali adducts. For example, the lipopeptide with a mass number of m/z 
1031.5 produced by B. amyloliquefaciens FZB42 was identified as the protonated form of a 
bacillomycin D isoform with a fatty acid chain of 14 carbon atoms. Its sequence was 
determined from a series of bn1-, Yn‘‘(-H2O)-, and proline-directed bn2- fragment ions (Fig. 
17). The peptide ring of this bacillomycin D was cleaved both at the peptide bond between its 
amino fatty acid residue and threonine at position 7 as well as at the N terminus of proline-4. 
In the first case a series of bn1- and Yn‘‘(-H2O)-fragment ions were detected. In addition, bn2-
ions of highly intensity were observed. Based on all these data, this lipopeptide was identified 
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as the protonated form of a C14- bacillomycin D. The obtained sequence was corroborated by 
bn1- ions of dipeptide fragments at m/z values of 171.4, 212.3, 226.8 and 268.4, indicating 
nearest-neighbour relationships in the peptide ring of this lipopeptide for ES(-H2O), NP, PE 
and NY respectively. 
 
Figure 17: In situ structural analysis of the lipopeptide product of B. amyloliquefaciens 
FZB42 with mass number m/z 1031.5 by PSD-MALDI-TOF-MS (performed in 
collaboration with Dr. J. Vater). 
The structure was derived from a series of f bn1-, Yn‘‘(-H2O)-, and proline-directed bn2- fragment ions. 
FA, fatty acid 
 
 
Production of lipopeptides along the growth curve 
The production of lipopeptides during growth in liquid cultures was monitored by MALDI-
TOF MS. This type of spectrometry is not suitable for determining their exact concentrations, 
mainly because of inhomogeneities in the analytical distribution of the crystalline matrix and 
different ionization efficiencies of the investigated compounds. However, the relative 
quantities of the three antibiotics at different points of growth can be estimated by calculating 
the ratios of the intensity values of the peaks corresponding to the various antibiotics. 
For this reason, culture filtrate extracts from B. amyloliquefaciens FZB42 grown in ACS 
medium at 37°C under vigorous shaking for 10, 20, 40 and 60 hours were subjected to 
MALDI-TOF MS analysis. Thereby it was shown that surfactins and bacillomycins were 
present at similar intensities but reached their zenith in different stages of growth. Maximum 
levels of surfactin appeared in samples obtained after 10 to 40 hours of growth, whereas after 
60 hours production dropped. On the other hand, bacillomycin D accumulated after 40 to 60 
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hours of growth. The time course of fengycin resembled that of surfactin, but its intensity was 
clearly lower compared to the other lipopeptides (Table 9). The same pattern of lipopeptide 
production was obtained also when B. amyloliquefaciens FZB42 was grown in Landy 
medium and samples were drawn at 12, 24 and 48 hours. In this case, surfactin peaked 
already at 12 hours, whereas bacillomycin D at 24 hours. The intensities of fengycin peaks 
maintained rather low all along growth. 
 
Table 9: Time-dependent production of lipopeptides by B. amyloliquefaciens FZB42 
grown in ACS medium 
Lipopeptide m/z Species  Intensity at:  
   10 hours 20 hours 40 hours 60 hours 
Surfactin 1044.8 C14 [M + Na]+ 15500 10300 10100 2500 
 1058.8 C15 [M + Na]+ 16500 11700 10000 2400 
Bacillomycin 1053.7 C14 [M + Na]+ 3800 6600 11700 12300 
D 1067.7 C15 [M + Na]+ 2500 2500 7600 7000 
Fengycin 1485.9 C16 [M + Na]+ 3500 2950 3630 470 
 1449.9 C17 [M + Na]+ 1800 1810 2510 170 
 
Lipopeptide production was monitored by MALDI-TOF mass spectrometry. Culture filtrate extracts 
were prepared after 10, 20, 40 and 60 hours of growth in ACS medium. Only the main peaks (m/z) of 
each lipopeptide were selected for analysis. 
 
 
Lipopeptide deficient mutants 
In order to confirm that bmy and fen operons are directing bacillomycin D and fengycin 
biosynthesis, disruption mutants at the bmyA and fenA genes were created. B. 
amyloliquefaciens FZB42 mutant strains were generated via double-crossover recombination 
[199] according to a modified protocol that has been originally developed for B. subtilis (see 
materials and methods). 
In detail, a 1,2 kb fragment of bmyA was amplified by PCR using primers bmyAa and 
bmyAb (Table 4) and cloned into pGEM-T. After digestion with the restriction endonuclease 
AvaI, an erythromycin cassette was inserted inside the bmyA-fragment, resulting in plasmid 
pAK2 which was transformed in B. amyloliquefaciens FZB42. Disruption of bmyA in the 
resistant colonies was demonstrated by PCR with primers bmyAa and bmyAb and by 
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Southern hybridization. Disruption of fenA was achieved in a similar manner by insertion of a 
chloramphenicol cassette in a fragment obtained by PCR with primers fenAa and fenAb and 
digested with HindIII and KpnI. Correct integration of the antibiotic cassette was verified by 
PCR and Southern hybridization. Furthermore, a double mutant of both bmyA and fenA genes 
was created. 
Analysis of the mutant strains by MALDI-TOF MS, verified that strains ∆bmyA::Emr 
and ∆fenA::Cmr failed to produce bacillomycin D and fengycin respectively, since the 
corresponding groups of mass peaks were absent (Fig. 18). Moreover, strain AK3 
(∆bmyA::Emr ∆fenA::Cmr) was deficient in the production of both lipopeptides. Disruption of 
srfAA was performed by Xiao-Hua Chen and resulted in the strain’s inability to produce 
surfactin (data not shown). Consequently, the NRPS gene clusters that were identified on the 
chromosome are responsible for the biosynthesis of the respective lipopeptides in B. 
amyloliquefaciens FZB42. 
 
Biological activity of wild type and mutant strains 
B. amyloliquefaciens FZB42 stimulates plant growth and suppresses plant pathogenic 
organisms [5, 6], via mechanisms that have not been yet fully characterized. In order to check 
if the nonribosomal synthesized peptides produced by this bacterium contribute to its 
biocontrol capacity, the wild type and mutant strains deficient in biosynthesis of lipopeptides 
were assayed for their biological activities. 
For this purpose, growth of various phytopathogenic fungi in the presence of B. 
amyloliquefaciens FZB42 was investigated. Strain FZB42 was shown to inhibit the growth of 
Fusarium oxysporum, Gaeumannomyces graminis, Rhizoctonia solani, Alternaria alternate 
and Pythium aphanidermatum. Moreover, strain AK1 (∆bmyA::Emr) suppressed growth of all 
fungi at a smaller extent, suggesting that bacillomycin D contributes to the antifungal activity 
of B. amyloliquefaciens FZB42. Interestingly, even though growth inhibition in the presence 
of strain AK2 (∆fenA::Cmr) was comparable to the one caused by the wild type, no inhibition 
was observed in the double mutant strain AK3 (∆bmyA::Emr ∆fenA::Cmr) (Fig. 19A). The fact 
that fungi could grow uninfluenced by the presence of strain AK3 indicates a synergistic 
action of bacillomycin D and fengycin, against the target microorganism. The surfactin 





Figure 18: MALDI-TOF MS analysis of mutant strains in nonribosomal peptide 
synthetases (performed in collaboration with Dr. J. Vater). 
Spectra of culture filtrate extracts prepared from strains grown for 24 hours in Landy medium. A) 
Bacillomycin D is not produced by mutant AK1 (∆bmyA::Emr), whereas surfactin and fengycin are. B) 
Strain AK2 (∆fenA::Cmr) is deficient in fengycin production while (C) strain AK3 (∆bmyA::Emr 
∆fenA::Cmr) is deficient in both bacillomycin D and fengycin production. 
 
 
In parallel, it was observed that B. amyloliquefaciens FZB42 suppresses the growth of 
B. megaterium. This inhibitory activity was also shared by each one of the strains deficient in 
lipopeptide biosynthesis (Fig. 19B). Consequently, the antibacterial properties of strain 
FZB42 are driven by some antibiotic(s) produced by the strain other than nonribosomal 
peptides [197, 223]. 
 
 
Figure 19: Biological activity of B. amyloliquefaciens FZB42 and lipopeptide deficient 
mutant strains. 
A) Growth of Fusarium oxysporum f.sp.cucumerinum DSMZ 62313 in the presence of B. 
amyloliquefaciens FZB42 and lipopeptide deficient mutants. B) Growth of B. amyloliquefaciens 
FZB42 and lipopeptide deficient mutant strains on B. megaterium lawn. (1) wild type strain, (2) AK1 
(∆bmyA::Emr), (3) AK2 (∆fenA::Cmr), (4) AK3 (∆bmyA::Emr ∆fenA::Cmr) and (5) CH1 
(∆srfAA::Emr). 
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Analysis of functional domains in bmy operon 
Sequence analysis of the bmy operon revealed the presence of a cluster of four ORFs 
designated bmyD, bmyA, bmyB and bmyC, respectively (Fig. 20). bmyD encodes a putative 
malonyl coenzyme A transacylase and displays strong similarity to FabD, that is involved in 
fatty acid synthesis. Moreover, the protein is 98% and 80% identical to ItuD and FenF, 
respectively (ItuD and FenF are the first proteins participating in iturin and mycosubtilin 
biosynthesis[63, 101]. The ORFs encoding BmyA (3,982 aa), BmyB (5,633 aa) and BmyC 
(2,619 aa) show high similarity to members of the nonribosomal peptide synthetase family 
and display the ordered assembly of conserved condensation, adenylation and thiolation 
domains characteristic for such multienzymes (see introduction). As shown in figure 20, 
seven amino acid activating modules can be distinguished: one in BmyA (A1), four in BmyB 
(B1, B2, B3 and B4) and two in BmyC (C1, C2). Modules B1, B2 and C1 contain an 
epimerization domain, indicating that the activated amino acids are converted into D-
configuration. The number of modules corresponds to the number of incorporated amino 
acids while the location of epimerization domains within the peptide synthetase agrees with 
the position of D-configurated amino acids in the peptide moiety of bacillomycin D. The last 
domain of this multienzyme system is a thioesterase domain, which is presumably required 
for release and cyclization of the synthesized lipopeptide. The organisation of this 
nonribosomal peptide synthetase is similar to that already described for the closely related 
lipopeptides iturin A and mycosubtilin (see figure 9C) [63, 101]. Analogously bacillomycin D 
is also synthesized according to the multicarrier thiotemplate mechanism (see 1.3.2.1). 
Furthermore, the adenylation domains of bacillomycin D were compared to those of 
iturin A and mycosubtilin (Table 10). In the first case, more than 97% amino acid homology 
was observed within the first three modules of these synthetases, whereas in the second case 
the homology was less pronounced (>70%). However, homologies were lower within the 
adenylation domains responsible for activation of amino acids 4 to 7. This correlates well 
with the sequence variability between these antibiotics at amino acid positions 4 to 7, as 
shown in figure 8. The highest homology in this region was obtained for bmy_C1 and 
myc_C1 (81.4%), which both activate the amino acid serine in the sixth module. Furthermore, 
comparison of the 10 selectivity-conferring amino acid residues of adenylation domains (see 
introduction) revealed that Pro, Glu, Ser and Thr are activated by the last four modules, i.e. 
B3, B4, C1 and C2 respectively. 
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Table 10: Homologies and selectivity-conferring code of amino acid-specific adenylation 
domains (A-domains) of the bacillomycin D operon compared to the respective A 
domains extracted from the iturin A and mycosubtilin gene clusters 
 Position of selectivity conferring amino acids1 
A-domain amino acid2 Identity3 235 236 239 278 299 301 322 330 331 517
bmy_A1_Asn Asn (1) 100% D L T K I G E V G K 
itu_A1_Asn Asn (1) 98.6 % D L T K I G E V G K 
myc_A1_Asn Asn (1) 80.5 % D L T K I G E V G K 
BacC, TycC4 Asn  D L T K I G E V G K 
bmy_B1_Tyr Tyr (2) 100% D A L S V G E V V K 
itu_B1_Tyr Tyr (2) 99.5 % D A L S V G E V V K 
myc_B1_Tyr Tyr (2) 85.2 % D A L S V G E V V K 
TycB, TycC1 Tyr  D A L V T G A V V K 
bmy_B2_Asn Asn (3) 100% D L T K I G E V G K 
itu_B2_Asn Asn (3) 97.7 % D L T K I G E V G K 
myc_B2_Asn Asn (3) 80.1 % D L T K I G E V G K 
BacC, TycC4 Asn  D L T K I G E V G K 
bmy_B3_Pro Pro (4) 100% D V Q F I A H V V K 
myc_B4_Pro Pro (5) 44.8 % D V Q F I A H V V K 
itu_B4_Pro Pro (5) 42.7 % D V Q F I A H V V K 
Pps44 Pro  D V Q F I A H V V K 
bmy_B4_Glu Glu (5) 100% D A K D L G V V D K 
myc_B3_Gln Gln (4) 59.8 % D A Q D L G V V D K 
itu_B3_Gln Gln(4) 58.2 % D A Q D L G V V D K 
SrfAA4 Glu  D A K D L G V V D K 
bmy_C1_Ser Ser (6) 100% D V W H F S L I D K 
Myc_C1_Ser Ser (6) 81.4% D V W H F S L I D K 
Itu_A_C2 Ser (7) 72.4% D V W H F S L I D K 
EntF, CdaI4 Ser  D V W H F S L I D K 
itu_C1_Asn Asn (6) 43.8% D L T K I G E V G K 
bmyC2_Thr Thr (7) 100% D F W N I G M V H K 
FenD, Pps2, 
PvD4 Thr  D F W N I G M V H K 
A_C2 Ser (7) 50.2% D V W H F S L I D K 
mycC2_Asn Asn(7) 47.6% D L T K I G E V G K 
1As determined by [53]. Domains and conserved residues lining the substrate-binding pockets of adenylation 
domains of assigned functions are indicated in boldface.2The positions of the activated amino acid within the 
respective lipopeptides are given in parentheses.3This stands for the overall homology of the whole adenylation 
domain, about 440 amino acids, compared to the respective domain of the bmy operon. 4Domains and residues 
lining the substrate-binding pocket as described by [54] 
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Interestingly, BmyA displays a remarkable complexity, similar to MycA and ItuA. The 
first amino acid module present in these three nonribosomal peptide synthetases is preceded 
by several domains with homology to proteins involved in the synthesis of fatty acids and 
polyketides. Four different domains could be distinguished (Fig. 20). In BmyA, the first 
domain (AL) shows high similarity to long-chain fatty acid CoA-ligases as well as 98% and 
85% homology with the corresponding domains of ItuA and MycA, respectively. 
Furthermore, two domains similar to acyl carrier proteins (ACP) were recognized as well as 
one similar to β-ketoacyl synthetases (KS). Finally, one domain homologous to glutamate-1-
semialdehyde aminotransferase (AMT) was detected. These domains presumambly play a 
role in the incorporation of the β-amino fatty acid into the peptide moiety [63]. The 
condensation domain lying directly upstream of the first adenylation domain in BmyA, 
responsible for the activation and incorporation of Asn, probably catalyzes the transfer of the 
β-amino fatty acid to the first amino acid. 
According to the colinearity rule, arrangement of modules within a peptide synthetase 
determines the order of incorporation of specific amino acids in the peptide moiety. As the 
multicarrier thiotemplate mechanism proposes, elongation of the peptide occurs stepwise 
from the N to C end. However, in the case of bacillomycin D there was no experimental 
evidence proving the consequent activation and incorporation of the seven amino acids in the 
peptide chain. Therefore in order to verify our assumptions about the biosynthetic pathway of 
bacillomycin D six mutants were created by disrupting one by one the last six modules of the 
nonribosomal peptide synthetase. Thereby the multienzyme system was silenced at different 
points after the incorporation of a new amino acid resulting in intermediate products which 
reflect the stepwise elongation of the peptide. By identifying the intermediate elongation 
variants that were produced as the peptide moiety groew, it would be possible to monitor 
biosynthesis of bacillomycin D. 
For this purpose, a chloramphenicol cassette was integrated via double-crossover 
recombination at the beginning of each adenylation domain (bmy_B1, bmy_B2, bmy_B3, 
bmy_B4, bmy_C1 and bmy_C2) resulting in the bacillomycin D deficient mutant strains 
AK15, AK39, AK40, AK41, AK42 and AK43 respectively (Fig. 20, Table 3). The mutant 
strains were grown in Landy medium at 37°C for 24 hours under vigorous shaking. Culture 
filtrates and sonificated cell extracts from them were prepared and were subsequently 
analysed by MALDI-TOF MS. The peaks of the expected products, according to the 
multicarrier thiotemplate mechanism, were not detected in the spectra obtained from the 
culture filtrates. This probably means that the intermediates remained attached to the 
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multienzyme system and were not secreted from the cells; only the cyclic compound could be 
exported from the cell. Having this concept in our mind, we sought for the expected peaks in 
the spectra obtained from cell extracts. Even in these spectra, those peaks had very low 
intensity and in most cases were hardly distinguished from the background. This result 
indicates that the elongation variants were tightly attached to the complex and could be only 
partially detached from it by sonification (see also Discussion). 
 
Figure 20: Schematic representation of the bacillomycin D operon in B. 
amyloliquefaciens FZB42. 
The operon comprises of four ORFs bmyD, bmyA, bmyB and bmyC; their sizes are given in kb. The 
number of modules within each protein is indicated in parentheses. A more schematic overview of the 
four proteins depicts the exact location of the seven modules (A1, B1 etc). In parallel, the domains 
organisation within the modules is demonstrated. The activated amino acids are depicted within the 
adenylation domains while their configuration is presented under the respective domains. The arrows 
indicate the position where the chloramphenicol cassette was introduced within the bmy operon in 
order to construct strains that produce only intermediate products of bacillomycin D; the names of the 
obtained strains are also noted. AL, acyl coenzyme A ligase domain; ACP, acyl carrier protein 




Regulation of bacillomycin D production 
5'-deletion analysis of the bmy promoter region 
Determination of bmy expression in B. subtilis MO1099 
In order to monitor the transcriptional regulation of bacillomycin D of B. amyloliquefaciens 
FZB42, four reporter fusions of the postulated bmy promoter region (the upstream region of 
the first gene of the bmy operon, bmyD) to lacZ were generated. A series of nested fragments 
with a common downstream end (by the 42nd codon of BmyD) and variable upstream ends 
(400, 183, 120 and 30 bps upstream of the translational start) were amplified by PCR, using 
primers bmyD1 to bmyD5 (Fig. 21; see also Table 4). The obtained products carried suitable 
restriction sites (EcoRI and BamHI; embedded on the primers) in order to be cloned into 
pDG268, a plasmid extensively used for constructing transcriptional reporter fusions in B. 
subtilis that can be later integrated at the amyE locus of its chromosome [192]. The new 
pDG268 derivatives (pAK5 to pAK8; see also Table 2) were subsequently used for 
integrating our series of 5'-deletion bmy promoter variants into the chromosome of B. subtilis 
MO1099 as single-copies, via double-crossover recombination. The correct chromosomal 
integration of the transcriptional fusions was verified by Southern hybridization. The new 
strains contained decreasing lengths of the bmy promoter region fused to lacZ and were 
named AK4, AK5, AK6, and AK7 (Fig. 21; see also Table 3). 
 
Figure 21: Schematic representation of the 5'-deletion analysis conducted for the bmy 
promoter region. 
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The dark arrows indicate the primers used for generating bmyD::lacZ reporter fusions (bmyD1-D5). 
The 5' and 3' end termini of bmyD promoter regions are indicated by their nucleotide position relative 
to the translational start. The derivative strains of B. subtilis MO1099 and B. amyloliquefaciens FZB42 
that carry the respective fusions are presented on the right side of the scheme (Strains AK16-17 are 
isogenic to AK9-10 but have a different antibiotic cassette, see Table 3). 
 
 
The expression of the bmyD::lacZ reporter fusions was determined throughout the 
growth cycle. All four strains were silent during logarithmic phase, indicating that the 
promoter(s) of bacillomycin D is not active at this time point (Fig. 22A), in total agreement 
with the late production of the lipopeptide observed by the MALDI-TOF MS analysis (Table 
9). Upon entry into stationary phase, the transcriptional activity of AK4, AK5 and AK6 
increased and reached its maximum after 3 hours. On the contrary AK7 remained silent and 
did not show any β-galactosidase activity all along the growth curve, in consistence with its 
white colour on LB agar plates containing 40µg/ml X-Gal (all three other strains appeared 
blue on plates). This result was partially expected, as the DNA promoter region contained in 
the smallest fusion (AK7) reached only up to 19bp upstream of the potential Shine-Dalgarno 
site, and therefore could not include an entire promoter site. Furthermore, it is apparent that 
the smallest DNA fragment containing an intact promoter is that encoded in AK6 (reaching 
up to 120bp upstream of the bmyD coding region). The fact that the fusions of AK6 and AK5 
showed no difference in their expression pattern throughout the whole growth cycle suggested 
that no additional trans-activating factor binds to the region between –183 and –120bp (in 
respect with the bmyD translational start). On the other hand AK4 exhibited slightly but 
reproducibly higher activity than the other two strains (AK6 and AK5) during stationary 
phase (about 25%; Fig. 22A). This means that the bmyD promoter region between –400bp and 
–183bp (in respect with the bmyD translational start), harboured only by AK4 (see Fig. 21), 
possibly carries additional cis-activating elements. The question whether these elements code 
for a transcriptional activator’s binding-site or for an additional promoter was addressed later. 
 
Determination of bmy expression in B. amyloliquefaciens FZB42 
To monitor the expression pattern of bacillomycin D in its natural environment, plasmids 
pAK5 to pAK8 (derivatives of pDG268, carrying different 5'-end deletions of the bmy 
promoter region; see previous paragraph) were attempted to be integrated at the chromosome 
of B. amyloliquefaciens FZB42. Unfortunately, pDG268 carries parts of the amyE gene of B. 
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subtilis (used for the double-crossover recombination of the fusion to the chromosome) that 
show relatively low homology (less than 80%) to their corresponding regions of B. 
amyloliquefaciens FZB42. Therefore, our initial attempts to obtain single-copy bmyD::lacZ 
fusions as part of the chromosome of B. amyloliquefaciens FZB42 were unsuccessful. In 
order to overcome this problem, a new plasmid, pAK9, was constructed by replacing the 
amylase sequences from pDG268 with the respective sequences of B. amyloliquefaciens 
FZB42. All our bmyD::lacZ transcriptional fusions were further cloned to the new vector and 
then successfully integrated at the amyE locus of B. amyloliquefaciens FZB42. Therefore the 
four new strains, AK9, AK10, AK11 and AK12, carry decreasing sizes of the bmy promoter 
region, in complete analogy to strains AK4-AK7 (note also that strains AK16-17 are isogenic 
to AK9-10, but have a different antibiotic cassette; see also Table 3. Exchange of the 
chloramphenicol cassette to a kanamycin one was performed using the marker exchange 
plasmid pECE73; [193]. 
The β-galactosidase activity of the four new strains was also examined throughout the 
growth cycle. The overall expression pattern of the various fusions was quite similar to that 
observed in the background of B. subtilis MO1099 (compare Fig. 22.A and B), and therefore 
most of the conclusions drawn in the previous section are also valid here. In other words bmy 
was only expressed during stationary phase, the entire core promoter was encoded within the 
first 120bp upstream of the bmyD start codon, and the region directly upstream of that 
(between –183 and –120) did not play any role in bmy expression. However, the strain 
carrying the longest upstream promoter region, AK9, exhibited 4-5-fold higher β-
galactosidase activity in middle stationary phase (3-4 h after entering stationary phase when 
the β-galactosidase levels have reached their plateau; Fig. 22B) than the strains carrying the 
shorter fusions (AK10 and AK11). This difference in the expression levels between AK9 and 
AK10/AK11 is considerably higher than that observed for the corresponding strains of B. 
subtilis MO1099 (Fig. 22A), underlining thus the importance of this DNA upstream region in 
the full transcriptional activation of the bmy operon in its natural environment. 
Two straight forward explanations can be provided for the different influence of the far 
upstream DNA region (between bps –400 and –183) on bmy expression in the two Bacilli 
strains: the cis-acting element situated at this region is optimally bound i) by a regulator 
(transcriptional factor or sigma factor) only present in B. amyloliquefaciens FZB42 (in B. 
subtilis a regulator of the same family only weakly recognises these sequences and offers 
basal levels of activation) or ii) by a regulator that is significantly less expressed in B. subtilis 
MO1099. No matter of the nature of this regulator, transcriptional analysis of the bmy operon 
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proceeded further in its natural environment (B. amyloliquefaciens FZB42), despite the 
practical disadvantages that such a decision had (B. amyloliquefaciens FZB42 is more 
difficult to genetically manipulate and any regulatory mutant to be tested has to be de novo 
constructed), so that important regulatory elements of bacillomycin D expression were not to 
be missed or underestimated. 
 
 
Figure 22: Expression of bmyD::lacZ fusions carrying different 5′-deletions of the region 
upstream of bmyD. 
The expression of a series of transcriptional fusions of the bmy operon’s promoter region to lacZ (see 
also Fig. 21) was monitored both in B. subtilis MO1099 (panel A) and in B. amyloliquefaciens FZB42 
(panel B). Strains harbouring single copies of the 5′-deletion bmy promoter variants were grown in 
Difco medium at 37°C and optical densities (closed symbols) and specific β-galactosidase activities 
(in Miller Units; open symbols) were determined along the growth curve. The expression patterns 
shown here represent the average of more than three independent experiments. Squares, strains 
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AK4/AK9, carrying the longest promoter region of bmy (-400, +126 relative to the translational start 
of bmyD); diamonds, strains AK5/AK10, carrying the bmy promoter region between -183 and +126; 
triangles, strains AK6/AK11, harbouring the bmy promoter region between -120 and +126; circles, 
strains AK7/AK12, containing the shortest bmy promoter region between -30 and +126. 
 
DegQ is partially responsible for the differences in bmy expression in B. 
amyloliquefaciens FZB42 and B. subtilis MO1099 
It has been demonstrated that the horizontal transfer of functional gene clusters coding for 
peptide antibiotics and found in natural Bacilli isolates, in the chromosome of the 
domesticated B. subtilis 168 requires additional steps for the conversion of the latter into an 
antibiotic producer strain [172, 173]. Firstly the introduction of a functional sfp is absolutely 
necessary for peptide antibiotic production by B. subtilis 168, which carries a frame-shift 
mutation in this gene (see also introduction). Secondly it has been exhibited that increased 
expression of the pleiotropic regulator DegQ in B. subtilis 168 [224] enhances the antibiotic 
production [172, 173]. Interestingly most of the natural Bacilli isolates that express peptide 
antibiotics show significantly elevated degQ expression compared to that of B. subtilis 168, 
due to the fact that the degQ promoter has a more σA consensus-like -10 hexamer in those 
strains (TACACT instead of CACACT) [225]. However whether DegQ directly influences 
the transcriptional regulation of the antibiotic operons or it controls the expression of a post-
transcriptional regulator involved in the antibiotic synthesis (for example Sfp) has not been 
clarified. 
B. amyloliquefaciens FZB42 has the promoter version of degQ that yields higher DegQ 
cellular levels (data not shown). In contrast to that, B. subtilis MO1099, a derivative of the 
strain 168, carries the defected degQ promoter version. To test whether DegQ is responsible 
for the differential bmy expression patterns in its host strain and its B. subtilis counterpart, I 
constructed a plasmid that carried degQ under the IPTG-inducible Pspac promoter, pAK64 
(Table 2), using the replicated vector in B. subtilis, pDG148 [191]. pAK64 was subsequently 
transformed into AK4 and AK5 (the strains harbouring the two longer bmy promoter regions 
fused to lacZ; see also Fig. 21) and the expression of the reporter fusions was monitored along 
the growth curve for the following cases: i) AK4 and AK5 without the plasmid (control), ii) 
AK4 and AK5 with the plasmid uninduced and iii) AK4 and AK5 with the plasmid induced at 
OD600∼0.7. As seen in Fig. 23 the presence of uninduced pAK64 hardly changed bmy 
expression from the two strains. Upon induction of pAK64 though, a significant 2.5-fold 
increase could be observed in the activity of AK4 (Fig. 23), a strain that carries the whole 
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upstream promoter region of bmyD. In other words, the B. subtilis strains carrying the two 
longer bmy promoter fusions, AK4 and AK5, exhibit a more pronounced difference in their 
activity when DegQ is expressed in higher levels from a plasmid. The magnitude of the 
difference does not match that observed for the corresponding B. amyloliquefaciens FZB42 
strains (AK9 and AK10; Fig 22B), but with higher amounts of DegQ present in the cell, the 
pattern of bmy expression in B. subtilis approximates more the pattern observed in B. 
amyloliquefaciens FZB42. Since DegQ levels in B. amyloliquefaciens FZB42 are probably 
considerably higher than those in B. subtilis MO1099 (see above), DegQ accounts, at least 
partially, for the different bmy expression in the two host strains. Moreover, this is the first 
direct evidence that DegQ affects the transcriptional regulation of peptide antibiotics and not a 
subsequent step of their production. In the case of bacillomycin D the exertion of this effect 
seems to be dependent on a far upstream region of the promoter. Having in mind that DegQ is 
not a DNA-binding protein, the effect on bacillomycin D should be mediated in an indirect 
manner, possibly through modulating the activity of other transcriptional regulator(s) (see also 
Discussion). 
 
Figure 23: The effect of DegQ on the expression pattern of bmyD::lacZ fusions in B. 
subtilis MO1099. 
Strains AK4 and AK5, harbouring the longest promoter region of bmy fused to lacZ, were transformed 
with pAK64 (a replicated plasmid carrying DegQ under an IPTG-inducible promoter). After 3h of 
growth, pAK64 was induced in two of the cultures by addition of 1mM IPTG. Cells were grown in 
Difco medium (supplemented with 5 µg/ml kanamycin where applicable) at 37°C and optical densities 
(closed symbols) and specific β-galactosidase activities (in Miller Units; open symbols) were 
determined along the growth curve. Squares, strain AK4, carrying the longest promoter region of bmy 
(-400, +126 relative to the translational start of bmyD), without plasmid; cirles, strain AK5, carrying 
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the bmy promoter region between -183 and +126, without plasmid; diamonds, strain AK60 
(AK4+pAK64) with plasmid induced; triangles facing down, strain AK60 with plasmid uninduced; 
triangles facing up, strain AK61 (AK5+pAK64) with plasmid induced; rectangular triangle, strain 
AK61 with plasmid uninduced. 
 
Identifying the transcriptional start site of the bmy operon 
The transcriptional start site of the bmy operon was determined by primer extension. Total 
RNA of B. amyloliquefaciens FZB42 was isolated from cultures growing in Difco medium, 
2,5-3 hours after their entry into stationary phase, when expression of bmyD promoter peaked, 
as shown by the lacZ reporter fusions (Fig. 22). 
Primer extension using the radiolabelled primer rev1 (binding within the coding region 
of bmyD; see also Table 4) revealed two overlapping transcriptional start sites for bmyD: an 
adenine (A) and a thymine (T) nucleotide located 58 and 57 bp upstream of the gene’s 
initiation codon respectively (see Figs 24 and 25). Sequences resembling the consensus of the 
-10 and -35 elements of the housekeeping sigma factor, σA, were found upstream of the 
mapped transcriptional start site (Fig. 24). In particular, the -35 (TATACA) and -10 
(TAGGAT) hexamers identified upstream of bmyD carry 4/6 matches to the corresponding 
consensus sequences of σA [226]. The spacer between them is 18 bp long and within it also 
lays an extended -10 region, directly upstream of the –10 hexamer, i.e. CATGc (the bold 
faced nucleotides match the consensus, TRTGn; [227, 228]. Therefore the promoter of bmyD 
(Pbmy) seems to be recognised and utilised by the vegetative sigma factor, despite the fact that 
bmy shows stationary-phase induced expression. Consistently the entire core promoter is 
encompassed within the first 75 bp upstream of the gene’s translational start, as predicted by 
the deletion analysis of the reporter fusions (see Figs. 22 and 25). 
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Figure 24: Mapping of the transcriptional start of the bmy operon by primer extension 
analysis. 
Total RNA was isolated from B. amyloliquefaciens FZB42 cells grown in Difco medium, 2.5-3 hours 
after their entry into stationary phase. Primer extension was performed using the 5'-end 32P-labelled 
primer rev1. The first four lanes result from dideoxynucleotide sequencing reactions using the same 
primer. The positions of the transcripts corresponding to the bmyD transcriptional starts are indicated 
by arrows. The respective DNA sequences are shown on the right of the picture. Transcriptional starts 
are highlighted in bold face whereas the -10 hexamer is underlined. 
 
 
Extensive attempts to identify further upstream-situated promoters that would account 
for the differences in gene expression between strains AK9 and AK10 failed (data not 
shown). Consequently, a transcriptional regulator, binding at the region between -400 and -
183 bp upstream of the gene’s start codon, is partially responsible for the stimulation of the 
bmy operon’s expression during stationary phase. 
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Figure 25: Nucleotide sequence of the bmyD promoter region. 
The positions of the two adjacent transcriptional starts (bold face, +1), the translational start (bold 
face, Met), the putative ribosome binding site (underlined), the -35 and -10 hexamers (boxes) and the 
extended -10 region (double underlined) are indicated. The annealing site (5'-end) of the 
oligonucleotides used for primer extension (rev1) and for construction of reporter fusions (bmyD1-D5) 
are shown with arrows. Site I and II (shaded) represent the two DegU binding sites (see 3.4.4.3). The 
degenerate forms of the motif AGAA-N11-TTCAG, which was proposed by Dartois et al (1998) as the 
recognition site for DegU, are indicated by boxes within the shaded sites. 
 
Global regulators control the production of bacillomycin D 
Effect of global regulators on the activity of bmyD::lacZ reporter fusions 
In order to obtain further information concerning the transcriptional regulation of 
bacillomycin D, a series of mutations were introduced in transcriptional regulatory proteins 
and sigma factors of the bacterium. Some of the genes mutated are also found in the genome 
of B. subtilis, whereas others are novel members of the genome of B. amyloliquefaciens 
FZB42. The several mutations were then crossed over into strains AK9 and AK10 (AK11 was 
excluded from these experiments, since it displays the same pattern of gene expression as 
AK10). Thereby, it was possible to monitor the behaviour of the mutant strains by calculating 
their β-galactosidase activities along the growth curve and comparing them to that of the wild 
type strain. 
Using this approach, several players involved in the regulation of the bmy operon were 
identified. Two two-component response regulator proteins were found to be essential for full 
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activation of the operon: DegU, known to control the expression of degradative enzymes 
[229, 230] and to be involved in the initiation of competence [231] and ComA, a regulator of 
late-competence genes [232] and surfactin production [112]. Moreover, the sporulation sigma 
factor σH [233] regulates expression of bacillomycin D. 
The effects of DegU, ComA and σH on the activity of reporter fusions are analytically 
presented in Figure 26. Inactivation of the genes coding for each of the above proteins 
resulted in severely impaired promoter activity during stationary phase, especially in strains 
harbouring the whole promoter region (AK9 derivatives). bmy expression was 3-4-fold lower 
in the degU, comA and sigH mutant derivatives of AK9 (AK32, AK22 and AK52 
respectively) compared to the parental strain AK9 (Fig. 26), and similar to that of wild type 
strain AK10, carrying the shorter promoter region (its 5'-end is deleted 183 bp upstream of the 
bmyD translational start). Furthermore, in the absence of DegU, ComA or σH, the activity of 
AK10 derivatives (AK33, AK23 and AK53 respectively) was also reduced in comparison to 
that of the parental strain AK10, albeit to a much smaller extent (Fig. 26). 
Therefore DegU, ComA and σH are all required for the full activation of the bmyD 
promoter and their effects seem to be mostly exerted through the DNA region located 
between -400 and -183 bps upstream of the gene’s translational start. Despite the severity of 
the reported effects, the expression of bmy is not completely silenced by any of those 
mutations (on the contrary to the promoter silencing observed with strain AK12; (Fig. 22B), 
insinuating that the σA-dependent promoter retains both stationary phase induction and basic 
levels of bmy expression without any of these regulators (see also Discussion). 
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Figure 26: Effects of ComA, DegU and σH on the expression of the various bmyD::lacZ 
fusions. 
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Strains AK9 and AK10, carrying the two bmyD::lacZ fusions with the longest upstream promoter 
region and the highest activity (see also Fig. 21, 22), and their degU (A), comA (B) and sigH (C) 
mutant derivatives were grown in Difco medium at 37°C and optical densities (closed symbols) and 
specific β-galactosidase activities (in Miller Units; open symbols) were determined along the growth 
curve. In each panel the expression of the fusions in the wild-type background is provided for direct 
comparison to that of the mutants. Squares, AK9; diamonds, AK10; triangles, mutant derivatives of 
AK9 (AK32 in A, AK22 in B, AK52 in C); circles, mutant derivatives of AK10 (AK33 in A, AK23 in 
B, AK53 in C). 
 
 
In addition, the effect of σH cannot be associated with the presence of a second upstream 
promoter, since primer extension experiments ruled out such as a scenario (see above). 
Consistently, no similarity with the promoter consensus sequence of σH (AGGANNT-15-
17bp-GAAT; [234] could be found in the entire bmy promoter region. Thus, the effect of σH 
exerted on Pbmy is indirect. 
Deletion mutants of several other transcriptional regulators and sigma factors did not 
significantly influence the expression of the bmy operon, as shown by monitoring the 
activities of the respective reporter strains along the growth curve (data not shown). The 
genes/operons tested were: an uncharacterised two-component system RBAM01839-
RBAM01840 in the close proximity of bmy operon, present only in FZB42 (the homology to 
other known two-component systems of B. subtilis is very low; higher scores with yvrGH; 
[235]; yerPO, YerP belongs to a resistance-nodulation-cell division (RND) family proteins 
and is involved in surfactin immunity/production [170] whereas YerO is a putative 
transcriptional regulator encoded adjacent to it; spaR, encoding a response regulator that 
activates subtilin production and immunity [33], present in B. amyloliquefaciens FZB42 but 
not in B. subtilis MO1099; sigW, encoding an extracytoplasmic sigma factor involved in 
antibiotic resistance [236]; and aat, encoding a putative transcriptional regulator direct 
downstream of srfAD, that is only present in B. amyloliquefaciens FZB42 (see also Fig. 15). 
 
Effects of degU, comA, sigB and sigH mutations on transcriptional initiation by the 
identified promoter of bmy operon (Pbmy) 
Reporter fusions showed that DegU, ComA and σH positively regulate transcription of the 
bmy operon in B. amyloliquefaciens FZB42. To obtain further proof, the effects of these 
mutations on the activity of Pbmy were examined by primer extension. In addition the role of 
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σB, the general stress sigma factor in Bacilli [237, 238], was also investigated. Total RNA was 
extracted from wild type or mutant cells that had reached middle stationary phase, and primer 
extension was performed as described earlier (see 3.4.2 and materials and methods). 
A unique transcriptional start site was identified for the bmy operon in both the wild 
type and the four mutant strains, and as expected coincided with the one reported in the 
previous section (Fig. 24). However the intensity of the obtained transcripts varied 
enormously at the different genetic backgrounds; the wild type strain produced a strong and 
clearly distinguishable transcript whereas degU, comA, sigH and sigB mutant strains gave 
only weak but reproducible signals (Fig. 27), a sign of decreased Pbmy promoter activity. This 
finding is in perfect agreement with our previous results (Fig. 26), identifying DegU, ComA 
and σH as positive regulators of Pbmy in stationary phase. It also verifies our previous 
statement that cells lacking those regulators are still able to show basal expression of the σA-
dependent Pbmy. Moreover, σB serves as a new positive transcriptional regulator of the bmy 
operon; its effects were of similar magnitude to those of the other three regulators (Fig. 27), 
and most probably exerted through an indirect mechanism since there are no sequences in the 
bmyD promoter region that apparently resemble the promoter consensus sequence of σB 
(GTTT-15-17bp-GGGWAW, where W stands for A/T; [239] see also section 3.4.5). 
 
 T    G     C    A   1    5  4      3      2      1
 
 
Figure 27: Effects of degU, comA, sigB and sigH mutations on the activity of the bmy 
operon promoter (Pbmy). 
Cells were grown in Difco medium and 2.5-3 hours after entry into stationary phase, total RNA was 
extracted from B. amyloliquefaciens FZB42 and its mutant degU (TF1), comA (CH23), sigB (CH33) 
and sigH (AK50) derivative strains. Primer extension was performed using the same amount of total 
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RNA (40 µg) and the 5'-end 32P radiolabelled primer rev1. Sequencing ladders were generated with the 
same primer. Intensities of the obtained transcripts indicate the effects exerted by the respective 
mutations on the activity of the Pbmy promoter. 1, B. amyloliquefaciens FZB42; 2, TF1; 3, CH23; 4, 
AK50; 5, CH33; +1 and the arrow both indicate the transcriptional start. 
 
Several more transcriptional regulators and sigma factors were deleted or disrupted and 
their role on bmy operon’s transcription was further assessed by primer extension analysis: 
sig01, an extracytoplasmic sigma factor identified for the first time in FZB42; sigD, the 
Bacillus sigma factor involved in chemotaxis, flagella synthesis, motility [240]; three more 
extracytoplasmic sigma factors, encoded by sigX, sigV, sigW and different combinations of 
them [236, 241, 242]; and codY, encoding a global transcriptional regulator in B. subtilis 
[243] and a direct repressor of surfactin expression [169]. All these mutant strains produced 
an equally strong transcript signal as that of the wild type strain, indicating that they do not 
play a role in transcription of the bmy operon (data not shown). 
 
MALDI-TOF MS analysis of B. amyloliquefaciens FZB42 strains deficient of global 
regulators that are involved in transcription of the bmy operon; DegU has a post-
transcriptional effect on bacillomycin D production 
In order to decipher how the reported effects of DegU, ComA,  σB and σH on bmy 
transcription reflect to the end-production of bacillomycin D, we decided to monitor the 
antibiotic’s synthesis in the different mutant strains by mass spectrometric analysis. MALDI-
TOF MS was performed using culture filtrates of the degU, comA, sigH and sigB mutant 
derivatives of B. amyloliquefaciens FZB42 (grown with aeration for 24h in Landy medium), 
and the obtained spectra were compared to that of the wild type, in order to evaluate the 
relative production levels of bacillomycin D in the different genetic backgrounds. Even 
though this type of analysis does not provide accurate quantitative results, relative production 
of bacillomycin D can be roughly estimated by comparing the intensity values of the peaks 
that correspond to bacillomycin D with the intensity values of the surrounding peaks 
(belonging to other peptide products) in the wild type and mutant strains. 
It has been previously shown that mutations in degU, comA, sigH and sigB severely 
impair but do not silence transcription of the bmy operon. Consistently, bacillomycin D 
production was defected but not entirely blocked in the comA, sigH and sigB mutant strains, 
since the intensities of the peaks reflecting the presence of bacillomycin D were considerably 
weaker in the spectra of the mutant strains compared to the spectrum of the wild type strain 
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(Fig. 28). However, no bacillomycin D could be detected from a culture filtrate stemming 
from the degU strain (Fig. 28.E and F), suggesting that the role of DegU in bacillomycin D 
production goes beyond than the mere activation of the Pbmy promoter. 
 
Figure 28: MALDI-TOF MS analysis of comA, sigB, sigH and degU mutant strains. The 
absence of DegU deprives the cell of bacillomycin D production (performed in 
collaboration with Dr. J. Vater and Xiao-Hua Chen). 
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Spectra of culture filtrate extracts prepared from B. amyloliquefaciens FZB42 and its mutant 
derivatives, after 24 hours growth in Landy medium. A. In the wild type strain, bacillomycin D (m/z 
1053.3, 1097.4) is the antibiotic produced in the highest amounts under these conditions (see also 3.3), 
judged from the intensities of its peaks, whereas the siderophore bacillibactin (m/z 833, 905 and 921; 
see also 3.5) and surfactin (m/z 1044) follow in production scale. The peaks corresponding to fengycin 
production (m/z 1463.7, 1501.6) are the ones with the lowest intensity. For more details concerning the 
exact number of peaks that define the presence of an antibiotic in the external milieu of B. 
amyloliquefaciens FZB42 see also Table 8. B-D. The production pattern of the four compounds 
changes in comA (B), sigB (C) and sigH (D) mutants. In all three cases the levels of bacillomycin D 
are relatively low in comparison with the other the antibiotics and in most cases hardly exceed them. 
In addition the intensities of the peaks corresponding to fengycin seem increased in all three mutants, 
rendering thus fengycin as one of the major antibiotics produced by B. amyloliquefaciens FZB42 in 
these genetic backgrounds (see also 3.5 and Table 11). As expected, the comA mutant strain (B) is 
deficient of surfactin production [161, 162]. E-F Bacillomycin D is absent in the degU mutant strain. 
A zoomed in version of the panel E spectrum is presented in panel F, where only the peaks attributed 




Since in the absence of all four regulatory proteins, i.e. DegU, ComA, σB and σH, Pbmy 
retained its basal expression (Figs 26 and 27), but only in the absence of DegU the production 
of bacillomycin D was completely abolished, DegU seems to have an additional “control-
point” on bmy regulation, at a post-transcriptional level. To test whether the post-
transcriptional effect of DegU was associated with the export of bacillomycin D to the 
extracellular milieu, sonificated cell extracts of the degU strain (grown with aeration for 24h 
in Landy medium) were also analysed by MALDI-TOF MS. No bacillomycin D was apparent 
in the cell extracts too (data not shown), suggesting that DegU influences both transcription of 
the bmy operon, and also a step post to transcription of bmy but prior to its export to the 
surrounding environment. 
 
DegU directly binds to the bacillomycin D promoter 
DegU was shown to be essential for bacillomycin D production, both at transcriptional and 
post-transcriptional level. In order to fully decipher its role on the activation of Pbmy, the 
response regulator was purified as a C-terminal His6-Taq fusion protein [231], and was further 
used in EMSA and DNAse I experiments. Overexpression and purification of 6xHis-tagged 
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DegU have been already described in detail in material and methods. Analysis by SDS-PAGE 
(Fig. 29) and Western blot revealed that the purification of native 6xHis-tagged DegU (35 
kDa) protein was successful. 




Figure 29: Overexpression and purification of the 6xHis-tagged DegU 
Overexpression and purification of the 6xHis-tagged DegU protein was performed as described in 
detail in chapter 2.5.5. Samples collected from different steps of the purification process were 
analyzed by SDS-PAGE electrophoresis. 6xHis-tagged DegU was the only purified protein. FT, 
sample from flow through; W, sample from a wash step; E1 to E7, samples from elution steps 1 to 7; 




EMSA shows that DegU is a direct activator of the bmy promoter  
Our genetic analyses identified a positive role of the response regulator DegU in bmy 
transcription. To examine whether the bmy promoter is a direct target for DegU, gel 
retardation mobility shift assays (EMSA) of a 450 bp DNA fragment, harbouring regions 
between -342 and +108 relative to the transcriptional start (or -400 to +50 relative to the 
translational start) were performed using increasing concentrations of the response regulator. 
As seen in Figure 30A, the bmyD promoter indeed contains specific binding sites for DegU. 
The DNA fragment was already shifted with 0,2 and 0,4 µM unphosphorylated DegU, in an 
analogous manner to the DegU binding at the comK promoter [231]. Mobility of the 450 bp 
DNA fragment changed dramatically upon incubation with higher amounts of the protein (0,8 
and 1,6 µM), indicating the presence of more than one DegU binding-sites in the promoter 
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region of bmy. The observed shifts are DegU-specific since no migration of the DNA 
fragment was observed upon incubation with the same amounts of BSA (Fig. 30A). 
Since our reporter fusions’ results indicated that DegU influences both expression of the 
shorter and the longer versions of the bmyD::lacZ fusions (present in strains AK9 and AK10; 
Fig. 22), we sought to narrow down the regions that DegU binds. In order to accomplish this, 
gel retardation mobility shift assays were also performed with two smaller DNA fragments. 
Fragment D1 encompassed the region between -342 to –126 bp relative to the transcriptional 
start (or -400 to –184 bp relative to the translational start of bmyD), present only in AK9, 
while fragment D2 encompassed the DNA region between -125 to +108 bp relative to the 
transcriptional start (or -183 to +50 bp relative to the translational start of bmyD), present in 
both strains, AK9 and AK10. EMSA experiments with fragments D1, D2 and increasing 
concentrations of the response regulator revealed that unphosphorylated DegU directly bound 
to both DNA regions, with similar affinities (Fig. 30B). It is also apparent that higher amounts 
of DegU (0,4 or 0,8 µM) lead to a supershift of the two DNA fragments (similar to that 
observed in the EMSA experiments with the DNA fragment encompassing the whole 
promoter region; Fig. 30A). This indicated that the initial DegU binding to the bmy promoter 
region might trigger the co-operative binding of more DegU molecules to the promoter and/or 
change the promoter’s architecture (see also Discussion). 
 
Figure 30: Gel retardation mobility shift assays (EMSA) of the bmyD promoter region 
A) Gel retardation mobility shift assays of a 32P-labeled bmyD promoter fragment using increasing 
concentrations of DegU, as indicated on the top of the gel. The DNA fragment used harbours regions 
 113
between -342 and +108 bp, relative to the transcriptional start. The incubation of the bmy promoter 
region with the BSA protein (same amount as that of the highest DegU concentration used) did not 
cause migration of the DNA fragment.  
B) Gel retardation mobility shift assays using two smaller DNA fragments of the bmyD promoter 
region, D1 and D2, ranging from -342 to -126 bp and -125 to +108 bp respectively (relative to the 
transcriptional start). Gel mobility shifts were performed using 30ng of DNA fragments D1 (left gel) 
and D2 (right gel) and increasing concentrations of DegU, indicated on the top of the gels. A control 
using BSA protein was also performed. Visualization was obtained by ethidium bromide staining. 
 
 
Mapping the location of the DNA-binding sites of DegU on the bmy promoter region 
DNase I footprinting analysis was performed in order to determine the exact location of the 
DegU binding-sites in the bmy promoter region. DNase I treatment followed incubation of 
either a linear DNA fragment encompassing the whole bmyD promoter region or the same 
promoter fragment cloned in a plasmid, and thus supercoiled, with unphosphorylated DegU 
(0, 0,8, 1,6 µM DegU). Primer extension with two different primers enabled the visualization 
of both the template and non-template strand (only the data obtained using the supercoiled 
DNA can be seen in Fig. 31; similar data were obtained with the linear DNA fragment). 
The footprinting patterns obtained with the coding and the non-coding strand lead to 
similar conclusions. In detail, the presence of DegU lead to the protection of a region 
spanning from -123 to -106 (relative to the transcriptional start) on the top strand, followed by 
an extended region of hypersensitive sites ranging from -103 to -85 (Fig. 31). Moreover, 
directly downstream of a series of hypersensitive sites at around -210 of the top strand, is 
situated a relative protected region from DegU between -201 and -172. Consistently the 
bottom strand revealed a strongly protected area from -116 to -99 and a relatively more 
weakly protected region between -198 and -172 upon DegU addition (Fig. 31). Strong 
hypersensitive sites could be observed in the region between -98 and –66, and at -201 and -
203 of the same strand (Fig. 31). 
In conclusion, unphosphorylated DegU binds two distinct sites at the promoter of bmy, 
i.e. Site I (-123 to -99) and Site II (-201 to -172) (see also Fig. 26), inducing bends and local 
changes in the DNA architecture adjacently to these sites (seen as hypersensitive sites). The 
two DNA binding-sites bear the A/T-rich signature of DegU recognition-sites (see also 
Discussion; [244, 245], and their location is also consistent with the data obtained by the gel 
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retardation assays. It is worth mentioning that phosphorylated DegU (after incubation with 
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Figure 31: DNase I footprinting analysis of DegU at the bmy promoter region  
The DNase I digestion patterns were obtained using primer extension in order to be able to monitor 
both linear and supercoiled DNA (here shown the results with the latter). On the left panel can be seen 
the footprint pattern of the coding strand in the presence of increasing concentrations of DegU, 
whereas on the right panel is presented the footprint pattern of the non-coding strand. The protected 
and hypersensitive regions are marked with bars and arrows respectively. The sequence reactions of 
the appropriate DNA strand were used as size markers. 
 
 
The effect of DegU on bmy transcription is epistatic to that of DegQ 
It has been previously observed that DegQ exerts a positive effect on bacillomycin D 
expression (see Fig. 23 and corresponding text), similarly to its role in the production of other 
peptide antibiotics such as iturin A and plipastatin [172, 173]. This effect is most probably 
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mediated in an indirect manner (no DNA-binding ability is predicted for DegQ), requiring the 
existence of a far upstream region in the case of the Pbmy promoter region (between –400 and 
–183 bps in respect with the translational start of the first gene of the operon, bmyD). Since 
DegU has a DNA binding-site in this region (see Figs. 25 and 31), a plausible scenario is that 
the effect of DegQ is mediated through DegU. In addition DegU is known to stimulate the 
expression of degQ [171], and an alternative scenario would be that the transcriptional effects 
of DegU on bmy expression are indirect and are due to decreased DegQ levels. To test these 
hypothesises, the plasmid carrying an IPTG inducible copy of degQ, pAK64, was transformed 
in the degU mutant derivative of B. amyloliquefaciens FZB42. The strain was grown until 
middle-late exponential phase (OD600∼0.7), pAK64 was induced with IPTG, and cells were 
harvested after 4h for total RNA preparation. The supernatants were lyophilized and further 
analyzed by MALDI-TOF mass spectrometry (see Fig. 32B). Primer extension analysis 
revealed that the Pbmy activity was equally low in both the degU mutant and the degU mutant 
with an overexpressed DegQ, in contrast to the strong activity that Pbmy showed in the wild 
type background (Fig. 32A). In addition, bacillomycin D was not detected in the spectrum of 
the degU mutant strain carrying an induced pAK64 (Fig. 32B), similarly to the spectrum 
obtained by the degU mutant strain (Fig. 28F). This means that the effect of DegU on bmy 
expression is epistatic to that of DegQ, and that the latter needs the former in order to exert its 
role. 
 
Figure 32: Increased DegQ cellular levels cannot restore bacillomycin D production in a 
degU- background 
Strain TF1 (degU-) containing pAK64, which carries the degQ gene under an IPTG inducible 
promoter (strain AK58), was grown in Difco medium, supplemented with 5 µg/ml kanamycin, until 
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mid-exponential phase. The plasmid was then induced with 1mM IPTG, the strain was further grown 
for 4 hours and the cells were harvested for total RNA extraction and MALDI-TOF MS analysis.  
A. Primer extension analysis was performed as described previously (see Material and Methods and 
Fig. 27). Intensities of the obtained transcripts indicate the effects exerted on Pbmy promoter activity by 
the respective mutations. 1, B. amyloliquefaciens FZB42; 2, TF1; 3, AK58 (TF1 with pAK64). 
Induction of DegQ expression cannot alleviate the defect that the absence of DegU imposes on Pbmy 
activity. 
B. MALDI-TOF MS analysis of the culture filtrate extracts of strain AK58. Bacillomycin D is not 
synthesized (the obtained peaks are only due to surfactin production, see Table 8). The analysis has 
been done in collaboration with Dr. J. Vater. 
 
 
The fact that ComA is also known to positively regulate the expression of degQ and to 
have an even more pronounced effect than DegU [171], motivated us to clarify whether the 
effect of ComA on bmy expression is imposed through DegQ. However extensive efforts to 
transform a wild type B. amyloliquefaciens FZB42 with pAK64 (that subsequently would be 
modified to a comA- mutant) were unsuccessful. This result deprived us of testing the truth of 
this hypothesis, but generated interesting implications considering the cellular role of DegQ 
(see Discussion). 
 
σB mediates its control on Pbmy by indirectly controlling the repression of 
a novel member of the Rap protein family 
The effects of σB and σH on Pbmy are most probably indirect for reasons explicitly stated above 
(see chapter 3.4.3.2). Since DegU and ComA are also involved in bmy transcription (the 
former also acts directly; see above), we reasoned that several Rap proteins should be also 
indirectly involved in the expression of bacillomycin D. Rap proteins extensively regulate the 
activity of response regulators in B. subtilis, and five of them (out of eleven present in B. 
subtilis) have been shown to directly inhibit the DNA-binding ability of either ComA or 
DegU, i.e. RapC [246], RapF [167], RapK [247], RapG [248] and RapH [249]. Most Rap 
proteins (including all five members named before) come as pair with a small-sized Phr 
protein, which after its synthesis is excreted from the cell and processed to a signal 
pentapeptide [250]. The pentapeptide is re-imported to the cell by an oligopeptide permease 
[251] and inhibits the activity of its cognate Rap protein [166]. The rap-phr gene pairs usually 
constitute operons, but the expression of phr is often controlled by an extra σH- dependent 
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promoter ([234]; see also discussion). Recently RghR (formerly YvaN) was reported to 
repress the expression of rapG and rapH and thereby to have a positive effect in the 
expression of downstream targets of ComA and DegU [249]. Interestingly yvaN had been 
previously identified as a member of the σB regulon [252]. These data provided possible 
links-suggestions to the indirect effects of σB and σH on Pbmy that were further addressed. 
B. amyloliquefaciens FZB42 possesses 9 putative Rap proteins (carrying a TRP-
tetratricopeptide domain), among which only 6 are highly homologous to their B. subtilis 
counterparts (see also Discussion). Both rap targets of RghR (rapG and rapH) are not 
conserved in B. amyloliquefaciens FZB42, but tandem RghR binding-sites [249] are predicted 
in front of one of the novel rap members of the strain, rapX (data not shown). rapX is located 
at the same chromosomal locus as rapG in B. subtilis, but is encoded in the opposite strand, 
carries no obvious phr counterpart (in contrast to rapG) and shares only basic homology to 
rapG (27% in protein level; a percentage similar to that exhibited to other Rap proteins of B. 
subtilis; see also Discussion). 
Having in mind that σB exerts an indirect positive effect on Pbmy, we hypothesized that 
this effect can be mediated through a pathway involving RghR and RapX. To test this 
hypothesis a rapX - and a rapX -sigB- double mutant strain were constructed and assayed 
together with the wild type and sigB- strains for Pbmy activity by primer extension (Fig. 33). 
While the absence of σB (theoretically causes a decrease in RghR levels, and thereby an 
increase in those of RapX) significantly reduced Pbmy activity, the effect was alleviated when 
rapX was also mutated. This derepression observed verified that σB and RapX work on the 
same pathway (with RghR -conserved in B. amyloliquefaciens FZB42- as intermediate) to 
influence the activity of Pbmy. Nevertheless, the Pbmy activity was only slightly higher in the 
rapX - background, compared to that of the wild type (Fig. 33), indicating that RapX is not 
substantially repressing DegU or ComA in stationary phase, where σB activates the expression 
of RghR (see also Discussion and Fig. 39) 
.  
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Figure 33: σB activates expression of Pbmy due to the repression it exerts on a novel Rap 
protein found in B. amyloliquefaciens FZB42, RapX 
Cells were grown in Difco medium and 2.5-3 hours after entry into stationary phase, total RNA was 
extracted from B. amyloliquefaciens FZB42 and its mutant derivatives. Primer extension analysis was 
performed as described previously in detail (see Materials and Methods and Fig. 27). 1, B. 
amyloliquefaciens FZB42; 2, AK59 (rapX::Cmr); 3, CH33 (sigB::Emr); 4, AK57 (rapX::Cmr 
sigB::Emr). The absence of RapX increases Pbmy activity compared to that of the wild type, whereas 
introducing a rapX mutation on the sigB mutant strain leads to a de-repression of the Pbmy activity. This 
indicates that the positive effect of σB on bmy expression is mediated through the repression of RapX, 
which negatively regulates the promoter activity of Pbmy (see also text). 
 
 
From the Raps known to inhibit the function of DegU or ComA in B. subtilis, only 
RapC and RapF are also encoded in B. amyloliquefaciens FZB42. Their cognate Phrs (PhrC 
and PhrF) are both controlled by σH in B. subtilis [234] and the σH-dependent promoter sites 
are conserved in B. amyloliquefaciens FZB42 (data not shown). This insinuates that the 
indirect effect of σH in bmy expression can be mediated through PhrC and PhrF (see also 
Discussion and Fig. 39). 
 
Post-transcriptional effects in bacillomycin D production 
Sfp and YczE control bacillomycin D production in a post-transcriptional manner 
Nonribosomal peptide synthetases require posttranslational modification to be functionally 
active, as already mentioned in the introduction. Sfp, the 4'-phosphopantetheinyl transferase, 
catalyses conversion of the T-domain from its apo- to its holo-form and unblocks synthesis 
(see 1.3.2.3). As expected, MALDI-TOF MS analysis revealed that disruption of sfp gene in 
B. amyloliquefaciens FZB42 (strain CH3) resulted in deficiency in both lipopeptide and 
polyketide synthesis (Fig. 34B) [197]. 
Furthermore, yczE encodes a predicted membrane protein of unknown function and is 
located directly downstream of sfp. Disruption of the yczE gene in B. amyloliquefaciens 
FZB42 shut down the production of bacillomycin D (and polyketides; [197], whereas 
synthesis of fengycin and surfactin remained unimpaired, as demonstrated by MALDI-TOF 
MS analysis of culture filtrate extracts from the corresponding strains (Fig. 34C). Since YczE 
is similar to a membrane protein, its role could be associated with the export of bacillomycin 
 119
D. If this were the case, the antibiotic would be synthesized but would be entrapped inside the 
cell. To test this hypothesis, sonificated cell extracts of the yczE mutant strain were analyzed 
by MALDI-TOF mass spectrometry. Bacillomycin D was not detected inside the cells (data 
not shown) indicating that YczE is not involved in the antibiotic’s export but rather in its 
synthesis in a yet unidentified manner. 
 
Figure 34: MALDI-TOF MS analysis of sfp and yczE mutant strains (performed in 
collaboration with Dr. J. Vater and Xiao-Hua Chen) 
Spectra of culture filtrate extracts prepared from strains grown for 24 hours in Landy medium. A) B. 
amyloliquefaciens FZB42 produces the lipopeptides bacillomycin D (m/z 1053.7, 1097.4), surfactin 
(m/z 1030) and fengycin (m/z 1463, 1501) (see also Table 8 and Fig. 16). B. Introduction of an sfp 
mutation in B. amyloliquefaciens FZB42 causes deficiency in lipopeptide synthesis. C. A yczE mutant 
strain (CH4) produces surfactin (m/z 1030.7, 1058.7) and fengycin (m/z 1463.8, 1485.7) but no 
bacillomycin D. A zoomed in version of this spectrum is presented in panel D, where one can clearly 
see the peaks deriving from surfactin production, but not those expected for bacillomycin D 
production (m/z 1053.7, 1067.7, 1069.7). 
 
 
To test whether the effect of YczE on bacillomycin D synthesis was exerted at the 
transcriptional level, the yczE::Emr was introduced in strains AK9 and AK10 that carry 
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different sized bmyD::lacZ fusions (see also Fig. 22). The expression of the fusions was not 
influenced by the presence of the yczE mutation (Fig. 35). Therefore YczE does not have an 
impact on transcription of bmy operon but exerts its effect post-transcriptionally. The same 
conclusion was reached after checking the Pbmy activity in the yczE background by primer 



























Figure 35: YczE does not influence the expression of the bmy operon 
Strains AK9 and AK10, harbouring lacZ fusions of the bmyD upstream region between -400 and +126 
bp, and between -183 and +126 bp, respectively (see also Fig. 21), and their yczE mutant derivatives 
(AK26, AK27), were grown in Difco medium at 37°C and optical densities (closed symbols) and 
specific β-galactosidase activities (in Miller Units; open symbols) were determined along the growth 
curve. Promoter activity was not altered by the presence of a yczE mutation. Squares, parental strain 
AK9; diamonds, parental strain AK10; triangles, AK26, yczE mutant derivative of AK9; cycles, 
AK27, yczE mutant derivative of AK10. 
 
 
The post-transcriptional effect of DegU on bmy production is not mediated through 
YczE 
It has already been demonstrated that both DegU and YczE influence bacillomycin D 
synthesis in a post-transcriptional manner. Since DegU is a response regulator controlling 
various post-exponential phase responses, it was postulated that it could be involved in 
transcriptional activation of YczE. Thereby the post-transcriptional effect of DegU on 
bacillomycin D production could be also mediated through YczE. In order to test this 
scenario, the transcriptional site of yczE was mapped by primer extension analysis and the 
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promoter activity was measured in different genetic backgrounds; i.e. wild type strain (B. 
amyloliquefaciens FZB42), degU mutant (TF1) and comA (CH23) mutant strains. The latter 
strain was used as a control, since ComA was predicted not to affect yczE transcription, 
(remember that the disruption of comA does not abolish production of bacillomycin D; Fig. 
28). 
The primer extension analysis conducted in the wild type strain revealed three possible 
overlapping transcriptional starts for yczE, but no apparent promoter recognition sequences 
could be traced in front of them (Fig. 36). On the other hand a weaker transcriptional start is 
located directly upstream of these three signals (one and half turn of the DNA helix) and just 
downstream of a perfect extended -10 promoter recognition sequence for the housekeeping 
sigma factor σA (Fig. 36). We propose that this is the real transcriptional start and the other 
signals just derive from 5'-end processing of this main mRNA. Moreover, no significant 
difference in the intensity of the transcripts was detected in the degU and comA mutant strains 
(Fig. 36). These findings indicate that the post-transcriptional effects of DegU and YczE on 
bacillomycin D biosynthesis are mediated through different pathways (see also Discussion). 
 
Figure 36: Mapping of the transcriptional start of yczE by primer extension analysis. 
DegU and ComA do not influence transcriptional initiation from the identified yczE 
promoter (PyczE) 
Cells were grown and total RNA was prepared from them as described in detail in Fig. 24 and in 
Materials and Methods. Primer extension was performed using the 5'-end 32P-labelled primer yczeu 
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(see also Table 4). The first four lanes result from dideoxynucleotide sequencing reactions using the 
same primer. The positions corresponding to the putative yczE transcriptional starts are indicated by 
arrows. The respective DNA sequences are shown in the outside lanes. Transcriptional starts are 
highlighted in bold face, the putative -10 hexamer is underlined and highlighted in bold face, whereas 
the putative extended -10 element is only underlined. Primer extension analysis performed in the wild 
type strain and its mutant derivatives showed no change in the promoter activity. 1, wild type B. 
amyloliquefaciens FZB42; 2, TF1 (degU -); 3, CH23 (comA-). Therefore DegU and YczE eliminate 
bacillomycin D production in B. amyloliquefaciens FZB42 using different pathways. 
 
Global regulators affect the production of surfactin, fengycin and 
bacillibactin 
The MALDI-TOF MS analysis enabled us to monitor the effects that transcriptional 
regulatory proteins and sigma factors exert on the production of other non-ribosomally 
synthesized compounds, apart from bacillomycin D. In the spectra obtained by culture filtrate 
extracts of B. amyloliquefaciens FZB42, fengycin, surfactin, bacillomycin D and the 
siderophore bacillibactin are visible with distinct peaks (see Table 8 and later on in this 
paragraph). Although, as already mentioned before, this type of mass spectrometry does not 
provide accurate quantitative results in respect with the concentrations of the four compounds, 
a rough estimation of their relative abundance can be achieved by comparing the intensity 
values of the peaks belonging to each compound with those belonging to the other three in the 
different genetic backgrounds. Thereby, after 24 hours of growth at 37oC in Landy medium, 
bacillomycin D is the prominent lipopeptide synthesized by B. amyloliquefaciens FZB42, 
followed by bacillibactin and surfactin. Fengycin is the antibiotic with the lowest intensity 
values for its peaks and thus, the lowest abundance (see Figs. 16 and 28A). 
Although the presence of the dhb operon in the genome of B. amyloliquefaciens FZB42 
genome was known (see 3.2), it was uncertain whether the biosynthetic template for the 
catecholic siderophore 2,3-dihydroxybenzoate-glycine-threonine trimeric ester, bacillibactin 
[78], was functional. MALDI-TOF mass spectrometry of culture filtrate extracts prepared 
from B. amyloliquefaciens FZB42, grown for 24 hours at 37°C in Landy medium, verified the 
production of the compound. Peaks with mass numbers of 883, 905 and 921 m/z (Figs. 28A 
and 37A) correspond to the protonated [M+H]+ form and the [M+Na, K]+ alkali adducts of the 
compound, respectively [78]. 
The peaks attributed to bacillibactin were prominent in the spectrum of the wild type 
strain (Fig. 37A), showing higher intensity values than those of surfactin (and fengycin; see 
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Fig. 28A) but lower than the intensities of the bacillomycin D peaks. However, the production 
pattern of the three compounds changed significantly in the degU (TF1) and sigW (AK36) 
mutants (Fig. 37B and C). In the first case (Fig. 37B), surfactin peaks are significantly 
stronger than those of bacillibactin, in contrast to the wild type pattern (Fig. 37A), suggesting 
that the siderophore production is impaired in a degU - genetic background. In consistence 
with our results, microarray analysis combined with northern blot analysis and reporter 
fusions activity assays have previously shown that DegU is a positive regulator of the dhb 
operon in B. subtilis [253]. Moreover, the production of bacillibactin appeared also impaired 
in the sigW mutant strain (Fig 37C). There the intensity values of the peaks representing 
bacillibactin repeatedly dropped to the same levels (or lower) of their surfactin counterparts, 
whereas their difference to the bacillomycin D peaks increased compared to the wild-type 
strain (compare Figs. 37A and C). These findings suggest that σw might positively regulate the 
production and/or export of bacillibactin. Interestingly, stress conditions that provoke iron 
limitation for Bacillus (e.g. high salinity; [221]), trigger both DegU and σw mediated 
responses in order to aid the cell cope with the new conditions [254]. Iron limitation also 
triggers the production of bacillibactin [255], which is then secreted from the cell to work as 
an iron scavenger and then be re-imported into the cell, where its hydrolysis leads to release 
of cytosolic iron [256]. Therefore, a link between the three components, bacillibactin, DegU 
and σw seems plausible (see also Discussion). 
On the other hand, fengycin levels appeared significantly elevated in many cases where 
bacillomycin D production was defected. The comA (CH23), sigH (AK50) and sigB (CH33) 
mutant strains exhibited this behaviour (Fig. 28.B-D and Table 11). However, both the degU 
(TF1) and bmyD (AK1) mutant did not show any significant increase in fengycin synthesis, 
even though they are completely unable to produce bacillomycin D (Figs. 18 and 28D). These 
two results implied that although the same regulatory pathways may differentially act in 
fengycin and bacillomycin D production, it is not the per se production of bacillomycin D that 
represses fengycin expression (see also Discussion). 
Finally, most of the introduced mutations on transcriptional regulatory proteins and 
sigma factors had no apparent effect on the production of surfactin, as observed by MALDI-
TOF MS analysis, since the ratios of the intensity values of surfactin peaks to that of other 
peptide antibiotics were the same for the mutant strains and the wild type. The comA mutant 
strain (CH23) was deficient in surfactin production (Fig 28B), as already described for B. 
subtilis [161, 162]. On the contrary, surfactin production was moderately pronounced in the 
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Figure 37: DegU and σW influence bacillibactin production (performed in collaboration 
with Dr. J. Vater). 
Spectra of culture filtrate extracts prepared from strains grown for 24 hours in Landy medium. A. In 
the spectrum of B. amyloliquefaciens FZB42, the levels of bacillibactin (m/z 883, 905, 921) are lower 
than those of bacilllomycin D (m/z 1053, 1067, 1083) and clearly higher than those of surfactin (m/z 
1060), as judged by the intensity of their peaks. The ratios of the intensity values between the three 
compounds’ peaks change in the degU (B) and sigW (C) mutant strains at the cost of bacillibactin. As 
noticed before, bacillomycin D is not produced (and its peaks are absent) in a degU mutant strain (B), 
whereas the peaks belonging to surfactin (m/z 1044, 1058, 1074) have higher intensity than those of 
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bacillibactin. In the sigW mutant (C) the levels of bacillibactin are significantly lower than in the wild 
type strain (A) and are equivalent to those of surfactin (m/z 1058, 1074). 
 
Table 11: MALDI-TOF MS analysis reveals increased production of fengycin in comA, 
sigB and sigH mutant strains of B. amyloliquefaciens FZB42 
Lipopeptide m/z Species  Intensity in:  
   FZB42 CH23 CH33 AK50 
Surfactin 1044.8 C14 [M + Na]+ 6000 - 6000 1900 
 1058.8 C15 [M + Na]+ 3000 - 5000 1500 
Bacillomycin 1053.7 C14 [M + Na]+ 23000 7200 19000 2600 
D 1067.7 C15 [M + Na]+ 24000 4500 8000 6000 
Fengycin 1485.9 C16 [M + Na]+ 1600 4000 22000 6000 
 1449.9 C17 [M + Na]+ 1200 3200 18000 3400 
Bacillibactin 905 [M+Na]+ 9500 4500 7500 1000 
 921 [M+K]+ 11000 3500 6500 1000 
 
Here are presented the intensities of the main peaks corresponding to the four compounds produced by 
B. amyloliquefaciens FZB42 and its comA (CH23), sigB (CH33) and sigH (AK50) mutant derivatives. 
The entire spectra can be seen in detail in Fig. 28. Note that the intensity values of the peaks are not 
comparable between the different MALDI-TOF spectra (this method does not offer quantitative 
results), but the relative production pattern of the four compounds in the different genetic backgrounds 














Functional genomic analysis of B. amyloliquefaciens strain FZB42 
reveals features of the bacterium that might be associated with its 
biocontrol activity 
The first complete genome sequence of a Gram-positive bacterium was published in 1997 and 
belonged to the best characterized member of the group, i.e. B. subtilis strain 168. During the 
following years, complete genomes of various representatives of the Bacilli family were 
sequenced, such as that of the alkaliphilic bacterium B. halodurans (strain C-125, [258]), and 
those of the pathogenic bacteria B. cereus (strains ATCC 14579, [9]; ATCC 10987, [259] and 
E33L, accession number: NC_006274.1) and B. anthracis (strains Ames, [10] and Sterne, 
accession number: NC_005945). Meanwhile, the genome sequences of B. clausii KSM-K16 
(accession number: NC_006582.1), B. thuringiensis serovar konkukian str.97-27 
(NC_005957.1) and the industrially used bacterium B. licheniformis strain ATCC 14580 (note 
that the strain DSM13 is identical to ATCC 14580, [11, 260] have been completely defined. 
However, until recently no strain of the B. amyloliquefaciens species had been 
completely sequenced. We have determined the complete genomic sequence of the plant 
growth promoting strain FZB42 of B. amyloliquefaciens, which is already commercially 
available as bio-fertilizer. Furthermore, we have tried to identify pathways that contribute to 
the organism’s beneficial role. 
Having the complete sequence of the organism in hand, functional and comparative 
genomic studies can be initiated to fully comprehend the lifestyle of B. amyloliquefaciens 
FZB42. These studies may ultimately lead to the development of new strategies to improve 
the properties of other plant growth promoting Bacilli or, even more, to construction of novel 
bio-fertilizers with more predictable action. Moreover, such comparative genomic analyses 
can provide a better understanding of evolution and phylogenetic relatedness among the 
Bacillus species. 
Although the second round of annotation of the genome of B. amyloliquefaciens FZB42 
has not yet been completed, most of the microorganism’s genes have been assigned with a 




General features of the B. amyloliquefaciens FZB42 genome and 
comparison with genomes of other members of the Bacillus family 
Recent taxonomic studies have shown that B. amyloliquefaciens is closely related to B. 
subtilis and B. licheniformis, based on comparisons of their 16S rDNA and 16S-23S internal 
transcribed spacer (ITS) nucleotide sequences [261]. However, the genome size of B. 
amyloliquefaciens FZB42 is 3,9 Mb and thus significantly smaller than the genomes of all 
other sequenced Bacilli, including that of its close relatives B. subtilis (4,214 Mb; [7] and B. 
licheniformis (4,222 Mb; [11, 260]; Table 12). Furthermore, preliminary data revealed the 
presence of 3931 genes in the B. amyloliquefaciens FZB42 genome, whereas 4112 genes and 
4286 genes are present in the genomes of B. subtilis 168 and B. licheniformis ATCC 14580 
[7, 11], respectively. Almost 80% of the B. amyloliquefaciens FZB42 genes show more than 
50% homology at amino acid level to genes of B. subtilis 168. 
 
 
Table 12: Features of the B. amyloliquefaciens FZB42 genome and comparison with 
genomes of other Bacillus species 
 
B. subtilis 168 [7], B. licheniformis ATCC 14580 [11, 260], B. halodurans C-125 [258], B. anthracis 













































































3916 4214 4222 4202 5227 5427 
G+C content 
(%) 
46 43,5 46,2 43,7 35,4 35,4 
Number of 
genes 
3931 4112 4286 4006 5508 5642 
rRNA 
operons 
11 10 7 8 11 12 
Transposase 
genes 
5 0 10 93 18 10 
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Horizontal gene transfer 
The unique genes of B. amyloliquefaciens FZB42 were found distributed in at least 14 DNA 
islands and islets around the whole genome. Interestingly, most of the DNA islands are 
situated in the same genetic locus where prophage-like elements are found in the B. subtilis 
168 genome, indicating that those regions are susceptible to genetic rearrangements. This is 
the case for the first two DNA islands present in B. amyloliquefaciens FZB42. Both of them 
are inserted in the position of prophage-like elements 1 and 2 from B. subtilis 168, where they 
have replaced the majority of genes. The genome of B. amyloliquefaciens FZB42 includes 
only part of the prophage-like elements found in B. subtilis 168, but in addition it contains 
three transposases in different copy numbers (see Table 7). Interestingly, an insertion 
sequence element showing 51% homology to the IS3Bli1 element of B. licheniformis ATCC 
14580, appears in three copies in the genome of B. amyloliquefaciens FZB42. In contrast, B. 
licheniformis ATCC 14580 has nine copies of the IS3Bli1 element and one more putative 
transposase that is closely related to a transposase previously identified in the 
Thermoanaerobacter tengcogensis genome (Table 12, [260]). B. subtilis 168 does not contain 
any transposases, and it is assumed that horizontal gene transfer is mainly achieved by 
bacteriophages [7]. Obviously, this is not the case for B. amyloliquefaciens FZB42 and the 
other sequenced Bacillus species. An extreme case is that of B. halodurans, which contains 93 
transposase genes of IS elements (Table 12, [258]). On the other hand, the bacteriophages or 
the bacteriophage-like elements (SPβ, PBSX and the skin element) present in the genome of 
B. subtilis 168 are not found in the genomes of any other sequenced Bacilli, and that is also 
the case for B. amyloliquefaciens FZB42. 
 
Signal transduction proteins 
One of the most important and divergent features of microorganisms is their ability to receive 
and respond to different environmental signals. This ability to sense fluctuations in their 
environment defines the capacity of the microorganism to adapt and proliferate in its natural 
habitat. Signal transduction systems are responsible for such processes. Two-component 
regulatory systems (TCS) comprise a large family of signal transducing proteins that 
accomplish the task of monitoring, processing, and responding to a plethora of divergent 
environmental stimuli [262]. They usually consist of a membrane-bound sensor kinase, which 
sensing an environmental stimulus autophosphorylates at a specific histidine residue. 
Subsequently, this phosphate is transferred to a specific aspartate residue in the second 
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component of the system, the cytoplasmatic response regulator protein [263, 264]. Phosphoryl 
transfer to the Asp residue in the N-terminal receiver (REC) domain of the response regulator 
affects the properties of its C-terminal [265, 266, 267]. The activated response regulator 
initiates adaptive changes in behaviour, structure, or physiology of the cell, with most 
response regulators acting as transcriptional repressors or activators [263, 268]. 
TCS are widespread among prokaryotes. Thirty kinase-regulator pairs, that reside in an 
operon, have been found in B. subtilis 168 [7, 269]. Several of those two-component systems 
have been thoroughly characterized. BceRS, LiaRS, YxdJK and YvcPQ, located next to ABC 
transporter or transmembrane proteins, are the only TCS that control the cell envelope stress 
response in B. subtilis 168 [270, 271]. Only the biological function of BceRS and its 
neighbouring ABC transporter, BceAB, is known and that is to control the bacterium’s 
resistance against the cell wall antibiotic bacitracin [270]. BceRS, senses the presence of the 
toxic compound and activates the expression of the ABC transporter BceAB, which 
consequently facilitates the removal of the antibiotic [270, 272]. 
The sensor histidine kinases BceS, LiaS, YxdK and YvcQ of B. subtilis 168 belong to 
the recently-introduced subfamily of intramembrane-sensing histidine kinases (IM-HK) 
[273]. These proteins have striking similarities in their overall domain organisation: they are 
relatively small (less than 400aa) and their N-terminal sensing domain consists of two 
deduced transmembrane helices with a spacing of less than 25 amino acids. Therefore the N-
terminal domain is almost entirely buried in the cytoplasmic membrane, indicating that no 
extracellular stimulus is detected [270]. Moreover, the cytoplasmic transmitter domain 
harbors only the standard features characteristic for all histidine-kinases (HisKA, HATPase_c 
for kinase activity and in some cases the dimerization domain HAMP), but it lacks any 
additional domains that would allow signal detection within the cytoplasm [270]. A very 
recent screen, [273], searching for this group of histidine kinases in completely sequenced 
microbial genomes, revealed 147 intramembrane-sensing histidine kinases (out of 5000 
sensor kinases) with the majority of them found in the Firmicutes phylum (110). One striking 
feature of all studied IM-HKs is their common physiological role: they all seem to sense cell 
envelope stress and regulate genes important for the cell membrane organisation and integrity, 
detoxification and virulence [273]. Furthermore, most of those IM-HKs are located, together 
with their partner response regulator, adjacent to genes encoding ABC transporters or 
conserved transmembrane proteins [273]. 
The genome sequence of B. amyloliquefaciens FZB42 harbours thirty-one gene pairs 
encoding classical TCS. Twenty-one of them are orthologues to respective systems in B. 
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subtilis 168, whereas ten are novel TCS that exhibit high similarity to respective systems of 
other bacteria from the Firmicutes phylum (Table 13). B. amyloliquefaciens FZB42 lacks nine 
two-component regulatory systems encoded by B. subtilis 168 (YbdKJ, YcbLM, YccHG, 
YesMN, YfiJK, YkoGH, YvcPQ, YvfUT, YxjML). Among them, only YvcPQ is of known 
function, and that is associated with the sensing of cell envelope stress, as already mentioned 
above. 
The analysis of the thirty-one sensor kinases present in the genome of B. 
amyloliquefaciens FZB42, using the simple modular architecture research tool (SMART, 
http://smart.embl-heidelberg.de; [274]), accompanied by searches for genomic context 
conservation and sequence homology, revealed that the bacterium encodes five potential IM-
HK. Three of them (BceS, YxdK and LiaS) are direct orthologues to corresponding proteins 
encoded in B. subtilis 168 (70%, 97% and 75% similarity on amino acid level respectively) 
and two (RBAM00197, RBAM03294) are novel proteins. bceS, yxdK, liaS and their cognate 
response regulators are localized in the same genomic context in B. amyloliquefaciens FZB42 
as in B. subtilis 168, i.e. next to genes encoding ABC transporters (ytsCD, yxdLM) or a 
transmembrane protein (yvqF). The high degree of conservation of those TCS between B. 
amyloliquefaciens FZB42, B. subtilis 168 and B. licheniformis ATCC 14580, implies that 
their role in B. amyloliquefaciens FZB42 has also to do with sensing the cell envelope stress 
as it is the case for the other two organisms [270, 271, 275]. 
The histidine kinases RBAM00197 and RBAM03294 display all the structural 
characteristics of IM-HK. RBAM00197 (340 aa) and its cognate response regulator 
RBAM00196 are located next to genes that display similarity to ABC transporters 
(RBAM00198/00199) (Table 13). In addition, the RBAM00196/00197-RBAM00198/00199 
system displays similarity to the BceRS-BceAB, YxdJK- YxdLM systems of B. subtilis 168, 
strengthening our prediction that it also plays a role in cell envelope stress response. 
Interestingly, these sequences comprise part of a 22 kb size DNA island inserted in the 
genome of B. amyloliquefaciens FZB42 at the position where the prophage-like element 1 is 
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RBAM name is the protein name in B. amyloliquefaciens FZB42. The name of the proteins (omitting 
the RBAM prefix) and their positions, indicated in kb, are given in the first column. The two-
component sensor histidine kinase protein (HK) is written first, followed by the two-component 
response regulator (RR). Similarities to the closest homologue are derived by BLASTX alignment and 
are indicated on amino acid level for the overall protein length. The closest homologue’s protein name 
is given if it is known. Minus indicates the absence of a neighbouring ABC transporter to the two-
component system. IM-HK; intramembrane histidine kinase 
 
On the other hand, the two-component system RBAM03294/03295 comprises a two-
gene insertion in a region that is conserved between the genomes of B. amyloliquefaciens 
FZB42 and B. subtilis 168. It is located next to bmrA, a multidrug ABC transporter that is 
functionally active in B. subtilis and is constitutively expressed throughout growth [276]. 
Therefore, it would be intriguing to check if the inserted two-component system has a 
functional link with the multidrug ABC transporter, and whether it alters the regulation of 
bmrA in B. amyloliquefaciens FZB42. Furthermore, a more general function of the IM-HK 
RBAM03294 in the cell envelope stress response should not be excluded. 
The cell envelope is the first and major line of defence against threats from the 
environment. It gives the cell its shape, counteracts the high inner osmotic pressure and 
provides an important sensory interface and molecular sieve between a bacterial cell and its 
surroundings, mediating both information flow and controlled transport of solutes. Therefore, 
monitoring the cell envelope integrity and adequately changing its composition is critical for 
survival. B. amyloliquefaciens FZB42 possesses five candidate two-component systems 
involved in the cell envelope stress response, two of which are novel members among the 
sequenced bacteria, as mentioned above. The closely related bacterium B. licheniformis 
ATCC 14580 possesses only three TCS for the same scope, BceRS, LiaRS and YxdJK, 
shared by B. subtilis 168 and B. amyloliquefaciens FZB42 [275]. B. subtilis 168 has an 
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additional TCS, YvcPQ, that is not found in the two other organisms. All these data indicate 
substantial overlap, but also a degree of differentiation between the three closely related 
bacteria in respect with their response to envelope stress. Different environmental cues trigger 
presumably distinct responses in the three bacteria, which allow them to adopt different 
strategies to survive in their natural habitat, the soil. 
Apart from RBAM00196/00197 and RBAM03294/03295, B. amyloliquefaciens FZB42 
has eight more novel two-component regulatory systems that show similarity to systems 
present in other Bacilli or Clostridia (Table 13). Five of them are located adjacent to novel 
putative ABC transporters. For example, the TCS RBAM03780/03781 is highly homologous 
to the MrsK2R2 proteins of Bacillus sp.HIL-Y85 (92% and 99% similarity on amino acid 
level respectively), which control the immunity against the lantibiotic mersacidin, produced 
by the strain [36, 37]. In parallel, the adjacent putative ABC transporter proteins 
RBAM03782-03784 are almost identical to the MrsFGE transport system (99%, 87% and 
84% similarity on amino acid level respectively), which confers self-protection against 
mersacidin to the producer bacterium [36, 37]. Thereby, it can be assumed that B. 
amyloliquefaciens FZB42 is also immune to mersacidin. Taking into consideration that the 
combination of two-component and ABC transporter systems is characteristic of 
detoxification units, which can selectively sense a harmful for the cell compound and export it 
into the extracellular space [277, 278], we can postulate that the respective systems in B. 
amyloliquefaciens FZB42 control immunity against various antibiotics, produced either by B. 
amyloliquefaciens FZB42 itself or by other competing microorganisms. Thereby, these 
detoxification units provide FZB42 with defensive mechanisms in order to survive in a highly 
competitive environment such as the soil. This resistant capacity of B. amyloliquefaciens 
FZB42 makes the bacterium more competent of surviving in the plant roots, where it exerts its 
biocontrol activity. 
A key issue for the proper functioning of a signal transduction system is its ability to 
balance the input signalling with the output response. This is thought to occur through 
regulation of the overall phosphorylation state of the system and/or through regulation of the 
activity of the output domain of the response regulator. The Rap (response regulator aspartate 
phosphatase) phosphatases are a conserved family of regulatory proteins that negatively 
influence many response regulators [234]. B. subtilis 168 encodes 11 Rap proteins, eight of 
which constitute operons with downstream phr genes [249]. However, the expression of phr 
genes is usually controlled by an additional σH-dependent promoter [234]. Pre-Phr is 
synthesized as a small protein with a putative signal peptide, which is cleaved and secreted as 
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a pentapeptide to the external milieu [250]. The Phr pentapeptide is imported again into the 
cells by an oligopeptide permease [251], and inhibits the activity of its cognate Rap protein 
[166]. The Rap proteins inhibit the action of the target response regulators either by 
dephosphorylating them [279] or by binding to the DNA-binding domain of the response 
regulator [167, 246]. 
B. amyloliquefaciens FZB42 has six Rap proteins that are also present in B. subtilis 168; 
RapA, RapC, RapF, RapB, RapD and RapJ (also the cognate Phr of the first three are 
conserved). Due to high similarity of the Rap proteins and their target response regulators in 
B. amyloliquefaciens FZB42 and B. subtilis 168, it can be assumed that the function of the 
Rap proteins is conserved in the two bacteria. Therefore, RapA, RapB probably have a 
negative influence on the initiation of sporulation, by dephosphorylating Spo0F [279], while 
RapC and RapF probably inhibit binding of ComA to its target genes [167, 246]. It is 
noteworthy that B. amyloliquefaciens FZB42 lacks orthologues of RapG and RapH that 
negatively regulate DegU in B. subtilis 168. 
In addition, B. amyloliquefaciens FZB42 possesses three novel putative Rap proteins 
(Table 14). The novel Rap proteins contain tetratricopeptide (TRP) domains, similarly to 
other members of the Rap family [280]. The TRP domains are thought to be directly 
implicated in protein-protein interactions [281]. It is considered that TRP domains play an 
important role in the interaction between the Rap protein and its cognate Phr [250] and it is 
speculated that Rap proteins, whose inhibitory function is not associated with 
dephosphorylation of their target response regulators, bind to the target regulator through their 
TRP domains [167, 248]. Moreover, no cognate phr genes were identified downstream of the 
three novel rap genes of B. amyloliquefaciens FZB42. Interestingly, RBAM03282 is situated 
at the same genetic locus where RapG is in B. subtilis 168. However, RBAM03282 ows very 
low homology (maximum 27% on amino acid level) to all Rap proteins of B. subtilis 168 but 
relatively high homology to a putative Rap protein of Bacillus licheniformis ATCC 14580 
(YP_080123), which has not been studied so far (48% on amino acid level). We have shown 
that RBAM03282 is involved in the regulation of the bmyD operon and, therefore, designated 
it with a new name, RapX (see chapter 3.4 and later on in Discussion). The functions of the 





Table 14: Novel Rap (response regulator aspartate phosphatase) proteins in the genome 
of B. amyloliquefaciens FZB42 
Protein name Position Size 
(aa) 
Protein name/accession 





RBAM00430 462 358 RapH/P40771 152/353 
(43%) 
B. subtilis 168 
RBAM02010 2082 378 RapA/Q00828* 189/379 
(49%) 
B. subtilis 168 
RBAM03832 
(RapX) 









The position of the proteins is given in kb and the closest homologue is presented, as derived by 
BLASTX alignment. Similarities on amino acid level are indicated for the aligned part of the 
sequences. * The orthologous RapA protein of B. subtilis 168 is present in another position on the 




The model Gram-positive bacterium B. subtilis 168 has 17 σ factors [7], seven of which deal 
with extracytoplasmic functions and therefore are designated as ECF σ factors (σM, σV, σW, 
σX, σY, σZ, σylaC; [282]). On the other hand, B. amyloliquefaciens FZB42 possesses 16 σ 
factors with six of them being ECF σ factors. The two organisms retain conserved all their 
non-ECF σ factors. Five of the ECF σ factors are common between B. subtilis 168 and B. 
amyloliquefaciens FZB42 (σM, σV, σW, σX, σylaC), whereas the latter lacks σYand σZ, but has in 
addition a novel putative ECF σ factor, Sig01. 
ECF σ factors are typically regulated by a co-transcribed membrane-bound anti-sigma 
factor that keeps the sigma factor inactive, bound in the cell membrane [283]. Sig01 is not an 
exception of this rule, since a putative anti-sigma factor is located downstream of its coding 
region. σ01 and anti-σ01 of B. amyloliquefaciens FZB42 display low similarity on amino acid 
level to a novel ECF σ factor (Bli04171) and its cognate anti-sigma factor (Bli04170) (40% 
and 27%, respectively) found in B.licheniformis strain ATCC 14580 [11]. Recently it was 
shown that Bli04171 ECF σ factor (designated σecfH hereafter) is part of the regulatory 
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network that controls the cell envelope stress response in B. licheniformis ATCC 14580, since 
its expression was induced seven- and five-fold after vancomycin and bacitracin treatment, 
respectively [275]. These results indicate that σ01 could be also involved in the cell envelope 
stress response of B. amyloliquefaciens FZB42. Until now, the only knowledge we have about 
the function of σ01 is that it does not control the expression of bacillomycin D (see chapter 
3.4) and most probably the expression of all lipopeptides and polyketides produced by the 
strain (data not shown). Therefore, it would be intriguing to find out whether and how this 
novel ECF σ factor contributes to cell envelope stress response. 
It is noteworthy that a core of five ECF sigma factors are conserved in B. 
amyloliquefaciens FZB42, B. licheniformis ATCC 14580 and B. subtilis 168 (σM, σV, σW, σX, 
σylaC). B. amyloliquefaciens FZB42 has one additional ECF σ factor (Sig01), B. subtilis 168 
two (σY and σZ) [282] and B. licheniformis ATCC 14580 has three (σY, σefcG and σecfH) [275]. 
These findings indicate, once more again, regulatory divergence, but also a partial overlap 
between the three Bacilli in respect with their response to envelope stress. Interestingly, B. 
halodurans strain C-125 has 20 σ factors with only half of them conserved in B. subtilis 168 
[258]. Eleven σ factors belong to the ECF family, but only one (σW) is homologous to the 
ECF σ factors of B. subtilis 168, indicating that its unique ECF σ factors regulate special 
mechanisms that allow the bacterium to live in an alkaline environment [258]. 
Competence genes 
Genetic or natural competence is a physiological differentiation state in which bacteria are 
able to take up exogenous DNA from the medium. The molecular processes involved in the 
competence development in the model gram-positive bacterium B. subtilis have been studied 
extensively over the last decades. The establishment of competence requires at least 25 
different genes, acting together in a finely intertwined cascade of signal transduction 
pathways and regulatory circuits, reviewed in [284]. B. amyloliquefaciens FZB42 is a natural 
competent strain (deviating from the transformation protocol published for B. subtilis 168 
[205])was developed in this study, see Materials and Methods) and its genome contains 
orthologs of all genes involved in the development of competence in B. subtilis 168. In 
contrast, B. licheniformis ATCC 14580 is not naturally transformable due to the lack of a 
comS homologue and to a transposon insertion into the comP gene [260]. 
Despite that the majority of competence genes in B. amyloliquefaciens FZB42 are 
highly homologous to their counterparts of B. subtilis 168, the genes that control the 
competence quorum-sensing system of B. amyloliquefaciens FZB42 (comQ, comX, comP) 
exhibit low similarity to the respective genes of B. subtilis 168 (36%, 31% and 55%, 
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respectively). Such low sequence similarity of the competence quorum-sensing system has 
been already observed among various Bacillus isolates [285]. The genetic polymorphism 
extends through comQ, comX and the 5' two-thirds of comP [285], as it is the case in B. 
amyloliquefaciens FZB42. Furthermore, it was exhibited that this genetic variability is 
correlated with specificity in the quorum-sensing response, so that each pheromone is sensed 
only by its cognate receptor [286]. The quorum-sensing locus may have been introduced by 
horizontal transmission into a common ancestor of Bacillus strains and thereafter subjected to 
strong positive selection, which resulted into a dramatic sequence polymorphism and 
pheromone specificity [287]. 
In addition, B. amyloliquefaciens FZB42 was found to be competent in an earlier stage 
of growth than its closely related B. subtilis 168; the former showed increased transformation 
rates during mid to late exponential phase (see Materials and Methods), whereas the latter is 
known to become competent upon entry into stationary phase [204]. It is tempting to 
speculate that B. amyloliquefaciens FZB42 exhibits a distinct temporal regulation of its 
competence gene circuit from its sibling B. subtilis 168, apart from maintaining its specific 
pheromone (ComX)-modificator (ComQ) pair for initiating the competence process. 
Identifying the differentially regulated competence genes between the two organisms would 
be a future challenge, since it will permit the genetic manipulation of two organisms in order 
to modify/improve their DNA uptake, both in terms of yield and of chronological occurrence. 
 
Secondary metabolites 
B. amyloliquefaciens FZB42 encodes eight gene clusters which are responsible for the 
nonribosomal synthesis of secondary metabolites. These operons comprise 8% of the 
bacterium’s genome and encode for peptide/polyketide antibiotics and a siderophore. We 
have verified the functionality of all eight gene clusters and we believe that the secondary 
metabolites produced enable B. amyloliquefaciens FZB42 to dominate over competing 
organisms within its natural environment and/or serve as signals that trigger cellular responses 
to the receiving organisms in the surrounding [288, 289]. 
In detail, B. amyloliquefaciens FZB42 is able to produce three distinct lipopeptide 
antibiotics: surfactin, fengycin and bacillomycin D. All three lipopeptides are synthesized 
nonribosomally according to the multicarrier thiotemplate mechanism (see introduction; 
review by [48]. Surfactin is encoded by the srf operon, which is also found in the genome of 
B. subtilis 168, a strain unable to produce lipopeptides or polyketides due to frameshift 
mutation on the sfp gene [174]. The chromosomal locus, as well as the organisation of the 
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genes and modules within the srf, operon are identical among the two bacteria; only the 
downstream-flanking genes of the srf operon vary. One of these genes is aat, a putative 
transcriptional regulator. No dramatic change in the production of surfactin or of other 
lipopeptides was observed when aat was deleted in strain FZB42 (data not shown). Moreover, 
the aat deletion had no effect on the transcriptional regulation of bacillomycin D (see chapter 
3.4). However, we have no data about the effects caused by the aat deletion on the 
transcriptional regulation of surfactin, fengycin and the polyketides. Therefore, the putative 
function of aat in the regulation of lipopeptides and polyketides should be more closely 
examined. 
Surfactin is known to provide antibacterial activity to the producer strain, since it can 
penetrate bacterial membranes and disturb their function [290]. In addition, it is essential for 
the swarming motility of the microorganism [132, 133, 134, 135], as well as for the formation 
of biofilms [136, 137]. Thereby, surfactin controls colonization of surfaces and can aid in 
acquisition of nutrients though its surface-wetting and detergent properties [291]. Recently, it 
was shown that surfactin is required for the development of aerial structures in the biofilms 
produced by B. subtilis, which resemble the fruiting-body formation by myxobacteria [288, 
292]. Moreover, it was shown that the surfactin produced by B. subtilis acts antagonistically 
against Streptomyces coelicolor by inhibiting its development of aerial hyphae and spores 
[288]. Interestingly, surfactin did not inhibit the vegetative growth of Streptomyces coelicolor, 
as a typical antibiotic would do, but prevented a specific developmental process of 
Streptomyces coelicolor [288]. Therefore, surfactin protects B. amyloliquefaciens FZB42 
against bacteria [197] and enables it to form biofilms, equipping thus the bacterium with 
powerful antagonistic advantages during surface colonization. 
The bmy and fen operons are responsible for the biosynthesis of bacillomycin D and 
fengycin in B. amyloliquefaciens FZB42, respectively. These gene clusters are located at the 
same chromosomal locus with a distance of about 25 kb between them. Interestingly, the gene 
clusters directing the biosynthesis of bacillomycin L in B. subtilis A1/3 and iturin A (a 
lipopeptide with similar structure as bacillomycin D) in B. subtilis RB14 are situated at the 
same position as the bmy operon in B. amyloliquefaciens FZB42. In addition, the pps operon 
in B. subtilis 168, which is assigned to fengycin biosynthesis (despite of the strain’s inability 
to produce it), as well as the fen operon in the producer B. subtilis strains F29-3 [222] and 
A1/3 [140], are located at the same genetic locus as the fen operon in B. amyloliquefaciens 
FZB42. On the other hand, the genome of B. subtilis ATCC 6633 contains the myc operon 
(directing the biosynthesis of mycosubtilin, an iturin-like lipopeptide) at the same position 
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that the fen operon occupies in strains F29-3 and A1/3 [63]. These findings indicate high 
degree of genetic flexibility in this region and suggest that additional nonribosomal peptide 
synthetases (NRPS) can be integrated in it either as an insertion or as a substitution of already 
existing NRPS operons. 
Synthesis of bacillomycin D occurs according to the multicarrier thiotemplate 
mechanism. We have tried to verify the biosynthetic pathway of bacillomycin D by disrupting 
one by one the last six modules (in specific the respective adenylation domains) of the 
nonribosomal peptide synthetase and then by trying to identify the intermediate elongation 
variants (see Fig. 20 and chapter 3.3). However, the expected products could not be detected 
by MALDI-TOF MS analysis of neither culture filtrate extracts nor sonificated cell extracts. 
This indicates that only the full length lipopeptide is exerted from the cell, whereas the 
intermediate products are covalently attached to the multienzyme system, from which they 
can not be completely detached, even after sonification. A possible way to achieve 
detachment of the products from the enzymes would be reaction with a suitable thiol- 
compound, such as cysteine or cysteamine. Reaction with such a compound, under the 
appropriate conditions, could lead in the transfer of the thioester bound product onto the free 
thiol-group, rendering thus possible the identification of the obtained intermediate variants of 
bacillomycin D by MALDI-TOF MS. We are currently pursuing this issue further, in 
collaboration with Dr. J. Vater. 
Bacillomycin D and fengycin inhibit the growth of various phytopathogenic fungi. 
Abolishment of each antibiotic led to decreased inhibition of the fungal growth, compared to 
the wild type strain; the effect of fengycin was smaller than that of bacillomycin D. Deletion 
of both antibiotics deprived B. amyloliquefaciens FZB42 of its antifungal abilities (see 
chapter 3.3). Thereby, we have demonstrated a synergistic action of both lipopeptide 
antibiotics against the target microorganism, a phenomenon previously described for 
secondary metabolites produced by actinomycetes. The synergistic activity of the antibiotics 
had been interpreted as an evolved adaptation mechanism of the producer organism in order 
to compete with other microorganisms and maintain its sessile lifestyle [293]. In the case of 
B. amyloliquefaciens FZB42, the level of fengycin production is considerably lower than that 
of bacillomycin D and thus the observed synergistic effect of the antifungal compounds was 
unexpected. 
Interestingly, several of the mutant derivatives of B. amyloliquefaciens FZB42 have 
opposing effects on the production of bacillomycin D and fengycin. In particular, we have 
shown that the comA, sigH and sigB mutations reduce bmy expression by several-fold (Fig. 
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28A-D), whereas preliminary data obtained by MALDI-TOF MS analysis of the respective 
mutant strains show enhanced production of fengycin (see chapter 3.5). On the other hand, the 
bmyD (AK1) and degU (TF1) mutant strains, that completely lack bacillomycin D, did not 
display an elevated production of fengycin. These results suggest that the same regulatory 
pathways (and not itself the production of bacillomycin D) may opposingly direct the 
regulation of both antifungal compounds. The bacterium can, thereby, enhance the expression 
of fengycin in conditions where the expression of bacillomycin D is low. In this way, any 
single fengycin or bacillomycin D mutant retains a considerable inhibitory effect on fungal 
growth compared to the double mutant. 
It is noteworthy that bacillomycin D and fengycin, in contrast to surfactin, have no 
effect on biofilm formation (data not shown; [137]). Recently, iturin A (that belongs to the 
same family of peptide antibiotics like bacillomycin D) was shown to inhibit sporulation of 
Streptomyces scabies, but not its growth [289]. This suggests that bacillomycin D and 
fengycin might have additional roles as secondary messengers. 
The genome of B. amyloliquefaciens FZB42 contains three giant modular polyketide 
gene clusters (for details see [197]. The bae operon is responsible for the biosynthesis of 
bacillaene, a conjugated hexaene with a linear structure [294], whose chemical structure is 
still unknown. The dif gene cluster is devoted to the synthesis of difficidin and oxydifficidin, 
which are highly unsaturated 22-member macrolides with a rare phosphate group [295]. The 
third polyketide gene cluster is designated pks2 and is involved in the synthesis of 
macrolactin (K.Schneider and Xiao-Hua Chen, unpublished results). Notably, this is the first 
time that the complete gene clusters involved in the biosynthesis of bacillaene and 
difficidin/oxydifficidin are defined. Modular organisation of the three pks clusters in B. 
amyloliquefaciens FZB42 revealed an unusual trans-AT architecture, which indicates that all 
PKS modules lack an AT domain and are complemented by ATs encoded on isolated genes 
[197]. This unusual trans-AT architecture was recently described for a polyketide synthase-
peptide synthetase gene cluster of an uncultured bacterial symbiont of Paederus beetles [296]. 
B. subtilis 168 possesses only one large polyketide gene cluster, designated pksX. 
However, this strain is unable to produce the respective polyketide, due to a mutation in the 
sfp (4'-phosphopantetheinyl transferase) gene [174]. Therefore, until recently it was not 
known which polyketide is synthesized by the pksX cluster. We have demonstrated that B. 
subtilis OKB105, a sfp+ derivative of B. subtilis 168, is able to produce bacillaene indicating 
that pksX directs synthesis of this polyketide [197]. 
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Bacillaene and difficidin/oxydifficidin exhibit strong antibacterial activities, whereas 
macrolactin inhibits the growth of B. megaterium and E. carotovora only weakly [197]. 
Interestingly, bioautographs of the wild type strain and the sfp (CH3) mutant derivative of B. 
amyloliquefaciens FZB42 (that is deficient in lipopeptide and polyketide synthesis) on B. 
megaterium lawn, revealed the production of an antibacterial compound with unknown 
structure [197]. 
In addition, the genome of B. amyloliquefaciens FZB42 contains the bac operon that 
controls the synthesis of the dipeptide bacilysin [217]. Organisation and localization of the 
bac operon in the genomes of B. amyloliquefaciens FZB42 and B. subtilis 168 are identical. 
Recently it was shown in B. subtilis 168 that genes bacDE are involved in amino acid ligation 
and bacilysin immunity, respectively [297]. 
Bacilysin is active against a wide range of bacteria [218]. It was suggested that its 
antibacterial spectrum overlaps with that of the polyketide compounds bacillaene and 
difficidin [137]. However, bacilysin does not account for the remaining antibacterial 
compound detected in the sfp mutant derivative of B. amyloliquefaciens FZB42, as observed 
in bioautographs on B. megaterium lawn [298]. This is the first evidence for an additional 
ribosomally produced, antibacterial compound of B. amyloliquefaciens FZB42. 
The last operon involved in the nonribosomal synthesis of a compound in B. 
amyloliquefaciens FZB42 is that of dhb. The dhbACEBF operon is involved in the synthesis 
of 2,3-dihydroxybenzoate (DHB) as well as its modification and esterification to the iron 
siderophore bacillibactin [78] that enables microorganisms to efficiently scavenge iron [220, 
221]. Bacillibactin was detected in the culture filtrate extracts of B. amyloliquefaciens FZB42, 
verifying the functionality of the dhb operon (Fig. 37). Both the organisation and the 
localization of the operon are conserved between B. amyloliquefaciens FZB42 and B. subtilis 
168. 
Iron is an essential trace element for all bacteria [299]. In many aerobic, neutral or 
alkaline environments, Fe+2 is present in only suboptimal concentrations due to its low 
solubility. Microorganisms have therefore developed elaborate systems for scavenging iron 
from environmental sources. These systems frequently involve the synthesis of high-affinity 
chelators, their excertion into the environment, and the recapturing of the iron-loaded chelator 
via affinity transport systems [300, 301]. Similarly, iron limitation triggers the production of 
bacillibactin [255] in Bacilli, which is then secreted from the cell to act as an iron scavenger 
and then is re-imported into the cell, where its hydrolysis leads to release of cytosolic iron 
[256]. In a highly competitive environment, such as the plant rhizosphere, the microorganisms 
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that can make use of the environmental iron are more likely to survive. Therefore, it is 
possible that B. amyloliquefaciens FZB42 enhances plant growth by depriving soil pathogenic 
microorganims of iron, like already proposed for other plant growth promoting rhizobacteria 
(PGPR) [302]. 
In conclusion, the genome of B. amyloliquefaciens FZB42 contains eight operons that 
direct nonribosomal synthesis of three lipopeptides, three polyketides, one dipeptide and a 
siderophore. These compounds exhibit strong antifungal and antibacterial activities and 
enable the bacterium to survive in its natural environment. As B. amyloliquefaciens FZB42 
colonizes the plant roots, it inhibits growth of phytopathogenic bacteria or fungi either by 
depriving them of the essential iron (through the action of bacillibactin) or by directly 
inhibiting their growth and/or certain of their developmental processes (through the actions of 
lipopeptides and polyketides). We must note that antibiotic activity is possibly not the only 
function of lipopeptides and polyketides produced by B. amyloliquefaciens FZB42. Surfactin 
is involved in intercellular signalling [288] and may be other secondary metabolites play also 
a role in interspecies communication and thereby affect the developmental pathway of a 
bacterium without influencing its vegetative growth. Until now, only preliminary studies have 
been performed with cocultivated bacteria, a situation that resembles more the natural 
settings. 
Interestingly, B. amyloliquefaciens FZB42 does not produce most of the ribosomally 
synthesized peptide antibiotics that B. subtilis 168 does. The genome of B. amyloliquefaciens 
FZB42 does not contain the gene clusters of bacteriocins subtilosin (sbo-alb) and the SPβ 
proghage-encoded sublancin (see chapter 1.3.1). Moreover, the bacterium does not produce 
the antibiotic-like killing factor Skf (sporulation killing factor) or the toxic protein SdpC 
(sporulation delay protein) [303]. Notably, SdpC is present only in B. subtilis strains and 
orthologues of it have not been identified in other bacteria including all Bacillus species 
sequenced to date [223]. 
Recently, it was reported that the sfp derivative of B. amyloliquefaciens FZB42 inhibits 
the growth of a sigW deficient strain of B. subtilis as strongly as the wild-type strain FZB42 
[223]. B. amyloliquefaciens FZB42 exhibited one of the strongest inhibitory effects on a sigW 
mutant of B. subtilis, among several members of the Bacilli family tested. This indicates that 
B. amyloliquefaciens FZB42 encodes ribosomally synthesized peptide(s) or toxic protein(s) 
with antibacterial function, as observed in experiments on B. megaterium lawn performed in 
our lab. The ydbST and fosB (yndN) genes, present also in the genome of B. amyloliquefaciens 
FZB42, contribute to resistance against these antimicrobial compound(s), albeit to a smaller 
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extent than σW [223]. Other members of the σW regulon could be also involved in promoting 




A complex network controls the expression of bacillomycin D in B. 
amyloliquefaciens FZB42 
Bacillomycin D is a nonribosomally-synthesised heptapeptide with a β-amino fatty acid 
moiety that belongs to the same structural family of peptide antibiotics as iturin and 
mycosubtilin. Several studies have successfully elucidated the physicochemical and biological 
properties of several peptides that belong to this group [115, 304, 305]. Furthermore the 
mechanism of the compounds’ synthesis has been documented and the multienzyme 
complexes responsible for the biosynthesis of mycosubtilin and iturin A have been identified 
and partially characterized [63, 101]. In contrast, neither the regulatory pathways that control 
the expression of the iturin-like lipopeptides, nor the mechanisms that govern their export into 
the surrounding milieu of the cell, have been studied until now. 
In this study we have shown that the expression of bacillomycin D is driven by a 
stationary-phase induced σA promoter, Pbmy, in B. amyloliquefaciens FZB42 (Figs. 22B and 
24). An identically organised promoter has been reported to control the expression of iturin A 
in B. subtilis RB14 [101], though the reported transcriptional start differs from the one we 
identify here (it is situated 1bp downstream). In addition, we have identified three global 
regulators, DegU, DegQ, ComA and two sigma factors σB and σH that positively influence the 
transcriptional activation of Pbmy in B. amyloliquefaciens FZB42, and a novel Rap protein that 
exerts a negative effect on Pbmy. Interestingly, Pbmy retains basal levels of activity even in the 
absence of the above-mentioned activators. Taking into consideration the strong similarity of 
the upstream regions between the promoters of itu and bmy, it would be not surprising if the 
same global regulators control the expression of iturin A. 
 
The role of DegU on bmy expression and bacillomycin D production 
DegU is a two-component system response regulator of the LuxR-FixJ family, whose 
members have a helix-turn-helix (HTH) structure at their C-terminus [306]. It is known to 
control many cellular processes, including exoprotease production, competence development, 
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motility and to trigger post-exponential-phase responses under growth limiting conditions 
[245, 307]. Recently, two genome-wide transcriptional profiling studies have been published 
for the role of DegU in B. subtilis [253, 257]. Although none of them directly compared the 
gene expression in the wild-type strain versus that of the isogenic degU mutant, an extensive 
regulon was identified for DegU. In addition, DegU has been associated with response of B. 
subtilis to high salinity [205, 254]. 
To our knowledge, this is the first time that DegU is demonstrated to play a central role 
in the regulation of a nonribosomally synthesized antibiotic. A series of in-vivo and in-vitro 
data demonstrated that DegU directly activates the expression of Pbmy (see also Figs. 26, 27 
and 30). In addition, the results from the EMSA and the DNase I footprinting experiments 
(see also Figs. 30 and 31) coincided and pointed out that DegU retains two distinct DNA 
binding-sites at the bmy promoter. The first site, Site I, is located relative near to the 
transcriptional start, between bps -123 and -99 (relative to the transcriptional start), whereas 
the second one, Site II, is situated further upstream between -201 and -172 (see Figs 25 and 
31). Binding of DegU to the latter upstream site is absolutely essential for the optimal 
activation of the promoter (see Figs. 22B and 26A). The existence of a third DegU binding-
site that is located more upstream than –230 bps should not be excluded, since our in-vitro 
footprint data do not provide conclusive evidence for this region. 
This is the second study to date, which has directly monitored the binding of DegU to a 
promoter by footprinting analysis. The protection that DegU offers to the DNA at its two 
binding-sites is quite weak, similarly to that exhibited in the previous study by Hamoen et al. 
(2000). On the contrary, strong hypersensitive sites can be observed adjacently to the two 
DNA binding-sites, implying that the binding of DegU to its sites rearranges the local DNA 
architecture, probably by inducing strong DNA-bending, constraint or even unwinding, which 
makes the DNA more accessible to DNase I attack. This correlates well to the role of DegU in 
the activation of the comK promoter [231]. Based on a series of data, Hamoen et al. proposed 
that DegU alters the shape of the ∼ 4 DNA helixes that separate the tandem ComK boxes 
(possibly by unwinding and/or bending the DNA), and, thereby, facilitates the binding of 
ComK to them; ComK can then stimulate the transcription of its own promoter. 
There are several reasons why the binding of DegU to the DNA only weakly protects 
the latter against DNase I attack. First, both in our experiments and the Hamoen et al. (2000) 
study, unphosphorylated DegU was used for the footprinting analysis. Although in many 
studies response regulators are used in their unphosphorylated form in order to demonstrate 
DNA-binding, the use of the phosphorylated response regulator can often result in more 
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distinct/extended regions being protected against DNAse I cleavage [162, 308]. I also 
performed the footprinitng analysis with phosphorylated DegU (after incubation with “cold” 
acetyl phosphate) and obtained very similar results to those of the unphosphorylated DegU. 
Even though incubation of a response regulator with acetyl phosphate should result in its 
phosphorylation, no direct proof can be provided whether transphosphorylation actually took 
place, without using radioactive acetyl phosphate. Nevertheless, experiments with 
unphosphorylated response regulator can provide important information on its DNA-binding 
ability as seen before in many cases, such as that of UhpA, ComA and Spo0A [162, 308]. 
Another reason for the weak protection patterns of DegU is the nature of its binding-
sites. A/T-rich DNA regions, such as the DNA-binding-sites of DegU, are more curved and 
therefore less accessible to DNase I, even when the DNA is naked without any protein bound 
to it. Thus, the A/T-rich DNA-binding-sites appear protected even in the absence of their 
binding partner. Hydroxyl radical footprinting has given more clear results in such cases, and 
should be considered as an alternative method in future studies. 
Despite the fact that in-vitro assays monitoring the binding of DegU to DNA promoter 
regions are limited [231, 244, 248], two possible motifs have been suggested as putative 
DegU recognition-sites [244, 245]. Shimane et al (2004) based on in-vivo data from the aprE 
and comK promoters proposed that DegU recognises an A/T-rich motif (either a tandem 
repeat of a 5-nucloetide sequence TAAAT or an inverted repeat of ATTTA-N7-TAAAT), 
whereas Dartois et al. (1998) based on in-vivo studies in the wapA promoter and an alignment 
of DegU-regulated promoters, proposed AGAA-N11-TTCAG as the recognition site for 
DegU. Although none of these studies provides conclusive evidence and they are 
contradicting to each other, degenerate forms of the latter motif could be identified in the 
DegU protected regions at the bmy promoter region (both sites I and II; see also Fig. 25), 
whereas the A/T-rich motifs proposed by Shimane et al (2004) were part of the hypersensitive 
sites that were generated at the bmy promoter region upon addition of DegU in the DNase I 
footprints. In any case, further experimental evidence, involving extensive site-directed 
mutagenesis, will be required to identify the consensus sequence recognised by DegU in Pbmy 
and/or other promoters. 
All previous studies which have carefully assessed the binding of DegU (always 
unphosphorylated DegU used) to different promoter regions (comK and aprE; [231, 244, 
248]) have shown a picture similar to the one exhibited in this study (Fig. 30). Increasing 
amounts of DegU cause a gradual shift of the DNA fragment. In most cases, DNA binding-
proteins that recognise defined motifs at the DNA and bind tightly to it produce distinct shifts 
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that their number reflects how many binding-sites are present at this DNA fragment. If there 
is not enough protein in the assay to fully occupy the DNA binding-site(s) then the bound 
(shifted) and the unbound DNA are in equilibrium. The pattern of the band-shift assays 
produced by DegU at the bmy promoter raise interesting mechanistic scenarios in respect with 
how DegU binds to the promoter and activates transcription. It seems plausible that initial 
DegU binding serves as an anchor to further recruit DegU molecules to the promoter. 
However till now, little is known about the multimerisation state of DegU when it binds to its 
target sites, or what the helix-turn-helix of each DegU molecule recognises as DNA binding-
motif. 
As mentioned above, the in-vivo data (see also Figs. 22 and 26) of this study pinpoint an 
upstream regulatory region as absolutely essential for the maximal activation of the Pbmy 
promoter by DegU and the rest of the global regulators identified here to be involved in the 
bmy expression (see also below; most of them are shown or proposed to mediate their effects 
indirectly, via DegU). Nevertheless, the in-vitro data (Figs. 30 and 31) suggest that DegU 
retains at least two DNA binding-sites. The first of them (site I) is centred in a region that is 
not shown to be able to activate per se the Pbmy promoter, i.e site I is included in AK10, which 
does not show a significant difference in its activity from AK11, which lacks the DegU 
recognition site I (Figs. 21, 22 and 25). On the contrary site II of DegU is located within the 
upstream DNA region that is necessary for the promoter activation (Figs. 21, 22 and 25). We 
propose that the binding of DegU to Site I triggers a sharp DNA bend directly downstream of 
it and thus enables the DegU bound to Site II to activate the promoter (Fig. 38). This is a 
rather common transcriptional activation mechanism. 
 
Figure 38: Proposed mechanism of action of DegU on the Pbmy promoter. 
This figure illustrates how DegU might activate the function of the vegetative RNA polymerase 
(RNAP) on the Pbmy promoter. DegU is shown to bind to its identified DNA sites in dimers for 
presentational reasons (direct information for this is missing). Site I and site II are located between -
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123 and -99 bps, and between -201 and -177 bps (relative to the transcriptional start), respectively. 
The DNA U-turn, shown directly downstream of site I, reflects to the strong hypersensitivity that this 
site exhibits in the DNase I footrpinting experiments. The DNA bending that possibly occurs directly 
upstream of site II (see DNase I footprints) is not shown in this picture for presentational reasons. The 
two C-terminal domains of the α subunit (designated as αCTD) are tethered with a flexible linker to 
the RNAP-bound N-terminal domains of the α subunit (designated as αNTD). Stars indicate possible 
interactions between RNAP and DegU. The binding of DegU to its site I alters the relative location of 




It is generally accepted that DegU has two modes of action: phosphorylated DegU 
directly activates degradative enzyme production and represses motility, whereas 
unphosphorylated DegU directly stimulates competence [307] through binding to the comK 
promoter [231]. The belief that only unphosphorylated DegU is required for competence was 
supported by the observation that hyperphosphorylation of DegU (degU32(Hy) shows a 7-
fold increase in the stability of the phosphorylated form of DegU) or inactivation of the 
degSU operon decreased competence, whereas inactivation of degS alone left competence 
unaffected. Moreover, a DegU mutant with an impaired phosphorylation site had no effect in 
competence [307]. However there are alternative explanations why the hyperactive form of 
DegU, or the complete absence of DegU, hinder competence, whereas the modest activity of 
the unphosphorylated DegU is enough to activate competence. DegU has opposing effects to 
different members of the DNA uptake gene-cascade. On one hand, it co-activates with ComK 
the comK promoter [231], but on the other hand it represses the srf operon [257] and 
therefore, also inhibits the expression of comS. Reduced ComS levels result into an enhanced 
MecA/ClpCP-mediated degradation of ComK [309]. Thus, it may well be that the final output 
of DegU on ComK is only positive, when the levels of DegU and/or its DNA binding affinity 
are relatively low (remember that the unphosphorylated form of response regulators has 
usually weaker binding affinity to its DNA targets; see above). On the contrary, when the 
cellular amounts or activity of DegU increase then the negative effect on comS expression 
prevails. Further evidence for such a scenario can be deduced by the genome-wide 
transcriptional profiling by Ogura et al (2001). In this study, the DegU regulon was identified 
by comparing a degS mutant strain with its isogenic strain (degS mutant too), having though 
DegU overexpressed from a plasmid. comK was not part of the induced genes, whereas all the 
phosphorylated DegU-dependent genes were. This insinuated that the phosphorylation state of 
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DegU alone does not dictate the targets of DegU. It is probably the DegU amounts and 
relative activity (which can be modulated by the phosphorylation state of the protein) that do 
so. 
In our case, DegU activates the expression of the bmy operon during stationary phase 
growth, and therefore it seems plausible that the phosphorylated form of DegU is more 
suitable for optimal promoter binding and activation. However more direct evidence would be 
required for verifying this suggestion (see also above). 
Finally, DegU seems to have a pronounced role in the synthesis of bacillomycin D since 
in its absence, B. amyloliquefaciens FZB42 is defected solely in the production of this peptide 
antibiotic (Fig. 28). This detrimental effect on bacillomycin D production cannot be only due 
to the reported effect of DegU on the Pbmy promoter, since several other regulators exert 
effects of similar extent on the promoter activity, but do not completely inhibit the synthesis 
of the antibiotic (Figs. 26-28). Two scenarios can explain this situation. First, it is possible 
that DegU also controls the activity of a second, yet unidentified, internal promoter in the bmy 
operon. In this case, the mutation of degU would be deleterious for bacillomycin D 
biosynthesis, since more than one promoter responsible for the expression of the bmy operon 
would be strongly hindered. However, till now, there are no reports about internal promoters 
regulating the expression of gene clusters encoding nonribosomal peptide synthetases. A 
second more plausible scenario would be that DegU is involved in the post-transcriptional 
regulation of bacillomycin D. DegU would then have to control the expression of a protein 
involved in the synthesis of bacillomycin D, but not in its export (no bacillomycin D was 
detected in sonificated cell extracts of the degU– mutant). The possibility that this protein is 
Sfp should be ruled out, since DegU exerts a specific effect only on bacillomycin D. In 
contrast, production of surfactin, fengycin and the three polyketides was not impaired in the 
degU mutant stain. Moreover, DegU is not involved in the transcriptional regulation of yczE, 
which also controls the production of bacillomycin D in a post-transcriptional manner (see 
later and Fig. 36). Therefore, the putative post-transcriptional effect of DegU on the synthesis 
of bacillomycin D should be mediated through pathways independent of Sfp and YczE, and 
prior to the antibiotic’s export out of the cell. 
 
The role of DegQ on bmy expression 
DegQ is a small pleiotropic regulatory protein, which consists of 46 amino acids and controls 
the expression of degradative enzymes, intracellular proteases and several other secreted 
enzymes (levansucrase, β-glucanase, xylanase, subtilisin and α-amylase) [171, 224]. Lately it 
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was also shown to stimulate the expression of several peptide antibiotics [172, 173]. DegQ 
shares no homology to typical transcriptional regulators, i.e. DNA-binding proteins. It may be 
located adjacently to the competence genes in the chromosome of different Bacilli organisms, 
but its function has been associated with that of DegU, with which they exhibit a significant 
target overlap [171]. In the absence of DegU, DegQ ceases to control the expression of sacB 
(encoding a levansucrase), implying that the effects of DegQ on sacB expression are indirect 
and mediated through DegU [171]. Our results show also that the effects of DegU are 
epistatic to those of DegQ on bacillomycin D production, since DegQ overexpression cannot 
complement for the loss of DegU in terms of bacillomycin D synthesis (see also Fig. 32). 
Thus, it seems plausible that DegQ regulates the transcription of its target genes only in an 
indirect manner, via DegU. DegQ possibly modulates the activity of DegU, via a yet 
unidentified mechanism. It is worth mentioning that DegQ shows homology to a region of the 
eukaryotic A-kinase anchor proteins (Dransfield et al., 1997), and therefore a plausible role of 
it would be that it anchors DegS and facilitates the transphosphorylation to DegU. 
Earlier studies had shown that Bacilli harbour two different versions of the σA-
dependent promoter that is responsible for the transcription of degQ. B. subtilis 168 (and its 
derivative MO1099 used here) carry the degenerated promoter version, whereas B. 
amyloliquefaciens FZB42 possesses the optimised promoter version with a more consensus-
like -10 hexamer, designated as degQ36(Hy) (for more details see corresponding text in 
results). Consistently, strains that carry the degQ36(Hy) show more prominent production of 
the enzymes DegQ regulates [225]. I have shown here that supplying the defected on degQ 
expression, B. subtilis MO1099, with ectopically produced DegQ, results into a 3-fold 
increase in the activity of the bacillomycin D promoter (see also Fig. 23). Moreover, this 
increase could be observed only when both DegU recognition sites were intact in the 
promoter region, verifying that DegQ exerts its role on the promoter activity via the action of 
DegU. In addition, this has been the first time that degQ was demonstrated to have an effect 
on the transcriptional regulation of a nonribosomally synthesized antibiotic. However, this 
effect was not as pronounced as the effect of DegQ on the overall production levels of iturin 
A or plipastatin, where an increase of 8- to 10-fold was observed [172, 173]. This insinuates 
that DegQ has an additional post-transcriptional role on lipopeptide synthesis. Consistently, 
DegU seems to exert a post-transcriptional effect on bmy expression (see above), and 
therefore, the two proteins may act again as a “pair” in the post-transcriptional control of the 
bacillomycin D synthesis. 
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The role of ComA on bmy expression 
A further player that positively influenced the expression of bacillomycin D was the two-
component system response regulator ComA (see also Figs 26 and 27). ComA is known to be 
involved in the regulation of several central developmental processes in the cell. 
Phosphorylated ComA activates the promoter of the srf operon [162], which encodes the 
enzyme complex that catalyzes the synthesis of the surfactin and also the competence 
regulation factor ComS, that lies within and out-of-frame in the srfAB gene. Consequently, 
ComS destabilizes the ternary ComK/MecA/ClpC complex with which ComK is degraded 
[309], releasing, thereby, the competence transcription factor that acts as a key regulator 
element in the development of competence [310]. Thus, ComA triggers the expression of 
surfactin and that of late competence genes. In addition, ComA controls the expression of 
rapA [311], a phosphatase which negatively regulates the initiation of sporulation by 
dephosphorylating Spo0F [279]. rapC and rapF, are also activated by ComA, creating thus a 
negative feedback loop, since both Rap proteins inhibit the function of ComA [167, 311]. 
Finally, ComA has a crucial role in the activation of degQ, along with DegU, which shows a 
more subtle effect on this process [171]. 
Here, we have shown that ComA exhibits similar effects in the activity of Pbmy as DegU 
(Figs. 26 and 27). The effects of ComA were mostly dependent on the presence of an 
upstream DNA region (-342 to -126 bp, relative to the transcriptional start), again similarly to 
those of DegU, raising the possibility that the two proteins mediate their effects on Pbmy 
through the same pathway. Since DegU is shown to directly bind to a DNA-site within this 
region, and ComA controls the expression of DegQ [171], which presumably serves as an 
auxiliary factor to DegU (see above), it would be plausible that the effects of ComA on the 
expression of the bmy operon are indirect and mediated through the DegQ-DegU system (Fig. 
39). It is noteworthy that two ComA-boxes are located upstream of the degQ gene in B. 
amyloliquefaciens FZB42, similarly to the situation in B. subtilis 168 (data not shown). In 
addition, ComA activates both degQ promoter versions [171], and therefore it would be 
expected to promote the expression of DegQ in B. amyloliquefaciens FZB42, too. 
Unfortunately, our attempts to verify the proposed indirect role of ComA, by constructing a 
comA deficient strain of B. amyloliquefaciens FZB42, with degQ being expressed from an 
IPTG-inducible promoter, were unsuccessful (see corresponding section in the Results). 
However, the recognition sequences of ComA have already been identified and consist 
of a palindromic segments, termed as ComA-box, i.e. TTGCGG-N4-CCGCAA [162, 312]. 
The centres of dyad symmetry of the ComA-boxes are separated by about 45 bp. A screen for 
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the above-mentioned motif did not reveal any putative ComA-binding sites at the bmyD 
upstream region. This supports our suggestion that ComA only indirectly controls the 
transcriptional regulation of the bmy operon. Nevertheless, further experimental proof has to 
be provided for this statement. Either band-shift assays or assaying the role of ComA (in the 
presence of degQ being expressed from an IPTG-inducible promoter) on bmy expression in B. 
subtilis MO1099 would tackle the problem. 
It is worth mentioning that the effect of ComA on the final production of bacillomycin 
D was not as devastating as that of DegU (Fig. 28), indicating that the transcriptional control 
of DegU and ComA on bmy expression might be exerted through the same pathway, but this 
is not the case for the post-transcriptional effects on bacillomycin D production (Fig. 39). 
 
The role of σB and σH on bmy expression 
Two sigma factors were shown to positively regulate bacillomycin D transcription: σH, the 
sporulation sigma factor [233] and regulator of late-growth activities [162], and σB, the 
general stress sigma factor in Bacilli [237, 238]. Both of them stimulate the activity of the σA-
dependent Pbmy promoter (Figs. 26 and 27). Their effects on bmy expression are of the same 
magnitude to those of DegU and ComA (Figs. 26 and 27), and are most probably exerted in 
an indirect manner, since there are no sequences in the bmyD promoter region that resemble 
the promoter consensus sequences of σH (AGGANNT-15-17bp-GAAT; [234]) and σB (GTTT-
15-17bp-GGGWAW, where W stands for A/T; [239]). 
Bacillomycin D production was not silenced in the absence of σH and σB, similarly to 
the comA deletion. This indicates that either these sigma factors act principally on ComA or 
that they just moderately modulate the activity of DegU and do not completely abolish it. 
Based on our results and on former studies, we propose that the effects of σH and σB are 
mediated through various Rap proteins that control the activities of ComA and DegU. 
RapC/RapF/RapK and RapG/RapH have been shown to inhibit ComA and DegU, 
respectively, from binding to their target sequences, in B. subtilis 168 [167, 246, 247, 248, 
249]. These Rap proteins directly bind to the C-terminally located DNA-binding domain of 
the two response regulators and, thereby, hinder their transcriptional regulatory function 
[279]. The activity of the above-mentioned five Rap proteins is inhibited by specific, 
adjacently encoded, Phr pentapeptides (see also section 4.1.3). Interestingly, rap and phr 
genes are co-transcribed by a σA-dependent promoter [312], while the phr genes are 
additionally controlled by a σH-dependent promoter [234]. 
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B. amyloliquefaciens FZB42 also encodes rapC, rapF, and their cognate phr genes, but 
lacks orthologues of rapK, rapG, rapH and/or their cognate phr genes (see also section 4.1.3). 
In addition, the bacterium possesses three novel Rap proteins (see also Table 14), which do 
not have a cognate Phr partner. Based on studies performed in B. subtilis 168 [167, 246], and 
our results demonstrating that ComA positively regulates expression of bacillomycin D, it is 
very likely that the effect of σH on the transcriptional regulation of the bmy operon is 
mediated through RapC and RapF. Deletion of σH decreases expression of PhrC and PhrF, 
and, thereby, RapC and RapF can more efficiently inhibit ComA from activating the 
expression of bacillomycin D (Fig. 39). 
In B. subtilis 168, the σB–controlled RghR [252] was recently shown to specifically 
repress rapG and rapH by directly binding to their promoter regions [249]. RghR has no 
effect on other Rap proteins of B. subtilis 168 [249]. Although B. amyloliquefaciens FZB42 
lacks rapG and rapH orthologues, RghR binding-sites were found upstream of one of its 
novel rap members, rapX (see also section 3.4.5). We have shown that a deletion of rapX 
results in enhancement of the Pbmy promoter activity (Fig. 33), which indicates the 
participation of RapX in the antibiotic’s complex regulatory circuit (Fig. 39). However, due to 
its low homology to any of the Rap proteins of B. subtilis 168, it remains unclear whether 
RapX inhibits ComA or DegU or both of them. If the target of RapX is DegU, then the 
presence of increased amounts of RapX (in a sigB mutant) do not completely silence the 
activity of DegU since the sigB deficient strain can still produce bacillomycin D (see also Fig. 
28). RapX could either dephosphorylate its target response regulator(s) or bind to its DNA-
binding site and inhibit its function. Even though there is no direct evidence, we postulate that 
ComA and DegU are inhibited by Rap proteins via the same mechanisms in B. subtilis 168 
and in B. amyloliquefaciens FZB42, i.e. the Rap protein binds to the DNA-binding site of the 
response regulator and blocks its action. 
Furthermore, a double sigB rapX mutation clearly derepressed the expression of 
bacillomycin D, which was defected in the sigB single mutant (Fig. 33). This indicates that 
the effect of σB is mediated through RapX. We presume that the intermediate link is RghR 
(Fig. 39), since rghR (and its promoter region) is highly conserved between B. subtilis 168 
and B. amyloliquefaciens FZB42 and the promoter region of rapX carries optimal DNA 
binding-sites for RghR. Further experimental evidence will be required for our assumption to 
be verified. In addition, it seems plausible that RghR might repress further Rap proteins (that 
inhibit the function of DegU or ComA), since the derepression effect on bmy expression 
observed after introducing a rapX mutation on the sigB mutant strain was not complete. A 
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good candidate would be RBAM00430, which shows 43% similarity on amino acid level to 
RapH of B.subtilis 168, but preliminary searches for RghR binding-sites on its promoter 
region revealed only relatively degenerate motifs in comparison to the published consensus 
sequence of the RghR DNA binding-site [249]. 
 
Post-transcriptional control of bacillomycin D expression 
Sfp and YczE were both shown to post-transcriptionally regulate the expression of 
bacillomycin D. The essentiality of Sfp on nonribosomal synthesis is already known and 
thereby, the strain’s deficiency to produce lipopeptides and polyketides in a sfp- strain was 
expected. Surprisingly, the deletion of the adjacently located gene, yczE, encoding for a 
predicted membrane protein, specifically abolished the production of bacillomycin D (Fig. 
34.C), even though the activity of the Pbmy promoter was not impaired (Fig. 35). YczE is not 
involved in the export of the lipopeptide into the external milieu, similarly to DegU, and it 
exerts its effects through a separate pathway than that of DegU (Fig. 36). Both DegU (see also 
above) and YczE exert distinct control over the expression and the synthesis of bacillomycin 
D than Sfp, and therefore their mechanism of action remains an issue for further research. 
 
Figure 39: A complex regulatory network governs bacillomycin D production in Bacillus 
amyloliquefaciens strain FZB42 
Boxes and cycles indicate ORFs and proteins respectively. Arrows and T-bars indicate activation and 
repression respectively. Interactions that have not been proven are represented by the dotted lines. σA 
and σH represent the promoters of the corresponding genes. Sites I and II are binding sites of DegU at 
the upstream region of bmyD. 
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Finally, the genes governing the export of bacillomycin D or securing the organism’s 
immunity against the lipopeptide have not been identified yet. A novel TCS located upstream 
of the bmy operon (RBAM01839/RBAM01840) was investigated for its role on export of 
bacillomycin D (or other peptide antibiotics) and/or on self-resistance to B. amyloliquefaciens 
FZB42 against the antibacterial compounds produced by the strain. Deletion of this TCS did 
not impair the export of lipopeptides/polyketides, nor did the mutant strain show growth 
disadvantages when mixed with equal amounts of wild-type cells and let grow for several 
generations (data not shown). This indicates that the TCS RBAM01839/RBAM01840 is not 






























Hiermit versichere ich, die vorliegende Dissertation selbstständig verfasst und keine anderen 
als die angegebenen Quellen und Hilfsmittel verwendet zu haben. 
 
 






























































Teile dieser Arbeit sind in folgenden Veröffentlichungen 
erhalten: 
 
1. Alexandra Koumoutsi, Xiao-Hua Chen, Anke Henne, Heiko Liesegang, Gabriele 
Hietzeroth, Peter Franke, Joachim Vater and Rainer Borriss (2004) Structural and 
functional characterization of gene clusters directing nonribosomal synthesis of bioactive 
cyclic lipopeptides in Bacillus amyloliquefaciens strain FZB42, J.Bacteriol, 186(4), 
1084-96 
2. Xiao-Hua Chen, Joachim Vater, Jörn Piel, Peter Franke, Romy Scholz, Katrin Schneider, 
Alexandra Koumoutsi, Gabriele Hietzeroth, Nicolas Grammel, Axel W. Strittmatter, 
Gerhard Gottschalk, Roderich Sussmuth and Rainer Borriss (2006) Structural and 
functional characterization of three Polyketide Sythase Gene Clusters in Bacillus 
amyloliquefaciens FZB42 J.Bacteriol, 188, 4024-4036 
3. Alexandra Koumoutsi, Xiao-Hua Chen, Joachim Vater and Rainer Borriss 
A complex regulatory network governs bacillomycin D expression in Bacillus 
amyloliquefaciens strain FZB42, in Vorbereitung. 
4. Xiao Hua-Chen, Alexandra Koumoutsi, Romy Scholz, Axel Strittmatter, Heiko 
Liesegang, Gerhard Gottschalk, Oleg Reva, Helmut Junge, Rainer Borriss 
Complete genome sequence of the plant growth promoting Bacillus amyloliquefaciens 
strain FZB42, in Vorbereitung. 
5. Xiao-Hua Chen, Alexandra Koumoutsi, Joachim Vater and Rainer Borriss 
More than anticipated - production of novel antibiotics by Bacillus amyloliquefaciens 
FZB42, Review inVorbereitung. 
6. Patent title: Sequenz für die Bacillomycin D Synthese in Bacillus amyloliquefaciens 
FZB42 
Erfinder: Prof. Dr. Rainer Borriss, Alexandra Koumoutsi, Dr. Joachim Vater, Dr. 
Helmut Junge 
Anmeldetag: 14.12.2004 
Amtliches Aktenzeichen : DE 10326394.2  Int. Cl. C12N 15/31 
7. Patent title: Sequences for the synthesis of antibacterial polyketides 
Erfinder: Prof. Dr. Rainer Borriss, Xiao-Hua Chen, Alexandra Koumoutsi, Dr. Joachim 
Vater 
Internationales Veröffentlichungsdatum: 08.12.2005 









































Name   Alexandra Koumoutsi 
Geburtsdatum 12.10.1978 





1984-990   3e Grundschule Volos / Griechenland 
1990–1993   3e Gymnasium Volos / Griechenland 
1990–1996   3e Lyzeum Volos / Griechenland 
 
Studium 
10.1996–09.2001 Studium in der Fachrichtung Chemie an der Aristoteles Universität 
Thessaloniki/Griechenland, Diplomabschluss, Benotung: 7.3/10 
02-09.2000 Diplomarbeit im Biochemischen Labor, Abteilung Biochemie und 
Biotechnologie, Aristoteles Universität Thessaloniki, unter die 
Betreuung von Prof. Dr. P. Arzoglou 





02.2001-06.2001  Freie Mitarbeiterin im Labor von Genetik und Biotechnologie, 
am Institut für Biologie, Universität Athenes, unter die Betreuung von Prof. Dr. 
M. Typas 
Thema:“Mitochondrial gene polymorphisms in isolates of the phytogenic fungi of the 
genus Verticillium” 









































I would like to thank Prof. Dr. Rainer Borriss for giving me the opportunity to work in his 
group and to spend five very creative years in his laboratory. I greatly appreciate his 
continuous advice and interest in my work, but also in my future career. 
 
I would also like to thank Dr. Joachim Vater for his numerous mass spectrometric analyses 
and for stimulating scientific discussions. Apart from that, I am indebted to him for accepting 
to be a referee for this thesis, but also for always be willing to help me out with my future 
career. 
 
I would like to thank Dr. Martin Meixner for his support with the SSH experiments. 
 
Of course, I am grateful to all my colleagues from the “Bakteriengenetik” group for the 
pleasant atmosphere in the laboratory, numerous discussions and their continuous support. 
The time with them in the laboratory, but also outside of it, will always stay in my memory. I 
would especially like to thank Xiao-Hua Chen for the perfect collaboration in the sequencing 
project as well as for sharing with me several of her mutant strains. My special thanks to 
Christiana Müller and Sybille Striegl for their help in several experiments, but also for the 
continuous solving of several everyday problems in the lab; without them things could have 
only been more difficult for the completion of this thesis. 
 
I want also to thank Christina Pesavento for helping me out with writing the german version 
of the summary in my thesis. 
 












[1] Harwood, Colin (1989): Bacillus (vol. 2), Biotechnology Handbooks Plenum Press. 
[2] Ingle, M. B. and Erickson, R. J. (1978): Bacterial alpha-amylases, Adv Appl 
Microbiol (vol. 24), pp. 257-78. 
[3] Fogarty, W.M. (1983): Microbial amylases, Fogarty, W.M., Microbial enzymes and 
Biotechnology pp. pp 1-92, Applied Science, London. 
[4] M. Kilian, U.Steiner, B.Krebs, H.Junge, G.Schmiedeknecht, R.Hain (2000): FZB24 
Bacillus subtilis-mode of action of a microbial agent enhancing plant vitality, 1/00, 
Pflazenschutz-Nachrichten Bayer. 72-93 
[5] Krebs, B., Höding, B., Kübart, S. M., Workie, A., Junge, H., Schmiedeknecht, G., 
Grosch, R., Bochow, H. & Hevesi, M. (1998): Use of Bacillus subtilis as biocontrol 
agent. 1. Activities and characterization of Bacillus subtilis strains., J Plant Dis Prot 
(vol. 105), pp. 181-197. 
[6] Idriss, E. E.; Makarewicz, O.; Farouk, A.; Rosner, K.; Greiner, R.; Bochow, H.; 
Richter, T. and Borriss, R. (2002): Extracellular phytase activity of Bacillus 
amyloliquefaciens FZB45 contributes to its plant-growth-promoting effect, 
Microbiology (vol. 148), No. Pt 7, pp. 2097-109. 
[7] Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A. M.; Alloni, G.; Azevedo, V.; 
Bertero, M. G.; Bessieres, P.; Bolotin, A.; Borchert, S.; Borriss, R.; Boursier, L.; 
Brans, A.; Braun, M.; Brignell, S. C.; Bron, S.; Brouillet, S.; Bruschi, C. V.; Caldwell, 
B.; Capuano, V.; Carter, N. M.; Choi, S. K.; Codani, J. J.; Connerton, I. F.; Danchin, 
A. and et al. (1997): The complete genome sequence of the gram-positive bacterium 
Bacillus subtilis, Nature (vol. 390), No. 6657, pp. 249-56. 
[8] Fleischmann, R. D.; Adams, M. D.; White, O.; Clayton, R. A.; Kirkness, E. F.; 
Kerlavage, A. R.; Bult, C. J.; Tomb, J. F.; Dougherty, B. A.; Merrick, J. M. and et al. 
(1995): Whole-genome random sequencing and assembly of Haemophilus influenzae 
Rd, Science (vol. 269), No. 5223, pp. 496-512. 
[9] Ivanova, N.; Sorokin, A.; Anderson, I.; Galleron, N.; Candelon, B.; Kapatral, V.; 
Bhattacharyya, A.; Reznik, G.; Mikhailova, N.; Lapidus, A.; Chu, L.; Mazur, M.; 
Goltsman, E.; Larsen, N.; D'Souza, M.; Walunas, T.; Grechkin, Y.; Pusch, G.; 
Haselkorn, R.; Fonstein, M.; Ehrlich, S. D.; Overbeek, R. and Kyrpides, N. (2003): 
Genome sequence of Bacillus cereus and comparative analysis with Bacillus 
anthracis, Nature (vol. 423), No. 6935, pp. 87-91. 
[10] Read, T. D.; Peterson, S. N.; Tourasse, N.; Baillie, L. W.; Paulsen, I. T.; Nelson, K. 
E.; Tettelin, H.; Fouts, D. E.; Eisen, J. A.; Gill, S. R.; Holtzapple, E. K.; Okstad, O. 
A.; Helgason, E.; Rilstone, J.; Wu, M.; Kolonay, J. F.; Beanan, M. J.; Dodson, R. J.; 
Brinkac, L. M.; Gwinn, M.; DeBoy, R. T.; Madpu, R.; Daugherty, S. C.; Durkin, A. 
S.; Haft, D. H.; Nelson, W. C.; Peterson, J. D.; Pop, M.; Khouri, H. M.; Radune, D.; 
Benton, J. L.; Mahamoud, Y.; Jiang, L.; Hance, I. R.; Weidman, J. F.; Berry, K. J.; 
Plaut, R. D.; Wolf, A. M.; Watkins, K. L.; Nierman, W. C.; Hazen, A.; Cline, R.; 
Redmond, C.; Thwaite, J. E.; White, O.; Salzberg, S. L.; Thomason, B.; Friedlander, 
A. M.; Koehler, T. M.; Hanna, P. C.; Kolsto, A. B. and Fraser, C. M. (2003): The 
genome sequence of Bacillus anthracis Ames and comparison to closely related 
bacteria, Nature (vol. 423), No. 6935, pp. 81-6. 
[11] Veith, B.; Herzberg, C.; Steckel, S.; Feesche, J.; Maurer, K. H.; Ehrenreich, P.; 
Baumer, S.; Henne, A.; Liesegang, H.; Merkl, R.; Ehrenreich, A. and Gottschalk, G. 
(2004): The complete genome sequence of Bacillus licheniformis DSM13, an 
 163
organism with great industrial potential, J Mol Microbiol Biotechnol (vol. 7), No. 4, 
pp. 204-11. 
[12] Adams, M. D.; Celniker, S. E.; Holt, R. A.; Evans, C. A.; Gocayne, J. D.; Amanatides, 
P. G.; Scherer, S. E.; Li, P. W.; Hoskins, R. A.; Galle, R. F.; George, R. A.; Lewis, S. 
E.; Richards, S.; Ashburner, M.; Henderson, S. N.; Sutton, G. G.; Wortman, J. R.; 
Yandell, M. D.; Zhang, Q.; Chen, L. X.; Brandon, R. C.; Rogers, Y. H.; Blazej, R. G.; 
Champe, M.; Pfeiffer, B. D.; Wan, K. H.; Doyle, C.; Baxter, E. G.; Helt, G.; Nelson, 
C. R.; Gabor, G. L.; Abril, J. F.; Agbayani, A.; An, H. J.; Andrews-Pfannkoch, C.; 
Baldwin, D.; Ballew, R. M.; Basu, A.; Baxendale, J.; Bayraktaroglu, L.; Beasley, E. 
M.; Beeson, K. Y.; Benos, P. V.; Berman, B. P.; Bhandari, D.; Bolshakov, S.; 
Borkova, D.; Botchan, M. R.; Bouck, J.; Brokstein, P.; Brottier, P.; Burtis, K. C.; 
Busam, D. A.; Butler, H.; Cadieu, E.; Center, A.; Chandra, I.; Cherry, J. M.; Cawley, 
S.; Dahlke, C.; Davenport, L. B.; Davies, P.; de Pablos, B.; Delcher, A.; Deng, Z.; 
Mays, A. D.; Dew, I.; Dietz, S. M.; Dodson, K.; Doup, L. E.; Downes, M.; Dugan-
Rocha, S.; Dunkov, B. C.; Dunn, P.; Durbin, K. J.; Evangelista, C. C.; Ferraz, C.; 
Ferriera, S.; Fleischmann, W.; Fosler, C.; Gabrielian, A. E.; Garg, N. S.; Gelbart, W. 
M.; Glasser, K.; Glodek, A.; Gong, F.; Gorrell, J. H.; Gu, Z.; Guan, P.; Harris, M.; 
Harris, N. L.; Harvey, D.; Heiman, T. J.; Hernandez, J. R.; Houck, J.; Hostin, D.; 
Houston, K. A.; Howland, T. J.; Wei, M. H.; Ibegwam, C.; Jalali, M.; Kalush, F.; 
Karpen, G. H.; Ke, Z.; Kennison, J. A.; Ketchum, K. A.; Kimmel, B. E.; Kodira, C. 
D.; Kraft, C.; Kravitz, S.; Kulp, D.; Lai, Z.; Lasko, P.; Lei, Y.; Levitsky, A. A.; Li, J.; 
Li, Z.; Liang, Y.; Lin, X.; Liu, X.; Mattei, B.; McIntosh, T. C.; McLeod, M. P.; 
McPherson, D.; Merkulov, G.; Milshina, N. V.; Mobarry, C.; Morris, J.; Moshrefi, A.; 
Mount, S. M.; Moy, M.; Murphy, B.; Murphy, L.; Muzny, D. M.; Nelson, D. L.; 
Nelson, D. R.; Nelson, K. A.; Nixon, K.; Nusskern, D. R.; Pacleb, J. M.; Palazzolo, 
M.; Pittman, G. S.; Pan, S.; Pollard, J.; Puri, V.; Reese, M. G.; Reinert, K.; 
Remington, K.; Saunders, R. D.; Scheeler, F.; Shen, H.; Shue, B. C.; Siden-Kiamos, I.; 
Simpson, M.; Skupski, M. P.; Smith, T.; Spier, E.; Spradling, A. C.; Stapleton, M.; 
Strong, R.; Sun, E.; Svirskas, R.; Tector, C.; Turner, R.; Venter, E.; Wang, A. H.; 
Wang, X.; Wang, Z. Y.; Wassarman, D. A.; Weinstock, G. M.; Weissenbach, J.; 
Williams, S. M.; WoodageT; Worley, K. C.; Wu, D.; Yang, S.; Yao, Q. A.; Ye, J.; 
Yeh, R. F.; Zaveri, J. S.; Zhan, M.; Zhang, G.; Zhao, Q.; Zheng, L.; Zheng, X. H.; 
Zhong, F. N.; Zhong, W.; Zhou, X.; Zhu, S.; Zhu, X.; Smith, H. O.; Gibbs, R. A.; 
Myers, E. W.; Rubin, G. M. and Venter, J. C. (2000): The genome sequence of 
Drosophila melanogaster, Science (vol. 287), No. 5461, pp. 2185-95. 
[13] Mural, R. J.; Adams, M. D.; Myers, E. W.; Smith, H. O.; Miklos, G. L.; Wides, R.; 
Halpern, A.; Li, P. W.; Sutton, G. G.; Nadeau, J.; Salzberg, S. L.; Holt, R. A.; Kodira, 
C. D.; Lu, F.; Chen, L.; Deng, Z.; Evangelista, C. C.; Gan, W.; Heiman, T. J.; Li, J.; 
Li, Z.; Merkulov, G. V.; Milshina, N. V.; Naik, A. K.; Qi, R.; Shue, B. C.; Wang, A.; 
Wang, J.; Wang, X.; Yan, X.; Ye, J.; Yooseph, S.; Zhao, Q.; Zheng, L.; Zhu, S. C.; 
Biddick, K.; Bolanos, R.; Delcher, A. L.; Dew, I. M.; Fasulo, D.; Flanigan, M. J.; 
Huson, D. H.; Kravitz, S. A.; Miller, J. R.; Mobarry, C. M.; Reinert, K.; Remington, 
K. A.; Zhang, Q.; Zheng, X. H.; Nusskern, D. R.; Lai, Z.; Lei, Y.; Zhong, W.; Yao, 
A.; Guan, P.; Ji, R. R.; Gu, Z.; Wang, Z. Y.; Zhong, F.; Xiao, C.; Chiang, C. C.; 
Yandell, M.; Wortman, J. R.; Amanatides, P. G.; Hladun, S. L.; Pratts, E. C.; Johnson, 
J. E.; Dodson, K. L.; Woodford, K. J.; Evans, C. A.; Gropman, B.; Rusch, D. B.; 
Venter, E.; Wang, M.; Smith, T. J.; Houck, J. T.; Tompkins, D. E.; Haynes, C.; Jacob, 
D.; Chin, S. H.; Allen, D. R.; Dahlke, C. E.; Sanders, R.; Li, K.; Liu, X.; Levitsky, A. 
A.; Majoros, W. H.; Chen, Q.; Xia, A. C.; Lopez, J. R.; Donnelly, M. T.; Newman, M. 
H.; Glodek, A.; Kraft, C. L.; Nodell, M.; Ali, F.; An, H. J.; Baldwin-Pitts, D.; Beeson, 
K. Y.; Cai, S.; Carnes, M.; Carver, A.; Caulk, P. M.; Center, A.; Chen, Y. H.; Cheng, 
 164
M. L.; Coyne, M. D.; Crowder, M.; Danaher, S.; Davenport, L. B.; Desilets, R.; Dietz, 
S. M.; Doup, L.; Dullaghan, P.; Ferriera, S.; Fosler, C. R.; Gire, H. C.; Gluecksmann, 
A.; Gocayne, J. D.; Gray, J.; Hart, B.; Haynes, J.; Hoover, J.; Howland, T.; Ibegwam, 
C.; Jalali, M.; Johns, D.; Kline, L.; Ma, D. S.; MacCawley, S.; Magoon, A.; Mann, F.; 
May, D.; McIntosh, T. C.; Mehta, S.; Moy, L.; Moy, M. C.; Murphy, B. J.; Murphy, S. 
D.; Nelson, K. A.; Nuri, Z.; Parker, K. A.; Prudhomme, A. C.; Puri, V. N.; Qureshi, 
H.; Raley, J. C.; Reardon, M. S.; Regier, M. A.; Rogers, Y. H.; Romblad, D. L.; 
Schutz, J.; Scott, J. L.; Scott, R.; Sitter, C. D.; Smallwood, M.; Sprague, A. C.; 
Stewart, E.; Strong, R. V.; Suh, E.; Sylvester, K.; Thomas, R.; Tint, N. N.; Tsonis, C.; 
Wang, G.; Wang, G.; Williams, M. S.; Williams, S. M.; Windsor, S. M.; Wolfe, K.; 
Wu, M. M.; Zaveri, J.; Chaturvedi, K.; Gabrielian, A. E.; Ke, Z.; Sun, J.; 
Subramanian, G.; Venter, J. C.; Pfannkoch, C. M.; Barnstead, M. and Stephenson, L. 
D. (2002): A comparison of whole-genome shotgun-derived mouse chromosome 16 
and the human genome, Science (vol. 296), No. 5573, pp. 1661-71. 
[14] Dunham, I.; Shimizu, N.; Roe, B. A.; Chissoe, S.; Hunt, A. R.; Collins, J. E.; 
Bruskiewich, R.; Beare, D. M.; Clamp, M.; Smink, L. J.; Ainscough, R.; Almeida, J. 
P.; Babbage, A.; Bagguley, C.; Bailey, J.; Barlow, K.; Bates, K. N.; Beasley, O.; Bird, 
C. P.; Blakey, S.; Bridgeman, A. M.; Buck, D.; Burgess, J.; Burrill, W. D.; O'Brien, K. 
P. and et al. (1999): The DNA sequence of human chromosome 22, Nature (vol. 402), 
No. 6761, pp. 489-95. 
[15] Madigan M.T., J.M.  Martinko, J. Parker (2000): Microbial growth control, P.F.Corey, 
Brock biology of microorganisms, ninth. ed., Prentice Hall, New Jersey. 
[16] Priest, F.G. (1989): Products and Applications, Harwood, C. R., Bacillus (vol. 2) pp. 
303-305, Plenum Press, New York. 
[17] Katz, E. and Demain, A. L. (1977): The peptide antibiotics of Bacillus: chemistry, 
biogenesis, and possible functions, Bacteriol Rev (vol. 41), No. 2, pp. 449-74. 
[18] Hancock, R. E. and Chapple, D. S. (1999): Peptide antibiotics, Antimicrob Agents 
Chemother (vol. 43), No. 6, pp. 1317-23. 
[19] Finking, R. and Marahiel, M. A. (2004): Biosynthesis of nonribosomal peptides, Annu 
Rev Microbiol (vol. 58), pp. 453-88. 
[20] Sankaranarayanan, R.; Dock-Bregeon, A. C.; Romby, P.; Caillet, J.; Springer, M.; 
Rees, B.; Ehresmann, C.; Ehresmann, B. and Moras, D. (1999): The structure of 
threonyl-tRNA synthetase-tRNA(Thr) complex enlightens its repressor activity and 
reveals an essential zinc ion in the active site, Cell (vol. 97), No. 3, pp. 371-81. 
[21] Eriani, G.; Delarue, M.; Poch, O.; Gangloff, J. and Moras, D. (1990): Partition of 
tRNA synthetases into two classes based on mutually exclusive sets of sequence 
motifs, Nature (vol. 347), No. 6289, pp. 203-6. 
[22] Ogle, J. M.; Carter, A. P. and Ramakrishnan, V. (2003): Insights into the decoding 
mechanism from recent ribosome structures, Trends Biochem Sci (vol. 28), No. 5, pp. 
259-66. 
[23] McAuliffe, O.; Ross, R. P. and Hill, C. (2001): Lantibiotics: structure, biosynthesis 
and mode of action, FEMS Microbiol Rev (vol. 25), No. 3, pp. 285-308. 
[24] Sahl, H. G. and Bierbaum, G. (1998): Lantibiotics: biosynthesis and biological 
activities of uniquely modified peptides from gram-positive bacteria, Annu Rev 
Microbiol (vol. 52), pp. 41-79. 
[25] Sahl, H. G.; Jack, R. W. and Bierbaum, G. (1995): Biosynthesis and biological 
activities of lantibiotics with unique post-translational modifications, Eur J Biochem 
(vol. 230), No. 3, pp. 827-53. 
[26] Jung, G. (1991): Lantobiotics: a survey, Nisin and novel lantibiotics pp. 1-34, Escom, 
Leiden. 
 165
[27] Breukink, E. and de Kruijff, B. (1999): The lantibiotic nisin, a special case or not?, 
Biochim Biophys Acta (vol. 1462), No. 1-2, pp. 223-34. 
[28] Brotz, H.; Bierbaum, G.; Reynolds, P. E. and Sahl, H. G. (1997): The lantibiotic 
mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation, Eur J 
Biochem (vol. 246), No. 1, pp. 193-9. 
[29] Banerjee, S. and Hansen, J. N. (1988): Structure and expression of a gene encoding 
the precursor of subtilin, a small protein antibiotic, J Biol Chem (vol. 263), No. 19, pp. 
9508-14. 
[30] Klein, C.; Kaletta, C.; Schnell, N. and Entian, K. D. (1992): Analysis of genes 
involved in biosynthesis of the lantibiotic subtilin, Appl Environ Microbiol (vol. 58), 
No. 1, pp. 132-42. 
[31] Klein, C. and Entian, K. D. (1994): Genes involved in self-protection against the 
lantibiotic subtilin produced by Bacillus subtilis ATCC 6633, Appl Environ Microbiol 
(vol. 60), No. 8, pp. 2793-801. 
[32] Klein, C.; Kaletta, C. and Entian, K. D. (1993): Biosynthesis of the lantibiotic subtilin 
is regulated by a histidine kinase/response regulator system, Appl Environ Microbiol 
(vol. 59), No. 1, pp. 296-303. 
[33] Stein, T.; Borchert, S.; Kiesau, P.; Heinzmann, S.; Kloss, S.; Klein, C.; Helfrich, M. 
and Entian, K. D. (2002): Dual control of subtilin biosynthesis and immunity in 
Bacillus subtilis, Mol Microbiol (vol. 44), No. 2, pp. 403-16. 
[34] Stein, T.; Borchert, S.; Conrad, B.; Feesche, J.; Hofemeister, B.; Hofemeister, J. and 
Entian, K. D. (2002): Two different lantibiotic-like peptides originate from the ericin 
gene cluster of Bacillus subtilis A1/3, J Bacteriol (vol. 184), No. 6, pp. 1703-11. 
[35] Stein, T. (2005): Bacillus subtilis antibiotics: structures, syntheses and specific 
functions, Mol Microbiol (vol. 56), No. 4, pp. 845-57. 
[36] Altena, K.; Guder, A.; Cramer, C. and Bierbaum, G. (2000): Biosynthesis of the 
lantibiotic mersacidin: organization of a type B lantibiotic gene cluster, Appl Environ 
Microbiol (vol. 66), No. 6, pp. 2565-71. 
[37] Guder, A.; Schmitter, T.; Wiedemann, I.; Sahl, H. G. and Bierbaum, G. (2002): Role 
of the single regulator MrsR1 and the two-component system MrsR2/K2 in the 
regulation of mersacidin production and immunity, Appl Environ Microbiol (vol. 68), 
No. 1, pp. 106-13. 
[38] Paik, S. H.; Chakicherla, A. and Hansen, J. N. (1998): Identification and 
characterization of the structural and transporter genes for, and the chemical and 
biological properties of, sublancin 168, a novel lantibiotic produced by Bacillus 
subtilis 168, J Biol Chem (vol. 273), No. 36, pp. 23134-42. 
[39] Dorenbos, R.; Stein, T.; Kabel, J.; Bruand, C.; Bolhuis, A.; Bron, S.; Quax, W. J. and 
Van Dijl, J. M. (2002): Thiol-disulfide oxidoreductases are essential for the production 
of the lantibiotic sublancin 168, J Biol Chem (vol. 277), No. 19, pp. 16682-8. 
[40] Zheng, G.; Hehn, R. and Zuber, P. (2000): Mutational analysis of the sbo-alb locus of 
Bacillus subtilis: identification of genes required for subtilosin production and 
immunity, J Bacteriol (vol. 182), No. 11, pp. 3266-73. 
[41] Zheng, G.; Yan, L. Z.; Vederas, J. C. and Zuber, P. (1999): Genes of the sbo-alb locus 
of Bacillus subtilis are required for production of the antilisterial bacteriocin 
subtilosin, J Bacteriol (vol. 181), No. 23, pp. 7346-55. 
[42] Kleinkauf, H. and von Dohren, H. (1990): Nonribosomal biosynthesis of peptide 
antibiotics, Eur J Biochem (vol. 192), No. 1, pp. 1-15. 
[43] Stein, T.; Vater, J.; Kruft, V.; Otto, A.; Wittmann-Liebold, B.; Franke, P.; Panico, M.; 
McDowell, R. and Morris, H. R. (1996): The multiple carrier model of nonribosomal 
peptide biosynthesis at modular multienzymatic templates, J Biol Chem (vol. 271), 
No. 26, pp. 15428-35. 
 166
[44] von Döhren, H.; Keller, U.; Vater, J. and Zocher, R. (1997): Multifunctional Peptide 
Synthetases, Chem Rev (vol. 97), No. 7, pp. 2675-2706. 
[45] Marahiel, M. A. (1997): Protein templates for the biosynthesis of peptide antibiotics, 
Chem Biol (vol. 4), No. 8, pp. 561-7. 
[46] Mootz, H. D.; Schwarzer, D. and Marahiel, M. A. (2002): Ways of assembling 
complex natural products on modular nonribosomal peptide synthetases, 
Chembiochem (vol. 3), No. 6, pp. 490-504. 
[47] Stachelhaus, T. and Marahiel, M. A. (1995): Modular structure of genes encoding 
multifunctional peptide synthetases required for non-ribosomal peptide synthesis, 
FEMS Microbiol Lett (vol. 125), No. 1, pp. 3-14. 
[48] Sieber, S. A. and Marahiel, M. A. (2005): Molecular mechanisms underlying 
nonribosomal peptide synthesis: approaches to new antibiotics, Chem Rev (vol. 105), 
No. 2, pp. 715-38. 
[49] Cosmina, P.; Rodriguez, F.; de Ferra, F.; Grandi, G.; Perego, M.; Venema, G. and van 
Sinderen, D. (1993): Sequence and analysis of the genetic locus responsible for 
surfactin synthesis in Bacillus subtilis, Mol Microbiol (vol. 8), No. 5, pp. 821-31. 
[50] Dieckmann, R.; Lee, Y. O.; van Liempt, H.; von Dohren, H. and Kleinkauf, H. (1995): 
Expression of an active adenylate-forming domain of peptide synthetases 
corresponding to acyl-CoA-synthetases, FEBS Lett (vol. 357), No. 2, pp. 212-6. 
[51] May, J. J.; Kessler, N.; Marahiel, M. A. and Stubbs, M. T. (2002): Crystal structure of 
DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide 
synthetases, Proc Natl Acad Sci U S A (vol. 99), No. 19, pp. 12120-5. 
[52] Mootz, H. D. and Marahiel, M. A. (1997): The tyrocidine biosynthesis operon of 
Bacillus brevis: complete nucleotide sequence and biochemical characterization of 
functional internal adenylation domains, J Bacteriol (vol. 179), No. 21, pp. 6843-50. 
[53] Stachelhaus, T.; Mootz, H. D. and Marahiel, M. A. (1999): The specificity-conferring 
code of adenylation domains in nonribosomal peptide synthetases, Chem Biol (vol. 6), 
No. 8, pp. 493-505. 
[54] Challis, G. L.; Ravel, J. and Townsend, C. A. (2000): Predictive, structure-based 
model of amino acid recognition by nonribosomal peptide synthetase adenylation 
domains, Chem Biol (vol. 7), No. 3, pp. 211-24. 
[55] Stein, T.; Vater, J.; Kruft, V.; Wittmann-Liebold, B.; Franke, P.; Panico, M.; Mc 
Dowell, R. and Morris, H. R. (1994): Detection of 4'-phosphopantetheine at the 
thioester binding site for L-valine of gramicidinS synthetase 2, FEBS Lett (vol. 340), 
No. 1-2, pp. 39-44. 
[56] Gocht, M. and Marahiel, M. A. (1994): Analysis of core sequences in the D-Phe 
activating domain of the multifunctional peptide synthetase TycA by site-directed 
mutagenesis, J Bacteriol (vol. 176), No. 9, pp. 2654-62. 
[57] Schlumbohm, W.; Stein, T.; Ullrich, C.; Vater, J.; Krause, M.; Marahiel, M. A.; Kruft, 
V. and Wittmann-Liebold, B. (1991): An active serine is involved in covalent 
substrate amino acid binding at each reaction center of gramicidin S synthetase, J Biol 
Chem (vol. 266), No. 34, pp. 23135-41. 
[58] Stachelhaus, T.; Huser, A. and Marahiel, M. A. (1996): Biochemical characterization 
of peptidyl carrier protein (PCP), the thiolation domain of multifunctional peptide 
synthetases, Chem Biol (vol. 3), No. 11, pp. 913-21. 
[59] Stachelhaus, T.; Mootz, H. D.; Bergendahl, V. and Marahiel, M. A. (1998): Peptide 
bond formation in nonribosomal peptide biosynthesis. Catalytic role of the 
condensation domain, J Biol Chem (vol. 273), No. 35, pp. 22773-81. 
[60] Belshaw, P. J.; Walsh, C. T. and Stachelhaus, T. (1999): Aminoacyl-CoAs as probes 
of condensation domain selectivity in nonribosomal peptide synthesis, Science (vol. 
284), No. 5413, pp. 486-9. 
 167
[61] Linne, U. and Marahiel, M. A. (2000): Control of directionality in nonribosomal 
peptide synthesis: role of the condensation domain in preventing misinitiation and 
timing of epimerization, Biochemistry (vol. 39), No. 34, pp. 10439-47. 
[62] Ehmann, D. E.; Trauger, J. W.; Stachelhaus, T. and Walsh, C. T. (2000): Aminoacyl-
SNACs as small-molecule substrates for the condensation domains of nonribosomal 
peptide synthetases, Chem Biol (vol. 7), No. 10, pp. 765-72. 
[63] Duitman, E. H.; Hamoen, L. W.; Rembold, M.; Venema, G.; Seitz, H.; Saenger, W.; 
Bernhard, F.; Reinhardt, R.; Schmidt, M.; Ullrich, C.; Stein, T.; Leenders, F. and 
Vater, J. (1999): The mycosubtilin synthetase of Bacillus subtilis ATCC6633: a 
multifunctional hybrid between a peptide synthetase, an amino transferase, and a fatty 
acid synthase, Proc Natl Acad Sci U S A (vol. 96), No. 23, pp. 13294-9. 
[64] Roy, R. S.; Gehring, A. M.; Milne, J. C.; Belshaw, P. J. and Walsh, C. T. (1999): 
Thiazole and oxazole peptides: biosynthesis and molecular machinery, Nat Prod Rep 
(vol. 16), No. 2, pp. 249-63. 
[65] Walsh, C. T.; Chen, H.; Keating, T. A.; Hubbard, B. K.; Losey, H. C.; Luo, L.; 
Marshall, C. G.; Miller, D. A. and Patel, H. M. (2001): Tailoring enzymes that modify 
nonribosomal peptides during and after chain elongation on NRPS assembly lines, 
Curr Opin Chem Biol (vol. 5), No. 5, pp. 525-34. 
[66] Marshall, C. G.; Hillson, N. J. and Walsh, C. T. (2002): Catalytic mapping of the 
vibriobactin biosynthetic enzyme VibF, Biochemistry (vol. 41), No. 1, pp. 244-50. 
[67] Kohli, R. M.; Trauger, J. W.; Schwarzer, D.; Marahiel, M. A. and Walsh, C. T. 
(2001): Generality of peptide cyclization catalyzed by isolated thioesterase domains of 
nonribosomal peptide synthetases, Biochemistry (vol. 40), No. 24, pp. 7099-108. 
[68] Trauger, J. W.; Kohli, R. M. and Walsh, C. T. (2001): Cyclization of backbone-
substituted peptides catalyzed by the thioesterase domain from the tyrocidine 
nonribosomal peptide synthetase, Biochemistry (vol. 40), No. 24, pp. 7092-8. 
[69] Miller, D. A.; Luo, L.; Hillson, N.; Keating, T. A. and Walsh, C. T. (2002): 
Yersiniabactin synthetase: a four-protein assembly line producing the nonribosomal 
peptide/polyketide hybrid siderophore of Yersinia pestis, Chem Biol (vol. 9), No. 3, 
pp. 333-44. 
[70] Tseng, C. C.; Bruner, S. D.; Kohli, R. M.; Marahiel, M. A.; Walsh, C. T. and Sieber, 
S. A. (2002): Characterization of the surfactin synthetase C-terminal thioesterase 
domain as a cyclic depsipeptide synthase, Biochemistry (vol. 41), No. 45, pp. 13350-
9. 
[71] Patel, H. M. and Walsh, C. T. (2001): In vitro reconstitution of the Pseudomonas 
aeruginosa nonribosomal peptide synthesis of pyochelin: characterization of backbone 
tailoring thiazoline reductase and N-methyltransferase activities, Biochemistry (vol. 
40), No. 30, pp. 9023-31. 
[72] Sieber, S. A. and Marahiel, M. A. (2003): Learning from nature's drug factories: 
nonribosomal synthesis of macrocyclic peptides, J Bacteriol (vol. 185), No. 24, pp. 
7036-43. 
[73] Grunewald, J.; Sieber, S. A. and Marahiel, M. A. (2004): Chemo- and regioselective 
peptide cyclization triggered by the N-terminal fatty acid chain length: the 
recombinant cyclase of the calcium-dependent antibiotic from Streptomyces 
coelicolor, Biochemistry (vol. 43), No. 10, pp. 2915-25. 
[74] Scholz-Schroeder, B. K.; Soule, J. D.; Lu, S. E.; Grgurina, I. and Gross, D. C. (2001): 
A physical map of the syringomycin and syringopeptin gene clusters localized to an 
approximately 145-kb DNA region of Pseudomonas syringae pv. syringae strain 
B301D, Mol Plant Microbe Interact (vol. 14), No. 12, pp. 1426-35. 
 168
[75] Segre, A.; Bachmann, R. C.; Ballio, A.; Bossa, F.; Grgurina, I.; Iacobellis, N. S.; 
Marino, G.; Pucci, P.; Simmaco, M. and Takemoto, J. Y. (1989): The structure of 
syringomycins A1, E and G, FEBS Lett (vol. 255), No. 1, pp. 27-31. 
[76] Vanittanakom, N.; Loeffler, W.; Koch, U. and Jung, G. (1986): Fengycin--a novel 
antifungal lipopeptide antibiotic produced by Bacillus subtilis F-29-3, J Antibiot 
(Tokyo) (vol. 39), No. 7, pp. 888-901. 
[77] Shaw-Reid, C. A.; Kelleher, N. L.; Losey, H. C.; Gehring, A. M.; Berg, C. and Walsh, 
C. T. (1999): Assembly line enzymology by multimodular nonribosomal peptide 
synthetases: the thioesterase domain of E. coli EntF catalyzes both elongation and 
cyclolactonization, Chem Biol (vol. 6), No. 6, pp. 385-400. 
[78] May, J. J.; Wendrich, T. M. and Marahiel, M. A. (2001): The dhb operon of Bacillus 
subtilis encodes the biosynthetic template for the catecholic siderophore 2,3-
dihydroxybenzoate-glycine-threonine trimeric ester bacillibactin, J Biol Chem (vol. 
276), No. 10, pp. 7209-17. 
[79] Weber, G.; Schorgendorfer, K.; Schneider-Scherzer, E. and Leitner, E. (1994): The 
peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is 
encoded by a giant 45.8-kilobase open reading frame, Curr Genet (vol. 26), No. 2, pp. 
120-5. 
[80] Haese, A.; Schubert, M.; Herrmann, M. and Zocher, R. (1993): Molecular 
characterization of the enniatin synthetase gene encoding a multifunctional enzyme 
catalysing N-methyldepsipeptide formation in Fusarium scirpi, Mol Microbiol (vol. 
7), No. 6, pp. 905-14. 
[81] Becker, J. E.; Moore, R. E. and Moore, B. S. (2004): Cloning, sequencing, and 
biochemical characterization of the nostocyclopeptide biosynthetic gene cluster: 
molecular basis for imine macrocyclization, Gene (vol. 325), pp. 35-42. 
[82] Pfeifer, E.; Pavela-Vrancic, M.; von Dohren, H. and Kleinkauf, H. (1995): 
Characterization of tyrocidine synthetase 1 (TY1): requirement of posttranslational 
modification for peptide biosynthesis, Biochemistry (vol. 34), No. 22, pp. 7450-9. 
[83] Stachelhaus, T. and Walsh, C. T. (2000): Mutational analysis of the epimerization 
domain in the initiation module PheATE of gramicidin S synthetase, Biochemistry 
(vol. 39), No. 19, pp. 5775-87. 
[84] Clugston, S. L.; Sieber, S. A.; Marahiel, M. A. and Walsh, C. T. (2003): Chirality of 
peptide bond-forming condensation domains in nonribosomal peptide synthetases: the 
C5 domain of tyrocidine synthetase is a (D)C(L) catalyst, Biochemistry (vol. 42), No. 
41, pp. 12095-104. 
[85] Luo, L. and Walsh, C. T. (2001): Kinetic analysis of three activated phenylalanyl 
intermediates generated by the initiation module PheATE of gramicidin S synthetase, 
Biochemistry (vol. 40), No. 18, pp. 5329-37. 
[86] Luo, L.; Burkart, M. D.; Stachelhaus, T. and Walsh, C. T. (2001): Substrate 
recognition and selection by the initiation module PheATE of gramicidin S synthetase, 
J Am Chem Soc (vol. 123), No. 45, pp. 11208-18. 
[87] Luo, L.; Kohli, R. M.; Onishi, M.; Linne, U.; Marahiel, M. A. and Walsh, C. T. 
(2002): Timing of epimerization and condensation reactions in nonribosomal peptide 
assembly lines: kinetic analysis of phenylalanine activating elongation modules of 
tyrocidine synthetase B, Biochemistry (vol. 41), No. 29, pp. 9184-96. 
[88] Konz, D. and Marahiel, M. A. (1999): How do peptide synthetases generate structural 
diversity?, Chem Biol (vol. 6), No. 2, pp. R39-48. 
[89] Gehring, A. M.; DeMoll, E.; Fetherston, J. D.; Mori, I.; Mayhew, G. F.; Blattner, F. 
R.; Walsh, C. T. and Perry, R. D. (1998): Iron acquisition in plague: modular logic in 
enzymatic biogenesis of yersiniabactin by Yersinia pestis, Chem Biol (vol. 5), No. 10, 
pp. 573-86. 
 169
[90] Billich, A.; Zocher, R.; Kleinkauf, H.; Braun, D. G.; Lavanchy, D. and Hochkeppel, 
H. K. (1987): Monoclonal antibodies to the multienzyme enniatin synthetase. 
Production and use in structural studies, Biol Chem Hoppe Seyler (vol. 368), No. 5, 
pp. 521-9. 
[91] Mofid, M. R.; Finking, R.; Essen, L. O. and Marahiel, M. A. (2004): Structure-based 
mutational analysis of the 4'-phosphopantetheinyl transferases Sfp from Bacillus 
subtilis: carrier protein recognition and reaction mechanism, Biochemistry (vol. 43), 
No. 14, pp. 4128-36. 
[92] Lambalot, R. H.; Gehring, A. M.; Flugel, R. S.; Zuber, P.; LaCelle, M.; Marahiel, M. 
A.; Reid, R.; Khosla, C. and Walsh, C. T. (1996): A new enzyme superfamily - the 
phosphopantetheinyl transferases, Chem Biol (vol. 3), No. 11, pp. 923-36. 
[93] Walsh, C. T.; Gehring, A. M.; Weinreb, P. H.; Quadri, L. E. and Flugel, R. S. (1997): 
Post-translational modification of polyketide and nonribosomal peptide synthases, 
Curr Opin Chem Biol (vol. 1), No. 3, pp. 309-15. 
[94] Quadri, L. E.; Weinreb, P. H.; Lei, M.; Nakano, M. M.; Zuber, P. and Walsh, C. T. 
(1998): Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase for 
peptidyl carrier protein domains in peptide synthetases, Biochemistry (vol. 37), No. 6, 
pp. 1585-95. 
[95] Schwarzer, D.; Mootz, H. D.; Linne, U. and Marahiel, M. A. (2002): Regeneration of 
misprimed nonribosomal peptide synthetases by type II thioesterases, Proc Natl Acad 
Sci U S A (vol. 99), No. 22, pp. 14083-8. 
[96] Schneider, A. and Marahiel, M. A. (1998): Genetic evidence for a role of thioesterase 
domains, integrated in or associated with peptide synthetases, in non-ribosomal 
peptide biosynthesis in Bacillus subtilis, Arch Microbiol (vol. 169), No. 5, pp. 404-10. 
[97] Schwecke, T.; Aparicio, J. F.; Molnar, I.; Konig, A.; Khaw, L. E.; Haydock, S. F.; 
Oliynyk, M.; Caffrey, P.; Cortes, J.; Lester, J. B. and et al. (1995): The biosynthetic 
gene cluster for the polyketide immunosuppressant rapamycin, Proc Natl Acad Sci U 
S A (vol. 92), No. 17, pp. 7839-43. 
[98] Doekel, S. and Marahiel, M. A. (2001): Biosynthesis of natural products on modular 
peptide synthetases, Metab Eng (vol. 3), No. 1, pp. 64-77. 
[99] Weinig, S.; Hecht, H. J.; Mahmud, T. and Muller, R. (2003): Melithiazol biosynthesis: 
further insights into myxobacterial PKS/NRPS systems and evidence for a new 
subclass of methyl transferases, Chem Biol (vol. 10), No. 10, pp. 939-52. 
[100] Garwin, J. L.; Klages, A. L. and Cronan, J. E., Jr. (1980): Structural, enzymatic, and 
genetic studies of beta-ketoacyl-acyl carrier protein synthases I and II of Escherichia 
coli, J Biol Chem (vol. 255), No. 24, pp. 11949-56. 
[101] Tsuge, K.; Akiyama, T. and Shoda, M. (2001): Cloning, sequencing, and 
characterization of the iturin A operon, J Bacteriol (vol. 183), No. 21, pp. 6265-73. 
[102] Nougayrede, J. P.; Homburg, S.; Taieb, F.; Boury, M.; Brzuszkiewicz, E.; Gottschalk, 
G.; Buchrieser, C.; Hacker, J.; Dobrindt, U. and Oswald, E. (2006): Escherichia coli 
induces DNA double-strand breaks in eukaryotic cells, Science (vol. 313), No. 5788, 
pp. 848-51. 
[103] Black, P. N. and DiRusso, C. C. (1994): Molecular and biochemical analyses of fatty 
acid transport, metabolism, and gene regulation in Escherichia coli, Biochim Biophys 
Acta (vol. 1210), No. 2, pp. 123-45. 
[104] Marrakchi, H.; Zhang, Y. M. and Rock, C. O. (2002): Mechanistic diversity and 
regulation of Type II fatty acid synthesis, Biochem Soc Trans (vol. 30), No. Pt 6, pp. 
1050-5. 
[105] Marini, P.; Li, S. J.; Gardiol, D.; Cronan, J. E., Jr. and de Mendoza, D. (1995): The 
genes encoding the biotin carboxyl carrier protein and biotin carboxylase subunits of 
 170
Bacillus subtilis acetyl coenzyme A carboxylase, the first enzyme of fatty acid 
synthesis, J Bacteriol (vol. 177), No. 23, pp. 7003-6. 
[106] Guchhait, R. B.; Polakis, S. E.; Dimroth, P.; Stoll, E.; Moss, J. and Lane, M. D. 
(1974): Acetyl coenzyme A carboxylase system of Escherichia coli. Purification and 
properties of the biotin carboxylase, carboxyltransferase, and carboxyl carrier protein 
components, J Biol Chem (vol. 249), No. 20, pp. 6633-45. 
[107] Harder, M. E.; Ladenson, R. C.; Schimmel, S. D. and Silbert, D. F. (1974): Mutants of 
Escherichia coli with temperature-sensitive malonyl coenzyme A-acyl carrier protein 
transacylase, J Biol Chem (vol. 249), No. 23, pp. 7468-75. 
[108] D'Agnolo, G.; Rosenfeld, I. S.; Awaya, J.; Omura, S. and Vagelos, P. R. (1973): 
Inhibition of fatty acid synthesis by the antibiotic cerulenin. Specific inactivation of 
beta-ketoacyl-acyl carrier protein synthetase, Biochim Biophys Acta (vol. 326), No. 2, 
pp. 155-6. 
[109] Katz, L. (1997): Manipulation of Modular Polyketide Synthases, Chem Rev (vol. 97), 
No. 7, pp. 2557-2576. 
[110] Cane, D. E. (1997): Introduction: Polyketide and Nonribosomal Polypeptide 
Biosynthesis. From Collie to Coli, Chem Rev (vol. 97), No. 7, pp. 2463-2464. 
[111] Hopwood, D. A. (1997): Genetic Contributions to Understanding Polyketide 
Synthases, Chem Rev (vol. 97), No. 7, pp. 2465-2498. 
[112] Peypoux, F.; Bonmatin, J. M. and Wallach, J. (1999): Recent trends in the 
biochemistry of surfactin, Appl Microbiol Biotechnol (vol. 51), No. 5, pp. 553-63. 
[113] Lin, T. P.; Chen, C. L.; Chang, L. K.; Tschen, J. S. and Liu, S. T. (1999): Functional 
and transcriptional analyses of a fengycin synthetase gene, fenC, from Bacillus 
subtilis, J Bacteriol (vol. 181), No. 16, pp. 5060-7. 
[114] Umezawa, H.; Aoyagi, T.; Nishikiori, T.; Okuyama, A.; Yamagishi, Y.; Hamada, M. 
and Takeuchi, T. (1986): Plipastatins: new inhibitors of phospholipase A2, produced 
by Bacillus cereus BMG302-fF67. I. Taxonomy, production, isolation and preliminary 
characterization, J Antibiot (Tokyo) (vol. 39), No. 6, pp. 737-44. 
[115] Maget-Dana, R. and Peypoux, F. (1994): Iturins, a special class of pore-forming 
lipopeptides: biological and physicochemical properties, Toxicology (vol. 87), No. 1-
3, pp. 151-74. 
[116] Hosono, K. and Suzuki, H. (1983): Acylpeptides, the inhibitors of cyclic adenosine 
3',5'-monophosphate phosphodiesterase. II. Amino acid sequence and location of 
lactone linkage, J Antibiot (Tokyo) (vol. 36), No. 6, pp. 674-8. 
[117] Hosono, K. and Suzuki, H. (1983): Acylpeptides, the inhibitors of cyclic adenosine 
3',5'-monophosphate phosphodiesterase. I. Purification, physicochemical properties 
and structures of fatty acid residues, J Antibiot (Tokyo) (vol. 36), No. 6, pp. 667-73. 
[118] Menkhaus, M.; Ullrich, C.; Kluge, B.; Vater, J.; Vollenbroich, D. and Kamp, R. M. 
(1993): Structural and functional organization of the surfactin synthetase multienzyme 
system, J Biol Chem (vol. 268), No. 11, pp. 7678-84. 
[119] Fuma, S.; Fujishima, Y.; Corbell, N.; D'Souza, C.; Nakano, M. M.; Zuber, P. and 
Yamane, K. (1993): Nucleotide sequence of 5' portion of srfA that contains the region 
required for competence establishment in Bacillus subtilus, Nucleic Acids Res (vol. 
21), No. 1, pp. 93-7. 
[120] Galli, G.; Rodriguez, F.; Cosmina, P.; Pratesi, C.; Nogarotto, R.; de Ferra, F. and 
Grandi, G. (1994): Characterization of the surfactin synthetase multi-enzyme complex, 
Biochim Biophys Acta (vol. 1205), No. 1, pp. 19-28. 
[121] Nakano, M. M.; Marahiel, M. A. and Zuber, P. (1988): Identification of a genetic 
locus required for biosynthesis of the lipopeptide antibiotic surfactin in Bacillus 
subtilis, J Bacteriol (vol. 170), No. 12, pp. 5662-8. 
 171
[122] Steller, S.; Sokoll, A.; Wilde, C.; Bernhard, F.; Franke, P. and Vater, J. (2004): 
Initiation of surfactin biosynthesis and the role of the SrfD-thioesterase protein, 
Biochemistry (vol. 43), No. 35, pp. 11331-43. 
[123] Desai, J. D. and Banat, I. M. (1997): Microbial production of surfactants and their 
commercial potential, Microbiol Mol Biol Rev (vol. 61), No. 1, pp. 47-64. 
[124] Arima, K.; Kakinuma, A. and Tamura, G. (1968): Surfactin, a crystalline peptidelipid 
surfactant produced by Bacillus subtilis: isolation, characterization and its inhibition 
of fibrin clot formation, Biochem Biophys Res Commun (vol. 31), No. 3, pp. 488-94. 
[125] Bernheimer, A. W. and Avigad, L. S. (1970): Nature and properties of a cytolytic 
agent produced by Bacillus subtilis, J Gen Microbiol (vol. 61), No. 3, pp. 361-9. 
[126] Kameda, Y.; Oira, S.; Matsui, K.; Kanatomo, S. and Hase, T. (1974): Antitumor 
activity of bacillus natto. V. Isolation and characterization of surfactin in the culture 
medium of Bacillus natto KMD 2311, Chem Pharm Bull (Tokyo) (vol. 22), No. 4, pp. 
938-44. 
[127] Vollenbroich, D.; Ozel, M.; Vater, J.; Kamp, R. M. and Pauli, G. (1997): Mechanism 
of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus 
subtilis, Biologicals (vol. 25), No. 3, pp. 289-97. 
[128] Tsukagoshi, N.; Tamura, G. and Arima, K. (1970): A novel protoplast-bursting factor 
(surfactin) obtained from Bacillus subtilis IAM 1213. I. The effects of surfactin on 
bacillus megaterium KM, Biochim Biophys Acta (vol. 196), No. 2, pp. 204-10. 
[129] Vollenbroich, D.; Pauli, G.; Ozel, M. and Vater, J. (1997): Antimycoplasma properties 
and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus 
subtilis, Appl Environ Microbiol (vol. 63), No. 1, pp. 44-9. 
[130] Beven, L. and Wroblewski, H. (1997): Effect of natural amphipathic peptides on 
viability, membrane potential, cell shape and motility of mollicutes, Res Microbiol 
(vol. 148), No. 2, pp. 163-75. 
[131] Hamoen, L. W.; Eshuis, H.; Jongbloed, J.; Venema, G. and van Sinderen, D. (1995): 
A small gene, designated comS, located within the coding region of the fourth amino 
acid-activation domain of srfA, is required for competence development in Bacillus 
subtilis, Mol Microbiol (vol. 15), No. 1, pp. 55-63. 
[132] Kearns, D. B. and Losick, R. (2003): Swarming motility in undomesticated Bacillus 
subtilis, Mol Microbiol (vol. 49), No. 3, pp. 581-90. 
[133] Julkowska, D.; Obuchowski, M.; Holland, I. B. and Seror, S. J. (2005): Comparative 
analysis of the development of swarming communities of Bacillus subtilis 168 and a 
natural wild type: critical effects of surfactin and the composition of the medium, J 
Bacteriol (vol. 187), No. 1, pp. 65-76. 
[134] Connelly, M. B.; Young, G. M. and Sloma, A. (2004): Extracellular proteolytic 
activity plays a central role in swarming motility in Bacillus subtilis, J Bacteriol (vol. 
186), No. 13, pp. 4159-67. 
[135] Kinsinger, R. F.; Shirk, M. C. and Fall, R. (2003): Rapid surface motility in Bacillus 
subtilis is dependent on extracellular surfactin and potassium ion, J Bacteriol (vol. 
185), No. 18, pp. 5627-31. 
[136] Branda, S. S.; Gonzalez-Pastor, J. E.; Ben-Yehuda, S.; Losick, R. and Kolter, R. 
(2001): Fruiting body formation by Bacillus subtilis, Proc Natl Acad Sci U S A (vol. 
98), No. 20, pp. 11621-6. 
[137] Hofemeister, J.; Conrad, B.; Adler, B.; Hofemeister, B.; Feesche, J.; Kucheryava, N.; 
Steinborn, G.; Franke, P.; Grammel, N.; Zwintscher, A.; Leenders, F.; Hitzeroth, G. 
and Vater, J. (2004): Genetic analysis of the biosynthesis of non-ribosomal peptide- 
and polyketide-like antibiotics, iron uptake and biofilm formation by Bacillus subtilis 
A1/3, Mol Genet Genomics (vol. 272), No. 4, pp. 363-78. 
 172
[138] Nishikiori, T.; Naganawa, H.; Muraoka, Y.; Aoyagi, T. and Umezawa, H. (1986): 
Plipastatins: new inhibitors of phospholipase A2, produced by Bacillus cereus 
BMG302-fF67. II. Structure of fatty acid residue and amino acid sequence, J Antibiot 
(Tokyo) (vol. 39), No. 6, pp. 745-54. 
[139] Ongena, M.; Jacques, P.; Toure, Y.; Destain, J.; Jabrane, A. and Thonart, P. (2005): 
Involvement of fengycin-type lipopeptides in the multifaceted biocontrol potential of 
Bacillus subtilis, Appl Microbiol Biotechnol (vol. 69), No. 1, pp. 29-38. 
[140] Steller, S.; Vollenbroich, D.; Leenders, F.; Stein, T.; Conrad, B.; Hofemeister, J.; 
Jacques, P.; Thonart, P. and Vater, J. (1999): Structural and functional organization of 
the fengycin synthetase multienzyme system from Bacillus subtilis b213 and A1/3, 
Chem Biol (vol. 6), No. 1, pp. 31-41. 
[141] Deleu, M.; Paquot, M. and Nylander, T. (2005): Fengycin interaction with lipid 
monolayers at the air-aqueous interface-implications for the effect of fengycin on 
biological membranes, J Colloid Interface Sci (vol. 283), No. 2, pp. 358-65. 
[142] Nishikiori, T.; Naganawa, H.; Muraoka, Y.; Aoyagi, T. and Umezawa, H. (1986): 
Plipastatins: new inhibitors of phospholipase A2, produced by Bacillus cereus 
BMG302-fF67. III. Structural elucidation of plipastatins, J Antibiot (Tokyo) (vol. 39), 
No. 6, pp. 755-61. 
[143] Kimura, K.; Nakayama, S.; Nakamura, J.; Takada, T.; Yoshihama, M.; Esumi, Y.; 
Itoh, Y. and Uramoto, M. (1997): SNA-60-367, new peptide enzyme inhibitors against 
aromatase, J Antibiot (Tokyo) (vol. 50), No. 6, pp. 529-31. 
[144] Jenny, K.; Kappeli, O. and Fiechter, A. (1991): Biosurfactants from Bacillus 
licheniformis: structural analysis and characterization, Appl Microbiol Biotechnol 
(vol. 36), No. 1, pp. 5-13. 
[145] Yakimov, M. M.; Timmis, K. N.; Wray, V. and Fredrickson, H. L. (1995): 
Characterization of a new lipopeptide surfactant produced by thermotolerant and 
halotolerant subsurface Bacillus licheniformis BAS50, Appl Environ Microbiol (vol. 
61), No. 5, pp. 1706-13. 
[146] Konz, D.; Doekel, S. and Marahiel, M. A. (1999): Molecular and biochemical 
characterization of the protein template controlling biosynthesis of the lipopeptide 
lichenysin, J Bacteriol (vol. 181), No. 1, pp. 133-40. 
[147] Azevedo, E. C.; Rios, E. M.; Fukushima, K. and Campos-Takaki, G. M. (1993): 
Bacitracin production by a new strain of Bacillus subtilis. Extraction, purification, and 
characterization, Appl Biochem Biotechnol (vol. 42), No. 1, pp. 1-7. 
[148] Anker, H. S.; Johnson, B. A.; Goldberg, J. and Meleney, F. L. (1948): Bacitracin: 
Methods of Production, Concentration, and Partial Purification, with a Summary of 
the Chemical Properties of Crude Bacitracin, J Bacteriol (vol. 55), No. 2, pp. 249-55. 
[149] Konz, D.; Klens, A.; Schorgendorfer, K. and Marahiel, M. A. (1997): The bacitracin 
biosynthesis operon of Bacillus licheniformis ATCC 10716: molecular 
characterization of three multi-modular peptide synthetases, Chem Biol (vol. 4), No. 
12, pp. 927-37. 
[150] Neumuller, A. M.; Konz, D. and Marahiel, M. A. (2001): The two-component 
regulatory system BacRS is associated with bacitracin 'self-resistance' of Bacillus 
licheniformis ATCC 10716, Eur J Biochem (vol. 268), No. 11, pp. 3180-9. 
[151] Storm, D. R. and Strominger, J. L. (1973): Complex formation between bacitracin 
peptides and isoprenyl pyrophosphates. The specificity of lipid-peptide interactions, J 
Biol Chem (vol. 248), No. 11, pp. 3940-5. 
[152] Kratzschmar, J.; Krause, M. and Marahiel, M. A. (1989): Gramicidin S biosynthesis 
operon containing the structural genes grsA and grsB has an open reading frame 
encoding a protein homologous to fatty acid thioesterases, J Bacteriol (vol. 171), No. 
10, pp. 5422-9. 
 173
[153] Kondejewski, L. H.; Farmer, S. W.; Wishart, D. S.; Kay, C. M.; Hancock, R. E. and 
Hodges, R. S. (1996): Modulation of structure and antibacterial and hemolytic activity 
by ring size in cyclic gramicidin S analogs, J Biol Chem (vol. 271), No. 41, pp. 25261-
8. 
[154] Kondejewski, L. H.; Farmer, S. W.; Wishart, D. S.; Hancock, R. E. and Hodges, R. S. 
(1996): Gramicidin S is active against both gram-positive and gram-negative bacteria, 
Int J Pept Protein Res (vol. 47), No. 6, pp. 460-6. 
[155] Kaprel'yants, A.S., V.V. Nikiforou, A.I. Miroshnikov, L.G. Snezhkova, V.A. Eremin, 
D.N. Ostrovskij (1977): Bacterial membranes and action of gramicidin S, Biokhimiya 
(vol. 42), pp. 329-337. 
[156] Izumiya, N., T. Kato, H. Aoyaki, M. Waki, M.Kondo (1979), Synthetic aspects of 
biologically active cyclic peptides; gramicidin S and tyrocidines pp. 49-108, 
Kondansha International Ltd, Tokyo. 
[157] Duitman, E. (2003): Nonribosomal peptide synthesis in Bacillus subtilis, Groningen 
University, Groningen. 
[158] Bruner, S. D.; Weber, T.; Kohli, R. M.; Schwarzer, D.; Marahiel, M. A.; Walsh, C. T. 
and Stubbs, M. T. (2002): Structural basis for the cyclization of the lipopeptide 
antibiotic surfactin by the thioesterase domain SrfTE, Structure (vol. 10), No. 3, pp. 
301-10. 
[159] Conti, E.; Stachelhaus, T.; Marahiel, M. A. and Brick, P. (1997): Structural basis for 
the activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S, 
Embo J (vol. 16), No. 14, pp. 4174-83. 
[160] Gulick, A. M.; Starai, V. J.; Horswill, A. R.; Homick, K. M. and Escalante-Semerena, 
J. C. (2003): The 1.75 A crystal structure of acetyl-CoA synthetase bound to 
adenosine-5'-propylphosphate and coenzyme A, Biochemistry (vol. 42), No. 10, pp. 
2866-73. 
[161] Nakano, M. M.; Xia, L. A. and Zuber, P. (1991): Transcription initiation region of the 
srfA operon, which is controlled by the comP-comA signal transduction system in 
Bacillus subtilis, J Bacteriol (vol. 173), No. 17, pp. 5487-93. 
[162] Roggiani, M. and Dubnau, D. (1993): ComA, a phosphorylated response regulator 
protein of Bacillus subtilis, binds to the promoter region of srfA, J Bacteriol (vol. 175), 
No. 10, pp. 3182-7. 
[163] Magnuson, R.; Solomon, J. and Grossman, A. D. (1994): Biochemical and genetic 
characterization of a competence pheromone from B. subtilis, Cell (vol. 77), No. 2, pp. 
207-16. 
[164] Solomon, J. M.; Lazazzera, B. A. and Grossman, A. D. (1996): Purification and 
characterization of an extracellular peptide factor that affects two different 
developmental pathways in Bacillus subtilis, Genes Dev (vol. 10), No. 16, pp. 2014-
24. 
[165] Grossman, A. D. (1995): Genetic networks controlling the initiation of sporulation and 
the development of genetic competence in Bacillus subtilis, Annu Rev Genet (vol. 29), 
pp. 477-508. 
[166] Perego, M. (1997): A peptide export-import control circuit modulating bacterial 
development regulates protein phosphatases of the phosphorelay, Proc Natl Acad Sci 
U S A (vol. 94), No. 16, pp. 8612-7. 
[167] Bongiorni, C.; Ishikawa, S.; Stephenson, S.; Ogasawara, N. and Perego, M. (2005): 
Synergistic regulation of competence development in Bacillus subtilis by two Rap-Phr 
systems, J Bacteriol (vol. 187), No. 13, pp. 4353-61. 
[168] Hayashi, K.; Ohsawa, T.; Kobayashi, K.; Ogasawara, N. and Ogura, M. (2005): The 
H2O2 stress-responsive regulator PerR positively regulates srfA expression in Bacillus 
subtilis, J Bacteriol (vol. 187), No. 19, pp. 6659-67. 
 174
[169] Serror, P. and Sonenshein, A. L. (1996): CodY is required for nutritional repression of 
Bacillus subtilis genetic competence, J Bacteriol (vol. 178), No. 20, pp. 5910-5. 
[170] Tsuge, K.; Ohata, Y. and Shoda, M. (2001): Gene yerP, involved in surfactin self-
resistance in Bacillus subtilis, Antimicrob Agents Chemother (vol. 45), No. 12, pp. 
3566-73. 
[171] Msadek, T.; Kunst, F.; Klier, A. and Rapoport, G. (1991): DegS-DegU and ComP-
ComA modulator-effector pairs control expression of the Bacillus subtilis pleiotropic 
regulatory gene degQ, J Bacteriol (vol. 173), No. 7, pp. 2366-77. 
[172] Tsuge, K.; Ano, T.; Hirai, M.; Nakamura, Y. and Shoda, M. (1999): The genes degQ, 
pps, and lpa-8 (sfp) are responsible for conversion of Bacillus subtilis 168 to 
plipastatin production, Antimicrob Agents Chemother (vol. 43), No. 9, pp. 2183-92. 
[173] Tsuge, K.; Inoue, S.; Ano, T.; Itaya, M. and Shoda, M. (2005): Horizontal transfer of 
iturin A operon, itu, to Bacillus subtilis 168 and conversion into an iturin A producer, 
Antimicrob Agents Chemother (vol. 49), No. 11, pp. 4641-8. 
[174] Mootz, H. D.; Finking, R. and Marahiel, M. A. (2001): 4'-phosphopantetheine transfer 
in primary and secondary metabolism of Bacillus subtilis, J Biol Chem (vol. 276), No. 
40, pp. 37289-98. 
[175] Nakano, M. M.; Corbell, N.; Besson, J. and Zuber, P. (1992): Isolation and 
characterization of sfp: a gene that functions in the production of the lipopeptide 
biosurfactant, surfactin, in Bacillus subtilis, Mol Gen Genet (vol. 232), No. 2, pp. 313-
21. 
[176] Yakimov, M. M. and Golyshin, P. N. (1997): ComA-dependent transcriptional 
activation of lichenysin A synthetase promoter in Bacillus subtilis cells, Biotechnol 
Prog (vol. 13), No. 6, pp. 757-61. 
[177] Podlesek, Z.; Comino, A.; Herzog-Velikonja, B.; Zgur-Bertok, D.; Komel, R. and 
Grabnar, M. (1995): Bacillus licheniformis bacitracin-resistance ABC transporter: 
relationship to mammalian multidrug resistance, Mol Microbiol (vol. 16), No. 5, pp. 
969-76. 
[178] Podlesek, Z.; Comino, A.; Herzog-Velikonja, B. and Grabnar, M. (2000): The role of 
the bacitracin ABC transporter in bacitracin resistance and collateral detergent 
sensitivity, FEMS Microbiol Lett (vol. 188), No. 1, pp. 103-6. 
[179] Bernard, R.; Joseph, P.; Guiseppi, A.; Chippaux, M. and Denizot, F. (2003): YtsCD 
and YwoA, two independent systems that confer bacitracin resistance to Bacillus 
subtilis, FEMS Microbiol Lett (vol. 228), No. 1, pp. 93-7. 
[180] Marahiel, M. A.; Zuber, P.; Czekay, G. and Losick, R. (1987): Identification of the 
promoter for a peptide antibiotic biosynthesis gene from Bacillus brevis and its 
regulation in Bacillus subtilis, J Bacteriol (vol. 169), No. 5, pp. 2215-22. 
[181] Robertson, J. B.; Gocht, M.; Marahiel, M. A. and Zuber, P. (1989): AbrB, a regulator 
of gene expression in Bacillus, interacts with the transcription initiation regions of a 
sporulation gene and an antibiotic biosynthesis gene, Proc Natl Acad Sci U S A (vol. 
86), No. 21, pp. 8457-61. 
[182] Stachelhaus, T.; Schneider, A. and Marahiel, M. A. (1995): Rational design of peptide 
antibiotics by targeted replacement of bacterial and fungal domains, Science (vol. 
269), No. 5220, pp. 69-72. 
[183] Stachelhaus, T.; Schneider, A. and Marahiel, M. A. (1996): Engineered biosynthesis 
of peptide antibiotics, Biochem Pharmacol (vol. 52), No. 2, pp. 177-86. 
[184] Mootz, H. D.; Kessler, N.; Linne, U.; Eppelmann, K.; Schwarzer, D. and Marahiel, M. 
A. (2002): Decreasing the ring size of a cyclic nonribosomal peptide antibiotic by in-
frame module deletion in the biosynthetic genes, J Am Chem Soc (vol. 124), No. 37, 
pp. 10980-1. 
 175
[185] Eppelmann, K.; Stachelhaus, T. and Marahiel, M. A. (2002): Exploitation of the 
selectivity-conferring code of nonribosomal peptide synthetases for the rational design 
of novel peptide antibiotics, Biochemistry (vol. 41), No. 30, pp. 9718-26. 
[186] de Ferra, F.; Rodriguez, F.; Tortora, O.; Tosi, C. and Grandi, G. (1997): Engineering 
of peptide synthetases. Key role of the thioesterase-like domain for efficient 
production of recombinant peptides, J Biol Chem (vol. 272), No. 40, pp. 25304-9. 
[187] Duerfahrt, T.; Eppelmann, K.; Muller, R. and Marahiel, M. A. (2004): Rational design 
of a bimodular model system for the investigation of heterocyclization in 
nonribosomal peptide biosynthesis, Chem Biol (vol. 11), No. 2, pp. 261-71. 
[188] Tamehiro, N.; Okamoto-Hosoya, Y.; Okamoto, S.; Ubukata, M.; Hamada, M.; 
Naganawa, H. and Ochi, K. (2002): Bacilysocin, a novel phospholipid antibiotic 
produced by Bacillus subtilis 168, Antimicrob Agents Chemother (vol. 46), No. 2, pp. 
315-20. 
[189] Pinchuk, I. V.; Bressollier, P.; Verneuil, B.; Fenet, B.; Sorokulova, I. B.; Megraud, F. 
and Urdaci, M. C. (2001): In vitro anti-Helicobacter pylori activity of the probiotic 
strain Bacillus subtilis 3 is due to secretion of antibiotics, Antimicrob Agents 
Chemother (vol. 45), No. 11, pp. 3156-61. 
[190] Inaoka, T.; Takahashi, K.; Yada, H.; Yoshida, M. and Ochi, K. (2004): RNA 
polymerase mutation activates the production of a dormant antibiotic 3,3'-
neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis, J Biol Chem 
(vol. 279), No. 5, pp. 3885-92. 
[191] Stragier, P.; Bonamy, C. and Karmazyn-Campelli, C. (1988): Processing of a 
sporulation sigma factor in Bacillus subtilis: how morphological structure could 
control gene expression, Cell (vol. 52), No. 5, pp. 697-704. 
[192] Antoniewski, C.; Savelli, B. and Stragier, P. (1990): The spoIIJ gene, which regulates 
early developmental steps in Bacillus subtilis, belongs to a class of environmentally 
responsive genes, J Bacteriol (vol. 172), No. 1, pp. 86-93. 
[193] Steinmetz, M. and Richter, R. (1994): Plasmids designed to alter the antibiotic 
resistance expressed by insertion mutations in Bacillus subtilis, through in vivo 
recombination, Gene (vol. 142), No. 1, pp. 79-83. 
[194] Ceglowski, P. and Alonso, J. C. (1994): Gene organization of the Streptococcus 
pyogenes plasmid pDB101: sequence analysis of the orf eta-copS region, Gene (vol. 
145), No. 1, pp. 33-9. 
[195] Gonzy-Treboul, G.; Karmazyn-Campelli, C. and Stragier, P. (1992): Developmental 
regulation of transcription of the Bacillus subtilis ftsAZ operon, J Mol Biol (vol. 224), 
No. 4, pp. 967-79. 
[196] Koumoutsi, A.; Chen, X. H.; Henne, A.; Liesegang, H.; Hitzeroth, G.; Franke, P.; 
Vater, J. and Borriss, R. (2004): Structural and functional characterization of gene 
clusters directing nonribosomal synthesis of bioactive cyclic lipopeptides in Bacillus 
amyloliquefaciens strain FZB42, J Bacteriol (vol. 186), No. 4, pp. 1084-96. 
[197] Chen, X. H.; Vater, J.; Piel, J.; Franke, P.; Scholz, R.; Schneider, K.; Koumoutsi, A.; 
Hitzeroth, G.; Grammel, N.; Strittmatter, A. W.; Gottschalk, G.; Sussmuth, R. D. and 
Borriss, R. (2006): Structural and functional characterization of three polyketide 
synthase gene clusters in Bacillus amyloliquefaciens FZB 42, J Bacteriol (vol. 188), 
No. 11, pp. 4024-36. 
[198] Sambrook J.; Fritsch, E.F. and Maniatis, T. (1989): Molecular Cloning: a laboratory 
manual, Cold Spring Harbor Laboratory, NY. 
[199] Cutting, S.M. and Vander Horn, P.B. (1990): Molecular Biological methods for 
Bacillus Harwood C., Cutting S.M., Ed, Wiley, Chichester. 
 176
[200] Landy M., Warren, G.H., Roseman S.B., Colio L.G. (1948): Bacillomycin, an 
antibiotic from Bacillus subtilis active against pathogenic fungi, Proc. Soc. Exp. Biol. 
Med (vol. 67), pp. 539-541. 
[201] Ebata, M.; Miyazaki, K. and Takahashi, Y. (1969): Studies on subsporin. I. Isolation 
and characterization of subsporins A, B and C, J Antibiot (Tokyo) (vol. 22), No. 10, 
pp. 467-72. 
[202] Cutting, S.M. and Van der Horn, P.B. (1990): Genetic Analysis, Harwood C.R., 
Cutting S.M, Molecular biological methods for Bacillus pp. 27-74, Wiley Interscience, 
Chichister, United Kingdom. 
[203] Dieffenbach, C.W. and Dveksler, G.S. (1995): PCR primer, a laboratory manual Cold 
Spring Harbor Laboratory Press. 
[204] Spizizen, J. (1958): Transformation of Biochemically Deficient Strains of Bacillus 
Subtilis by Deoxyribonucleate, Proc Natl Acad Sci U S A (vol. 44), No. 10, pp. 1072-
8. 
[205] Kunst, F. and Rapoport, G. (1995): Salt stress is an environmental signal affecting 
degradative enzyme synthesis in Bacillus subtilis, J Bacteriol (vol. 177), No. 9, pp. 
2403-7. 
[206] Diatchenko, L.; Lau, Y. F.; Campbell, A. P.; Chenchik, A.; Moqadam, F.; Huang, B.; 
Lukyanov, S.; Lukyanov, K.; Gurskaya, N.; Sverdlov, E. D. and Siebert, P. D. (1996): 
Suppression subtractive hybridization: a method for generating differentially regulated 
or tissue-specific cDNA probes and libraries, Proc Natl Acad Sci U S A (vol. 93), No. 
12, pp. 6025-30. 
[207] Clontech Laboratories, Inc. (2006): PCR-SelectTM Bacterial Genome Subtraction Kit 
User Manual  
[208] Birren, B. and Lai, E. (1993): Pulsed Field Gel Electrophoresis. a practical Guide, 
Academic Press, San Diego. 
[209] Typas, A. and Hengge, R. (2006): Role of the spacer between the -35 and -10 regions 
in σS promoter selectivity in Escherichia coli, Mol Microbiol (vol. 59), No. 3, pp. 
1037-51. 
[210] Leenders F., Stein T.H., Kablitz B., Franke P., Vater J. (1999): Rapid typing of 
Bacillus subtilis strains by their secondary metabolites using matrix-assisted laser 
desorption/ionisation mass spectrometry of intact cells, Rapid Commun. Mass 
spectrom. (vol. 13), pp. 943-949. 
[211] Vater, J.; Kablitz, B.; Wilde, C.; Franke, P.; Mehta, N. and Cameotra, S. S. (2002): 
Matrix-assisted laser desorption ionization--time of flight mass spectrometry of 
lipopeptide biosurfactants in whole cells and culture filtrates of Bacillus subtilis C-1 
isolated from petroleum sludge, Appl Environ Microbiol (vol. 68), No. 12, pp. 6210-9. 
[212] Miller, J.H. (1972): Experiments in molecular genetics, Cold Spring Harbor 
Laboratory Press, N.Y. 
[213] Ewing, B.; Hillier, L.; Wendl, M. C. and Green, P. (1998): Base-calling of automated 
sequencer traces using phred. I. Accuracy assessment, Genome Res (vol. 8), No. 3, pp. 
175-85. 
[214] Staden, R.; Beal, K. F. and Bonfield, J. K. (2000): The Staden package, 1998, 
Methods Mol Biol (vol. 132), pp. 115-30. 
[215] Finn, R. D.; Mistry, J.; Schuster-Bockler, B.; Griffiths-Jones, S.; Hollich, V.; 
Lassmann, T.; Moxon, S.; Marshall, M.; Khanna, A.; Durbin, R.; Eddy, S. R.; 
Sonnhammer, E. L. and Bateman, A. (2006): Pfam: clans, web tools and services, 
Nucleic Acids Res (vol. 34), No. Database issue, pp. D247-51. 
[216] Priest, F.G., Goodfellow, M., Shute L.A., Berkeley R.C.W. (1987): Bacillus 
amyloliquefaciens sp. nov., nom. rev., Int J Syst Bacteriol (vol. 37), pp. 69-71. 
 177
[217] Inaoka, T.; Takahashi, K.; Ohnishi-Kameyama, M.; Yoshida, M. and Ochi, K. (2003): 
Guanine nucleotides guanosine 5'-diphosphate 3'-diphosphate and GTP co-operatively 
regulate the production of an antibiotic bacilysin in Bacillus subtilis, J Biol Chem (vol. 
278), No. 4, pp. 2169-76. 
[218] Kenig, M. and Abraham, E. P. (1976): Antimicrobial activities and antagonists of 
bacilysin and anticapsin, J Gen Microbiol (vol. 94), No. 1, pp. 37-45. 
[219] Hilton, M. D.; Alaeddinoglu, N. G. and Demain, A. L. (1988): Synthesis of bacilysin 
by Bacillus subtilis branches from prephenate of the aromatic amino acid pathway, J 
Bacteriol (vol. 170), No. 1, pp. 482-4. 
[220] Ollinger, J.; Song, K. B.; Antelmann, H.; Hecker, M. and Helmann, J. D. (2006): Role 
of the Fur regulon in iron transport in Bacillus subtilis, J Bacteriol (vol. 188), No. 10, 
pp. 3664-73. 
[221] Hoffmann, T.; Schutz, A.; Brosius, M.; Volker, A.; Volker, U. and Bremer, E. (2002): 
High-salinity-induced iron limitation in Bacillus subtilis, J Bacteriol (vol. 184), No. 3, 
pp. 718-27. 
[222] Chen, C. L.; Chang, L. K.; Chang, Y. S.; Liu, S. T. and Tschen, J. S. (1995): 
Transposon mutagenesis and cloning of the genes encoding the enzymes of fengycin 
biosynthesis in Bacillus subtilis, Mol Gen Genet (vol. 248), No. 2, pp. 121-5. 
[223] Butcher, B. G. and Helmann, J. D. (2006): Identification of Bacillus subtilis sigma-
dependent genes that provide intrinsic resistance to antimicrobial compounds 
produced by Bacilli, Mol Microbiol (vol. 60), No. 3, pp. 765-82. 
[224] Amory, A.; Kunst, F.; Aubert, E.; Klier, A. and Rapoport, G. (1987): Characterization 
of the sacQ genes from Bacillus licheniformis and Bacillus subtilis, J Bacteriol (vol. 
169), No. 1, pp. 324-33. 
[225] Yang, M.; Ferrari, E.; Chen, E. and Henner, D. J. (1986): Identification of the 
pleiotropic sacQ gene of Bacillus subtilis, J Bacteriol (vol. 166), No. 1, pp. 113-9. 
[226] deHaseth, P. L.; Zupancic, M. L. and Record, M. T., Jr. (1998): RNA polymerase-
promoter interactions: the comings and goings of RNA polymerase, J Bacteriol (vol. 
180), No. 12, pp. 3019-25. 
[227] Voskuil, M. I. and Chambliss, G. H. (1998): The -16 region of Bacillus subtilis and 
other gram-positive bacterial promoters, Nucleic Acids Res (vol. 26), No. 15, pp. 
3584-90. 
[228] Barne, K. A.; Bown, J. A.; Busby, S. J. and Minchin, S. D. (1997): Region 2.5 of the 
Escherichia coli RNA polymerase sigma70 subunit is responsible for the recognition 
of the 'extended-10' motif at promoters, Embo J (vol. 16), No. 13, pp. 4034-40. 
[229] Kunst, F.; Pascal, M.; Lepesant-Kejzlarova, J.; Lepesant, J. A.; Billault, A. and 
Dedonder, R. (1974): Pleiotropic mutations affecting sporulation conditions and the 
syntheses of extracellular enzymes in Bacillus subtilis 168, Biochimie (vol. 56), No. 
11-12, pp. 1481-9. 
[230] Msadek, T.; Kunst, F.; Henner, D.; Klier, A.; Rapoport, G. and Dedonder, R. (1990): 
Signal transduction pathway controlling synthesis of a class of degradative enzymes in 
Bacillus subtilis: expression of the regulatory genes and analysis of mutations in degS 
and degU, J Bacteriol (vol. 172), No. 2, pp. 824-34. 
[231] Hamoen, L. W.; Van Werkhoven, A. F.; Venema, G. and Dubnau, D. (2000): The 
pleiotropic response regulator DegU functions as a priming protein in competence 
development in Bacillus subtilis, Proc Natl Acad Sci U S A (vol. 97), No. 16, pp. 
9246-51. 
[232] Guillen, N.; Weinrauch, Y. and Dubnau, D. A. (1989): Cloning and characterization of 
the regulatory Bacillus subtilis competence genes comA and comB, J Bacteriol (vol. 
171), No. 10, pp. 5354-61. 
 178
[233] Gaidenko, T. A. and Price, C. W. (1998): General stress transcription factor sigma(B) 
and sporulation transcription factor sigma(H) each contribute to survival of Bacillus 
subtilis under extreme growth conditions, J Bacteriol (vol. 180), No. 14, pp. 3730-3. 
[234] McQuade, R. S.; Comella, N. and Grossman, A. D. (2001): Control of a family of 
phosphatase regulatory genes (phr) by the alternate sigma factor σH of Bacillus 
subtilis, J Bacteriol (vol. 183), No. 16, pp. 4905-9. 
[235] Serizawa, M.; Kodama, K.; Yamamoto, H.; Kobayashi, K.; Ogasawara, N. and 
Sekiguchi, J. (2005): Functional analysis of the YvrGHb two-component system of 
Bacillus subtilis: identification of the regulated genes by DNA microarray and 
northern blot analyses, Biosci Biotechnol Biochem (vol. 69), No. 11, pp. 2155-69. 
[236] Huang, X.; Fredrick, K. L. and Helmann, J. D. (1998): Promoter recognition by 
Bacillus subtilis sigmaW: autoregulation and partial overlap with the sigmaX regulon, 
J Bacteriol (vol. 180), No. 15, pp. 3765-70. 
[237] Hecker, M. and Volker, U. (1998): Non-specific, general and multiple stress resistance 
of growth-restricted Bacillus subtilis cells by the expression of the sigmaB regulon, 
Mol Microbiol (vol. 29), No. 5, pp. 1129-36. 
[238] Hecker, M. and Volker, U. (2001): General stress response of Bacillus subtilis and 
other bacteria, Adv Microb Physiol (vol. 44), pp. 35-91. 
[239] Petersohn, A.; Bernhardt, J.; Gerth, U.; Hoper, D.; Koburger, T.; Volker, U. and 
Hecker, M. (1999): Identification of sigma(B)-dependent genes in Bacillus subtilis 
using a promoter consensus-directed search and oligonucleotide hybridization, J 
Bacteriol (vol. 181), No. 18, pp. 5718-24. 
[240] Marquez, L. M.; Helmann, J. D.; Ferrari, E.; Parker, H. M.; Ordal, G. W. and 
Chamberlin, M. J. (1990): Studies of sigma D-dependent functions in Bacillus subtilis, 
J Bacteriol (vol. 172), No. 6, pp. 3435-43. 
[241] Huang, X.; Decatur, A.; Sorokin, A. and Helmann, J. D. (1997): The Bacillus subtilis 
sigma(X) protein is an extracytoplasmic function sigma factor contributing to survival 
at high temperature, J Bacteriol (vol. 179), No. 9, pp. 2915-21. 
[242] Sorokin, A.; Bolotin, A.; Purnelle, B.; Hilbert, H.; Lauber, J.; Dusterhoft, A. and 
Ehrlich, S. D. (1997): Sequence of the Bacillus subtilis genome region in the vicinity 
of the lev operon reveals two new extracytoplasmic function RNA polymerase sigma 
factors SigV and SigZ, Microbiology (vol. 143 ( Pt 9)), No. Pt 9, pp. 2939-43. 
[243] Sonenshein, A. L. (2005): CodY, a global regulator of stationary phase and virulence 
in Gram-positive bacteria, Curr Opin Microbiol (vol. 8), No. 2, pp. 203-7. 
[244] Shimane, K. and Ogura, M. (2004): Mutational analysis of the helix-turn-helix region 
of Bacillus subtilis response regulator DegU, and identification of cis-acting 
sequences for DegU in the aprE and comK promoters, J Biochem (Tokyo) (vol. 136), 
No. 3, pp. 387-97. 
[245] Dartois, V.; Debarbouille, M.; Kunst, F. and Rapoport, G. (1998): Characterization of 
a novel member of the DegS-DegU regulon affected by salt stress in Bacillus subtilis, 
J Bacteriol (vol. 180), No. 7, pp. 1855-61. 
[246] Core, L. and Perego, M. (2003): TPR-mediated interaction of RapC with ComA 
inhibits response regulator-DNA binding for competence development in Bacillus 
subtilis, Mol Microbiol (vol. 49), No. 6, pp. 1509-22. 
[247] Auchtung, J. M.; Lee, C. A. and Grossman, A. D. (2006): Modulation of the ComA-
dependent quorum response in Bacillus subtilis by multiple Rap proteins and Phr 
peptides, J Bacteriol (vol. 188), No. 14, pp. 5273-85. 
[248] Ogura, M.; Shimane, K.; Asai, K.; Ogasawara, N. and Tanaka, T. (2003): Binding of 
response regulator DegU to the aprE promoter is inhibited by RapG, which is 
counteracted by extracellular PhrG in Bacillus subtilis, Mol Microbiol (vol. 49), No. 6, 
pp. 1685-97. 
 179
[249] Hayashi, K.; Kensuke, T.; Kobayashi, K.; Ogasawara, N. and Ogura, M. (2006): 
Bacillus subtilis RghR (YvaN) represses rapG and rapH, which encode inhibitors of 
expression of the srfA operon, Mol Microbiol (vol. 59), No. 6, pp. 1714-29. 
[250] Pottathil, M. and Lazazzera, B. A. (2003): The extracellular Phr peptide-Rap 
phosphatase signaling circuit of Bacillus subtilis, Front Biosci (vol. 8), pp. d32-45. 
[251] Perego, M.; Higgins, C. F.; Pearce, S. R.; Gallagher, M. P. and Hoch, J. A. (1991): 
The oligopeptide transport system of Bacillus subtilis plays a role in the initiation of 
sporulation, Mol Microbiol (vol. 5), No. 1, pp. 173-85. 
[252] Price, C. W.; Fawcett, P.; Ceremonie, H.; Su, N.; Murphy, C. K. and Youngman, P. 
(2001): Genome-wide analysis of the general stress response in Bacillus subtilis, Mol 
Microbiol (vol. 41), No. 4, pp. 757-74. 
[253] Ogura, M.; Yamaguchi, H.; Yoshida, Ki; Fujita, Y. and Tanaka, T. (2001): DNA 
microarray analysis of Bacillus subtilis DegU, ComA and PhoP regulons: an approach 
to comprehensive analysis of B.subtilis two-component regulatory systems, Nucleic 
Acids Res (vol. 29), No. 18, pp. 3804-13. 
[254] Steil, L.; Hoffmann, T.; Budde, I.; Volker, U. and Bremer, E. (2003): Genome-wide 
transcriptional profiling analysis of adaptation of Bacillus subtilis to high salinity, J 
Bacteriol (vol. 185), No. 21, pp. 6358-70. 
[255] Bsat, N. and Helmann, J. D. (1999): Interaction of Bacillus subtilis Fur (ferric uptake 
repressor) with the dhb operator in vitro and in vivo, J Bacteriol (vol. 181), No. 14, pp. 
4299-307. 
[256] Miethke, M.; Klotz, O.; Linne, U.; May, J. J.; Beckering, C. L. and Marahiel, M. A. 
(2006): Ferri-bacillibactin uptake and hydrolysis in Bacillus subtilis, Mol Microbiol 
(vol. 3), p. 3. 
[257] Mader, U.; Antelmann, H.; Buder, T.; Dahl, M. K.; Hecker, M. and Homuth, G. 
(2002): Bacillus subtilis functional genomics: genome-wide analysis of the DegS-
DegU regulon by transcriptomics and proteomics, Mol Genet Genomics (vol. 268), 
No. 4, pp. 455-67. 
[258] Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; 
Hirama, C.; Nakamura, Y.; Ogasawara, N.; Kuhara, S. and Horikoshi, K. (2000): 
Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and 
genomic sequence comparison with Bacillus subtilis, Nucleic Acids Res (vol. 28), No. 
21, pp. 4317-31. 
[259] Rasko, D. A.; Ravel, J.; Okstad, O. A.; Helgason, E.; Cer, R. Z.; Jiang, L.; Shores, K. 
A.; Fouts, D. E.; Tourasse, N. J.; Angiuoli, S. V.; Kolonay, J.; Nelson, W. C.; Kolsto, 
A. B.; Fraser, C. M. and Read, T. D. (2004): The genome sequence of Bacillus cereus 
ATCC 10987 reveals metabolic adaptations and a large plasmid related to Bacillus 
anthracis pXO1, Nucleic Acids Res (vol. 32), No. 3, pp. 977-88. 
[260] Rey, M. W.; Ramaiya, P.; Nelson, B. A.; Brody-Karpin, S. D.; Zaretsky, E. J.; Tang, 
M.; Lopez de Leon, A.; Xiang, H.; Gusti, V.; Clausen, I. G.; Olsen, P. B.; Rasmussen, 
M. D.; Andersen, J. T.; Jorgensen, P. L.; Larsen, T. S.; Sorokin, A.; Bolotin, A.; 
Lapidus, A.; Galleron, N.; Ehrlich, S. D. and Berka, R. M. (2004): Complete genome 
sequence of the industrial bacterium Bacillus licheniformis and comparisons with 
closely related Bacillus species, Genome Biol (vol. 5), No. 10, p. R77. 
[261] Xu, D. and Cote, J. C. (2003): Phylogenetic relationships between Bacillus species 
and related genera inferred from comparison of 3' end 16S rDNA and 5' end 16S-23S 
ITS nucleotide sequences, Int J Syst Evol Microbiol (vol. 53), No. Pt 3, pp. 695-704. 
[262] Hoch, JA. and Silhavy, TJ. (1995): Two-Component Signal Transduction, American 
Society of Microbiology, Washington D.C. 
[263] Parkinson, J. S. (1993): Signal transduction schemes of bacteria, Cell (vol. 73), No. 5, 
pp. 857-71. 
 180
[264] Stock, JB., Surette MG, Levit M., Park P. (1995): Two-component signal transduction 
systems: structure-function relationships and mechanisms of catalysis Hoch, JA. 
Silhavy TJ., Two-Component Signal Transduction pp. 25-51, American Society for 
Microbiology, Washington DC. 
[265] Stock, A. M.; Robinson, V. L. and Goudreau, P. N. (2000): Two-component signal 
transduction, Annu Rev Biochem (vol. 69), pp. 183-215. 
[266] West, A. H. and Stock, A. M. (2001): Histidine kinases and response regulator 
proteins in two-component signaling systems, Trends Biochem Sci (vol. 26), No. 6, 
pp. 369-76. 
[267] Galperin, M. Y. (2006): Structural classification of bacterial response regulators: 
diversity of output domains and domain combinations, J Bacteriol (vol. 188), No. 12, 
pp. 4169-82. 
[268] Stock, J. B.; Stock, A. M. and Mottonen, J. M. (1990): Signal transduction in bacteria, 
Nature (vol. 344), No. 6265, pp. 395-400. 
[269] Fabret, C.; Feher, V. A. and Hoch, J. A. (1999): Two-component signal transduction 
in Bacillus subtilis: how one organism sees its world, J Bacteriol (vol. 181), No. 7, pp. 
1975-83. 
[270] Mascher, T.; Margulis, N. G.; Wang, T.; Ye, R. W. and Helmann, J. D. (2003): Cell 
wall stress responses in Bacillus subtilis: the regulatory network of the bacitracin 
stimulon, Mol Microbiol (vol. 50), No. 5, pp. 1591-604. 
[271] Pietiainen, M.; Gardemeister, M.; Mecklin, M.; Leskela, S.; Sarvas, M. and Kontinen, 
V. P. (2005): Cationic antimicrobial peptides elicit a complex stress response in 
Bacillus subtilis that involves ECF-type sigma factors and two-component signal 
transduction systems, Microbiology (vol. 151), No. Pt 5, pp. 1577-92. 
[272] Ohki, R.; Giyanto; Tateno, K.; Masuyama, W.; Moriya, S.; Kobayashi, K. and 
Ogasawara, N. (2003): The BceRS two-component regulatory system induces 
expression of the bacitracin transporter, BceAB, in Bacillus subtilis, Mol Microbiol 
(vol. 49), No. 4, pp. 1135-44. 
[273] Mascher, T. (2006): Intramembrane-sensing histidine kinases: a new family of cell 
envelope stress sensors in Firmicutes bacteria, FEMS Microbiol Lett. 
[274] Schultz, J.; Milpetz, F.; Bork, P. and Ponting, C. P. (1998): SMART, a simple modular 
architecture research tool: identification of signaling domains, Proc Natl Acad Sci U S 
A (vol. 95), No. 11, pp. 5857-64. 
[275] Wecke, T.; Veith, B.; Ehrenreich, A. and Mascher, T. (2006): Cell Envelope Stress 
Response in Bacillus licheniformis: Integrating Comparative Genomics, 
Transcriptional Profiling and Regulon Mining to Decipher a Complex Regulatory 
Network, J Bacteriol (vol. 25), p. 25. 
[276] Steinfels, E.; Orelle, C.; Fantino, J. R.; Dalmas, O.; Rigaud, J. L.; Denizot, F.; Di 
Pietro, A. and Jault, J. M. (2004): Characterization of YvcC (BmrA), a multidrug 
ABC transporter constitutively expressed in Bacillus subtilis, Biochemistry (vol. 43), 
No. 23, pp. 7491-502. 
[277] Joseph, P.; Fichant, G.; Quentin, Y. and Denizot, F. (2002): Regulatory relationship of 
two-component and ABC transport systems and clustering of their genes in the 
Bacillus/Clostridium group, suggest a functional link between them, J Mol Microbiol 
Biotechnol (vol. 4), No. 5, pp. 503-13. 
[278] Stein, T.; Heinzmann, S.; Kiesau, P.; Himmel, B. and Entian, K. D. (2003): The spa-
box for transcriptional activation of subtilin biosynthesis and immunity in Bacillus 
subtilis, Mol Microbiol (vol. 47), No. 6, pp. 1627-36. 
[279] Perego, M.; Glaser, P. and Hoch, J. A. (1996): Aspartyl-phosphate phosphatases 
deactivate the response regulator components of the sporulation signal transduction 
system in Bacillus subtilis, Mol Microbiol (vol. 19), No. 6, pp. 1151-7. 
 181
[280] Perego, M. and Brannigan, J. A. (2001): Pentapeptide regulation of aspartyl-phosphate 
phosphatases, Peptides (vol. 22), No. 10, pp. 1541-7. 
[281] Blatch, G. L. and Lassle, M. (1999): The tetratricopeptide repeat: a structural motif 
mediating protein-protein interactions, Bioessays (vol. 21), No. 11, pp. 932-9. 
[282] Turner, M. S. and Helmann, J. D. (2000): Mutations in multidrug efflux homologs, 
sugar isomerases, and antimicrobial biosynthesis genes differentially elevate activity 
of the sigma(X) and sigma(W) factors in Bacillus subtilis, J Bacteriol (vol. 182), No. 
18, pp. 5202-10. 
[283] Helmann, J. D. (2002): The extracytoplasmic function (ECF) sigma factors, Adv 
Microb Physiol (vol. 46), pp. 47-110. 
[284] Albano, M.; Smits, W. K.; Ho, L. T.; Kraigher, B.; Mandic-Mulec, I.; Kuipers, O. P. 
and Dubnau, D. (2005): The Rok protein of Bacillus subtilis represses genes for cell 
surface and extracellular functions, J Bacteriol (vol. 187), No. 6, pp. 2010-9. 
[285] Tortosa, P.; Logsdon, L.; Kraigher, B.; Itoh, Y.; Mandic-Mulec, I. and Dubnau, D. 
(2001): Specificity and genetic polymorphism of the Bacillus competence quorum-
sensing system, J Bacteriol (vol. 183), No. 2, pp. 451-60. 
[286] Ansaldi, M.; Marolt, D.; Stebe, T.; Mandic-Mulec, I. and Dubnau, D. (2002): Specific 
activation of the Bacillus quorum-sensing systems by isoprenylated pheromone 
variants, Mol Microbiol (vol. 44), No. 6, pp. 1561-73. 
[287] Ansaldi, M. and Dubnau, D. (2004): Diversifying selection at the Bacillus quorum-
sensing locus and determinants of modification specificity during synthesis of the 
ComX pheromone, J Bacteriol (vol. 186), No. 1, pp. 15-21. 
[288] Straight, P. D.; Willey, J. M. and Kolter, R. (2006): Interactions between Streptomyces 
coelicolor and Bacillus subtilis: Role of surfactants in raising aerial structures, J 
Bacteriol (vol. 188), No. 13, pp. 4918-25. 
[289] Han, J. S.; Cheng, J. H.; Yoon, T. M.; Song, J.; Rajkarnikar, A.; Kim, W. G.; Yoo, I. 
D.; Yang, Y. Y. and Suh, J. W. (2005): Biological control agent of common scab 
disease by antagonistic strain Bacillus sp. sunhua, J Appl Microbiol (vol. 99), No. 1, 
pp. 213-21. 
[290] Ron, E. Z. and Rosenberg, E. (2001): Natural roles of biosurfactants, Environ 
Microbiol (vol. 3), No. 4, pp. 229-36. 
[291] Neu, T. R. (1996): Significance of bacterial surface-active compounds in interaction of 
bacteria with interfaces, Microbiol Rev (vol. 60), No. 1, pp. 151-66. 
[292] Elliot, M. A. and Talbot, N. J. (2004): Building filaments in the air: aerial 
morphogenesis in bacteria and fungi, Curr Opin Microbiol (vol. 7), No. 6, pp. 594-
601. 
[293] Challis, G. L. and Hopwood, D. A. (2003): Synergy and contingency as driving forces 
for the evolution of multiple secondary metabolite production by Streptomyces 
species, Proc Natl Acad Sci U S A (vol. 100 Suppl 2), pp. 14555-61. 
[294] Patel, P. S.; Huang, S.; Fisher, S.; Pirnik, D.; Aklonis, C.; Dean, L.; Meyers, E.; 
Fernandes, P. and Mayerl, F. (1995): Bacillaene, a novel inhibitor of procaryotic 
protein synthesis produced by Bacillus subtilis: production, taxonomy, isolation, 
physico-chemical characterization and biological activity, J Antibiot (Tokyo) (vol. 
48), No. 9, pp. 997-1003. 
[295] Wilson, K. E.; Flor, J. E.; Schwartz, R. E.; Joshua, H.; Smith, J. L.; Pelak, B. A.; 
Liesch, J. M. and Hensens, O. D. (1987): Difficidin and oxydifficidin: novel broad 
spectrum antibacterial antibiotics produced by Bacillus subtilis. II. Isolation and 
physico-chemical characterization, J Antibiot (Tokyo) (vol. 40), No. 12, pp. 1682-91. 
[296] Piel, J. (2002): A polyketide synthase-peptide synthetase gene cluster from an 
uncultured bacterial symbiont of Paederus beetles, Proc Natl Acad Sci U S A (vol. 
99), No. 22, pp. 14002-7. 
 182
[297] Steinborn, G.; Hajirezaei, M. R. and Hofemeister, J. (2005): bac genes for 
recombinant bacilysin and anticapsin production in Bacillus host strains, Arch 
Microbiol (vol. 183), No. 2, pp. 71-9. 
[298] Scholz, Romy (2005): Diploma Arbeit, Berlin 
[299] Andrews, S. C.; Robinson, A. K. and Rodriguez-Quinones, F. (2003): Bacterial iron 
homeostasis, FEMS Microbiol Rev (vol. 27), No. 2-3, pp. 215-37. 
[300] Escolar, L.; Perez-Martin, J. and de Lorenzo, V. (1999): Opening the iron box: 
transcriptional metalloregulation by the Fur protein, J Bacteriol (vol. 181), No. 20, pp. 
6223-9. 
[301] Hantke, K. (2001): Bacterial zinc transporters and regulators, Biometals (vol. 14), No. 
3-4, pp. 239-49. 
[302] Kloepper, J.W., Leong J., Teintze M., Schroth M.N. (1980): Enhanced plant growth 
by siderophores produced by plant growth-promoting rhizobacteria., Nature (vol. 
286), pp. 885-886. 
[303] Gonzalez-Pastor, J. E.; Hobbs, E. C. and Losick, R. (2003): Cannibalism by 
sporulating bacteria, Science (vol. 301), No. 5632, pp. 510-3. 
[304] Besson, F.; Peypoux, F.; Michel, G. and Delcambe, L. (1978): Mode of action of iturin 
A, an antibiotic isolated from Bacillus subtilis, on Micrococcus luteus, Biochem 
Biophys Res Commun (vol. 81), No. 2, pp. 297-304. 
[305] Peypoux, F.; Besson, F.; Michel, G. and Delcambe, L. (1981): Structure of 
bacillomycin D, a new antibiotic of the iturin group, Eur J Biochem (vol. 118), No. 2, 
pp. 323-7. 
[306] Pao, G. M.; Tam, R.; Lipschitz, L. S. and Saier, M. H., Jr. (1994): Response 
regulators: structure, function and evolution, Res Microbiol (vol. 145), No. 5-6, pp. 
356-62. 
[307] Dahl, M. K.; Msadek, T.; Kunst, F. and Rapoport, G. (1992): The phosphorylation 
state of the DegU response regulator acts as a molecular switch allowing either 
degradative enzyme synthesis or expression of genetic competence in Bacillus subtilis, 
J Biol Chem (vol. 267), No. 20, pp. 14509-14. 
[308] Dahl, J. L.; Wei, B. Y. and Kadner, R. J. (1997): Protein phosphorylation affects 
binding of the Escherichia coli transcription activator UhpA to the uhpT promoter, J 
Biol Chem (vol. 272), No. 3, pp. 1910-9. 
[309] Turgay, K.; Hamoen, L. W.; Venema, G. and Dubnau, D. (1997): Biochemical 
characterization of a molecular switch involving the heat shock protein ClpC, which 
controls the activity of ComK, the competence transcription factor of Bacillus subtilis, 
Genes Dev (vol. 11), No. 1, pp. 119-28. 
[310] Dubnau, D.; Hahn, J.; Roggiani, M.; Piazza, F. and Weinrauch, Y. (1994): Two-
component regulators and genetic competence in Bacillus subtilis, Res Microbiol (vol. 
145), No. 5-6, pp. 403-11. 
[311] Mueller, J. P.; Bukusoglu, G. and Sonenshein, A. L. (1992): Transcriptional regulation 
of Bacillus subtilis glucose starvation-inducible genes: control of gsiA by the ComP-
ComA signal transduction system, J Bacteriol (vol. 174), No. 13, pp. 4361-73. 
[312] Lazazzera, B. A.; Kurtser, I. G.; McQuade, R. S. and Grossman, A. D. (1999): An 
autoregulatory circuit affecting peptide signaling in Bacillus subtilis, J Bacteriol (vol. 
181), No. 17, pp. 5193-200. 
 
 
